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Abstract 
Allogeneic bone marrow transplantation (BMT) is an important and commonly used 
treatment for a variety of haematological malignancies. Central to the therapeutic 
benefits of allogeneic BMT is the role of donor T cells, which mediate a potent anti-
neoplastic effect against tumours in the recipient. However, the presence of donor T 
cells is also tightly associated with the development of the life-threatening condition 
graft-versus-host-disease (GVHD), a disorder where alloreactive donor T cells 
recognise the recipient as ‘non-self’ and elicit a potent anti-host immune response. 
Antigen presenting cells (APC) are critical to the induction of acute GVHD. However, 
recent studies have questioned whether any particular subset of APC has a non-
redundant role in the priming of an alloreactive donor T cell response. 
One of the most commonly affected organs in acute GVHD is the skin, which contains 
a diverse array of professional APC subsets capable of initiating potent immune 
responses. One such subset is Langerhans cells (LC), a population of radioresistant 
dendritic cells (DC) that form a dense interlacing network within the epidermis. Using 
an in vivo mouse model of acute GVHD where host LC can be conditionally depleted, 
LC were found to play an important role in the development of acute GVHD in the skin. 
The depletion of host LC significantly reduced the severity of cutaneous GVHD that 
developed following allogeneic BMT. Host LC were required in situ in the epidermis for 
both the accumulation and function of alloreactive donor CD8 T cells in the skin. A role 
for host Langerin+ dDC, a population shown to be critical for CD8-mediated T cell 
responses in the skin, was also ruled out. These findings describe a novel role for host 
LC in the regulation of cutaneous GVHD in situ, which could identify a novel target for 
organ specific immunosuppression following allogeneic BMT. 
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1 Introduction 
1.1 Bone marrow transplantation as a therapy in the clinic 
1.1.1 Autologous versus allogeneic BMT in the clinic today 
Bone marrow transplantation (BMT), or haematopoietic stem cell transplantation 
(HSCT), is a commonly used treatment in the clinic whereby the haematopoietic 
system of a patient is reconstituted (or replaced) by the intravenous (i.v.) injection of ex 
vivo haematopoietic stem cells derived from a suitable donor. Used to treat a variety of 
congenital and acquired haematological conditions (Figure 1), there are two forms of 
transplant predominantly used in the clinic today: autologous (self) and allogeneic (non-
self) transplants1.  
Autologous transplantation involves the collection and cryopreservation of a patient’s 
own stem cells before they receive myeloablative treatments such as high-dose 
chemotherapy or radiation. The harvested stem cells are subsequently infused back 
into the patient to reconstitute haematopoiesis. It accounts for around 60% of all 
transplants in the clinic and is mainly used to treat haematological malignancies that 
are sensitive to treatment, with multiple myeloma and non-Hodgkin lymphoma the most 
common indications for an autologous transplant1. The primary advantage of this form 
of transplant is the absence of any form of alloimmune responses against the recipient 
as the cells come from the patient. There is no need for immunosuppression or 
histocompatibility matching. However, this can also be a disadvantage in some 
instances as autologous transplants rely solely on the conditioning regime and 
chemotherapy as a therapeutic modality, limiting its use to certain clinical indications. In 
addition, neoplastic cells can also be collected when the stem cells are harvested, 
causing patients to relapse post transplant2. 
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Allogeneic transplantation differs in that it involves the transplant of haematopoietic 
stem cells from a healthy donor other than the recipient (Figure 2). The use of 
allogeneic BMT as a therapy was initially developed for two reasons. Firstly, it provided 
clinicians with a way to treat patients with congenital or acquired diseases that affect 
the function of bone marrow or bone marrow derived cells, by replacing the abnormal 
haematopoietic system of the patient with one from a healthy donor. Secondly, it 
allowed the delivery of myeloablative doses of radiation and/or chemotherapy to treat 
aggressive haematological malignancies while harnessing the potent anti-neoplastic 
graft-versus-leukemia (GVL) effect, associated with lower rates of malignant relapse2. 
Since the first allogeneic BMT in 19563, improvements in our understanding of the 
biology of transplantation has seen the number of transplants rapidly rise. Today, over 
60,000 transplants are carried out worldwide each year as a frontline treatment for a 
variety of life-threatening conditions that were previously considered incurable. 
However, significant challenges remain as BMT continues to be associated with a high 
rate of morbidity and mortality in the clinic with disease relapse, infection due to 
pancytopenia and the development of graft-versus-host-disease (GVHD) remaining 
problematic (Figure 3). To gain further insight into the challenges faced in the clinic 
today, we will first explore the series of observations and discoveries over the last 5 
decades that led to the development of the treatments we see today. 
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Figure 1: Clinical indications for HSCT in the United States in 2011. Autologous transplants accounted 
for around 60% of all transplants in the US and were primarily used to treat multiple myeloma and non-
Hodgkin lymphoma (NHL). Allogeneic transplants were mainly used to treat acute myeloid leukemia (AML) 
and acute lymphoblastic leukaemia (ALL). Reprinted with permission from the Center for International 
Bone Marrow Transplant Research (www.cibmtr.org)1. 
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Figure 2: Overview of an allogeneic haematopoietic stem cell transplant in the clinic today. A 
healthy donor, matched for histocompatibility, is injected with granulocyte colony-stimulating factor to 
stimulate the bone marrow to release stem cells into the peripheral blood. These cells are then harvested 
by leukapheresis. The recipient is conditioned with chemotherapy and/or radiotherapy to enhance stem 
cell engraftment, treat the haematological malignancy (if present) and to create a niche for the newly 
grafted haematopoietic stem cells. The recipient is then transfused with donor peripheral blood 
mononuclear cells (PBMCs) where the donor cells engraft over a period of time replacing the recipients 
own haematopoietic system. Reprinted with permission from the Nature Publishing Group4. 
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Figure 3: Transplant-related mortality between 2010-2011. For both autologous and allogeneic 
transplants, disease relapse remains the primary cause of mortality in the clinic. This is particularly 
problematic in autologous BMT, accounting for 70% of transplant-related mortality (TRM). The 
development of GVHD remains a major problem for allogeneic BMT using grafts from HLA-matched sibling 
and unrelated donors (HLA allelic identity at the HLA-A, HLA-B, HLA-C and HLA-ADRB1 loci, 8/8 match5) 
accounting for 17% and 19% of TRM respectively. Infection is also a major cause of mortality in the clinic. 
The type of infection is usually related to the time after transplant (pre-engraftment and post-engraftment). 
Infections commonly seen after BMT include the bacteria Pseudomonas aeruginosa and Costridium 
difficile, fungal species such as Aspergillus and Candida and viral infections with cytomegalovirus and 
Epstein-Barr virus. Reprinted with permission from the Center for International Bone Marrow Transplant 
Research (www.cibmtr.org)1. 
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1.1.2 The dawn of the haematopoietic stem cell 
The concept of a hematopoietic stem cell capable of reconstituting haematopoiesis in 
vivo dates back to the 1940’s when the US government allocated substantial funds to 
counter the effects of high-dose radiation exposure in humans, in particular bone 
marrow failure, after the detonation of nuclear weapons in Japan6. This surge of 
research led to the landmark observation by Jacobsen and colleagues in 1949, that 
mice could be protected from the lethal effects of ionizing radiation by shielding their 
spleens with lead7. Following on from his initial observations, Jacobsen demonstrated 
that mice could also be rescued from the lethal effects of radiation by the 
intraperitoneal injection of splenocytes (SC) from healthy donors immediately after 
radiation exposure8. This led to the belief by many investigators at the time of the 
‘humoral’ hypothesis; that an as yet unidentified “substance of non-cellular nature” in 
the spleen was responsible for stimulating recovery or that a toxin produced upon 
exposure to radiation was somehow neutralised by the shielded spleen (Figure 4)9.  
However, doubts surrounding the existence of a ‘humoral’ factor in the spleen soon 
began to emerge in the early 1950’s when Lorenz and colleagues demonstrated that 
protection against radiation induced bone marrow aplasia in mice and guinea pigs 
could also be conferred by the infusion of bone marrow cells from a healthy donor10. 
Support for a ‘cellular hypothesis’ gained momentum when Main and Prehn observed 
that skin grafts from different strains survived indefinitely on allogeneic chimeras that 
received marrow from the corresponding strain11. Shortly thereafter, the ‘humoral 
hypothesis’ was replaced by the ‘cellular hypothesis’ when firm evidence began to 
emerge from a number of studies that protection from radiation lethality was mediated 
entirely by haematopoietic stem cells found in the bone marrow6,12,13. In one prominent 
study, Ford et al. were able to demonstrate, using cytogenetically marked 
chromosomes in donor bone marrow, that recovery of the hematopoietic system in 
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lethally irradiated mice was entirely derived from donor bone marrow, thus confirming 
the ‘cellular hypothesis’12. 
Taken together, the idea that the haematopoietic system could be destroyed using 
ionizing radiation and subsequently reconstituted using pluripotent haematopoietic 
stem cells excited scientists and clinicians alike for its potential both in the lab and as a 
therapy in the clinic. It became possible for the first time to remove an abnormal 
haematopoietic system or cure patients with bone marrow aplasia, replacing diseased 
or dying bone marrow with a haematopoietic system from a healthy donor. It also 
provided oncologists with an opportunity to increase the dose of cytotoxic anti-cancer 
drugs beyond their normal non-myeloablative range, increasing their potential efficacy 
against tumour cells. 
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Figure 4: Summary of Jacobsen’s observations from his radiation protection experiments. CF-1 
mice lethally irradiated with 10 Gy would die from bone marrow aplasia between 7 and 14 days after 
radiation exposure. However, if either the spleen or hind leg of CF-1 mice was shielded from x-rays using 
lead, a significant cohort of mice would survive. Similarly, if CF-1 mice exposed to x-rays were injected 
with splenocytes from a healthy CF-1 donor immediately afterwards, a significant cohort would survive. 
These experiments led to the widespread adoption of the ‘humoral hypothesis’ at the time9.  
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1.1.3 First steps into the clinic 
Despite promising results in mouse models, the initial use of BMT as a therapy in the 
clinic was largely disappointing with allograft failure, infection due to leukopenia and 
disease relapse hampering efforts14. 
First attempted by E Donnall Thomas in the United States in 1956, 5 adult patients with 
end stage malignancies were transplanted with allogeneic (non-self) bone marrow 
derived from foetuses and adults. From a therapeutic standpoint, the results were 
disastrous with all patients dying a short time later from either allograft failure or a 
relapse of leukemia. However, the study did prove that high doses of donor bone 
marrow prepared properly could be safely transfused into humans, providing clinicians 
with a baseline for future studies3.  
By 1959, a number of new studies were published in patients with leukemia and victims 
of radiation exposure yielding only slightly better results15–17. Following on from their 
initial work, Thomas and colleagues treated two patients with acute lymphoblastic 
leukemia (ALL) with a lethal dose of total body irradiation (TBI) and subsequently 
transplanted them with bone marrow from identical twin siblings (syngeneic 
transplant)15. Although both patients died after their leukemia relapsed a number of 
months later, it was the first reported case where patients receiving a lethal dose of 
radiation showed prompt clinical and haematological recovery upon transplantation, 
validating the observations made in mice. More importantly, it also indicated that TBI 
alone would not be sufficient to destroy all leukemic cells and future treatments would 
need to be developed in combination with chemotherapy15. In another study of note 
published in 1959, McGovern et al. tried a different approach. Using cryopreserved 
stem cells harvested from an ALL patient in remission, they described the first instant 
of an autologous (self) transplant in humans, transplanting the harvested stem cells 
back into the patient after a myeloablative conditioning regime16. Despite the patient 
going into remission for a second time, the leukemia relapsed and the patient died. 
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In addition, in the absence of any detailed knowledge of histocompatibility for human 
leukocyte antigens (HLA), a lethal and often fatal new side effect began to emerge in 
patients shortly after the successful engraftment of a donor haematopoietic system. 
They developed a painful maculopapular skin rash, severe diarrhoea and jaundice in 
what became known as ‘secondary syndrome’ at the time17. The potential for a graft-
versus-host response after BMT was first described by Barnes and Loutit in mice in 
195718. They noted that lethally irradiated mice transfused with bone marrow from a 
different strain would survive the initial radiation induced bone marrow aplasia (primary 
disease) but develop a lethal and debilitating ‘secondary disease’ that caused weight 
loss and diarrhoea 2-3 weeks after transplant (Figure 5). For a number of years it was 
unclear whether this ‘secondary disease’ was a host-versus-graft or a graft-versus-host 
response until van Bekkum demonstrated that the severity of disease was directly 
related to the number of splenic lymphocytes grafted, providing firm evidence that cells 
from the donor graft were mounting an immune response against the host19. Similarly, 
when donor lymphocytes were depleted from the graft, mice failed to develop 
‘secondary disease’ across major histocompatibility complex-mismatched (MHC-
mismatched) donor-recipient combinations. Thus ‘secondary disease’ became known 
as graft-versus-host-disease (GVHD), and remains a major cause of morbidity and 
mortality in the clinic to this day.  
Despite the initial promise of BMT as a therapy in the clinic, enthusiasm for the therapy 
had waned tremendously by the mid-1960s20. The number of transplants performed 
sharply declined as clinicians realised the treatment was simply not working. In 1967, 
the concept of an allogeneic transplant in the clinic was declared dead when van 
Bekkum and de Vries noted that “the clinical applications were undertaken too soon, 
most of them before even the minimum of basic knowledge required to bridge the gap 
between mouse and patient had been obtained”21. This was brought to the fore in 1970 
when Bortin published a report reviewing the outcome of 203 transplants between 
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1958-196822. Out of 203 patients, 125 suffered from allograft failure, 49 developed 
GVHD and only 11 developed any kind of stable engraftment22,23. However, the most 
striking aspect of the report was that by the time it was published only 3 out of the 203 
patients remained alive23.   
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Figure 5: The infusion of bone marrow from an allogeneic donor after lethal irradiation causes a 
lethal and debilitating ‘secondary disease’. CBA/H mice were lethally irradiated with 10 Gy and 
reconstituted with bone marrow from the femora of either CBA/H (syngeneic) or C57/H (allogeneic) mice 
on the same day. As a control, a cohort of irradiated mice received no bone marrow. After 7 days, all mice 
that received no bone marrow died from bone marrow aplasia (primary disease). All mice that received 
bone marrow from either CBA/H or C57/H donors survived. Between 2-3 weeks after transplant, recipients 
that received bone marrow from C57/H donors began to develop a ‘secondary disease’ of wasting and 
diarrhoea. By day 21, all recipients of C57/H bone marrow had died. No evidence of ‘secondary disease’ 
was detected in recipients that received CBA/H bone marrow. 
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1.1.4 Progress in the lab and the second phase of clinical transplantation 
Parallel to the problems faced in the clinic, progress continued to be made in the lab 
with donor selection, the development of high-dose conditioning regimes and the 
control of GVHD through immunosuppression becoming areas of intense research23,24.  
One of key reasons that the findings in the lab initially failed to translate into the clinic 
was the complete lack of understanding at the time of the immunological mechanisms 
underpinning graft rejection and GVHD. Much of the research to date had focused on 
transplantation models using highly inbred mice, which did not require 
histocompatibility matching23. This combined with the observation that graft-versus-host 
responses were incomparably more severe in humans than rodents after transplant led 
to the growing appreciation of the role genetic factors played in transplantation21. 
The widespread availability of many different inbred strains of mice permitted the 
fundamental genetic basis of transplantation to be elucidated14. By the late 1950’s, it 
became clear that the severity of GVHD in mice after transplantation was controlled by 
genetic factors and that these in turn were governed by immunological responses 
driven by T cells to differences in the major histocompatibility complex (MHC)25,26. 
Although research using mouse models had been critical in elucidating the 
fundamental principles of transplantation, a more suitable preclinical model with greater 
genetic diversity needed to be identified. Dogs in particular appeared to be especially 
suitable, owing to their outbred nature, wide genetic diversity, large litter size and short 
gestation period27. 
Adapted from the MHC system in mice, a method to type MHC antigens in dogs, 
known as dog leukocyte antigen (DLA), was developed28. This allowed studies of 
donor-recipient combinations that were matched or mismatched for DLA antigens to be 
investigated. Early studies in dogs quickly highlighted the critical importance of DLA-
typing for successfully transplantation, when it was found that recipients receiving bone 
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marrow from DLA-matched donors survived significantly longer with less GVHD than 
their DLA-mismatched donor-recipient counterparts29. Furthermore, while GVHD had 
already been described across MHC-mismatched transplant models in mice and 
unrelated primates, studies in dogs showed for the first time that mismatches across 
minor histocompatibility (H) antigens was sufficient to induce GVHD. This emphasised 
the need to develop effective immunosuppressive drug regimes23,29.  
This led to the development and widespread use of the anti-metabolite methotrexate. 
Using methotrexate, which suppresses T cell replication, researchers were able to 
successfully suppress GVHD in both mice and dogs30–32. Furthermore, long-term 
immunity in the animal was not compromised as it was found that the 
immunosuppressive therapy could frequently be discontinued after 3-6 months with the 
establishment of graft/host tolerance23,31.  
Further work in pre-clinical models saw the development of high-dose conditioning 
regimes, incorporating the use of high dose TBI with chemotherapy agents such as the 
alkylating agent cyclophosphamide. This acted to not only kill cancerous cells but also 
to suppress the host’s own immune system, decreasing the chances of graft 
rejection20,33–35.  
The advances in our understanding of the MHC system in dogs, development of 
immunosuppressant’s to reduce GVHD and the refinement of high-dose conditioning 
regimes in preclinical animal models renewed optimism for the use of BMT in the clinic 
and brought about the second phase of human trials. 
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1.1.5 The second phase of clinical transplantation 
By the 1970’s, the second phase of human trails using allogeneic BMT from HLA-
matched sibling donors was well underway in patients with immunodeficiency diseases 
such as severe combined immunodeficiency (SCID), aplastic anemia and advanced 
leukemia/lymphoma20. 
With the discovery and characterisation of the MHC complex in humans, human 
leukocyte antigen (HLA), allogeneic transplantation in the clinic became feasible36. To 
account for differences in human leukocyte antigen (HLA), mixed lymphocyte cultures 
(MLC) were used to select donors, with weak responses in vitro being a good predictor 
of donor suitability24,37.  
Rapid advancements were also made in our understanding of the clinical management 
of transplant patients. Improvements in blood and platelet transfusions, the use of 
novel antibiotics and antifungal medications reduced the complications associated with 
pancytopenia and the intense conditioning regime6. 
By 1977, it was clear that the second phase of transplantation was achieving far 
greater success in the clinic when E Donnal Thomas and colleagues published articles 
reviewing the outcome of patients undergoing transplantation with advanced leukemia 
and aplastic anemia in which conventional treatment had failed. Despite a high 
transplant-related-mortality (TRM), long-term disease free survival was for the first time 
being achieved in the clinic20,38,39. Importantly, Thomas also noted in these studies that 
patients in good general condition at the time of transplant had significantly better 
outcomes than those in poorer conditions and that patients with advanced leukemia 
tended to have higher relapse rates (75%) regardless of the conditioning regime20,39. 
The 1980’s saw a rapid increase in the use of BMT (Figure 6), which can be attributed 
to two independent but closely linked developments6. The first and perhaps the most 
important of these moves was the use of BMT at a much earlier stage in the treatment 
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plan based on Thomas’s observations.  When BMT began to be used to treat patients 
with acute leukemia in the first complete remission, survival rates dramatically 
increased40,41. Similar increases in survival were also seen when BMT was used to 
treat patients with chronic myeloid leukemia (CML) in the first chronic stage42. BMT 
was no longer a treatment of last resort but a curative therapy, capable of treating 
malignancies like CML that were once thought incurable. 
The second was the development and use of the T cell activation inhibitor cyclosporine 
along with methotrexate. Although acute GVHD was managed well by the use of 
methotrexate, the development of chronic GVHD remained a problem, occurring in 
over 50% of patients receiving HLA-matched grafts and methotrexate23,38. The adoption 
of cyclosporine and tacrolimus into the treatment regime saw a reduction in GVHD and 
rapid improvement to patient survival rates23,43,44. 
An unexpected observation during clinical GVHD was the realisation that cells from the 
donor graft could also have potent anti-tumour properties. The potential of a graft-
versus-leukemia (GVL) effect from cells in the donor graft was first noted by Barnes 
and Loutit in 1957, when mice transplanted with allogeneic bone marrow were found to 
eradicate leukaemia cells (Figure 7)18. However, it’s potential in the clinic was first 
appreciated in 1979 when it was noted that onset of GVHD greatly reduced the chance 
that a patient’s leukemia would relapse45. Conversely, when patients were transplanted 
with allogeneic grafts depleted of T cells or grafts from identical twin siblings, the 
development of GVHD was markedly reduced but the risk of relapse and graft failure 
was greatly increased (Figure 8)46,47. Despite the clinical complications associated with 
GVHD, the GVL effect is now seen as one the primary therapeutic modalities of 
allogeneic BMT. 
Over the last two decades the field has continued to rapidly advance, enhancing both 
the range of indications that BMT is used to treat and the overall success of the 
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procedure. The establishment of detailed bone marrow registries, with over 23 million 
typed volunteers as of 2014 (www.bmdw.org), has enhanced a patient’s chance of 
finding a haploidentical match outside of their family. The use of peripheral blood 
mononuclear cells (PBMC) and cord blood as stem cell sources reduced the risks and 
invasiveness of the procedure for donors. The introduction of DNA-based typing for 
HLA enhanced the quality of recipient-donor matching48. The development of non-
myeloablative conditioning regimes has extended the use of allogeneic BMT, and as a 
result the therapeutic benefits of GVL, to elderly patients and patients with co-
morbidities, cohorts that were previously unable to undergo transplantation previously 
due to the high toxicity associated with conventional high-dose conditioning regimes. 
These advances, among others, have seen the number of transplants rapidly rise over 
the years and there are over 60,000 worldwide each year today. However, significant 
challenges remain as BMT continues to be associated with a high rate of morbidity and 
mortality in the clinic. For his work in the field of transplantation, E Donnal Thomas 
went on to receive the Nobel Prize for physiology and medicine in 1990. For a more 
comprehensive overview of the history of BMT, the following sources provide an 
excellent review6,23,24,49,50.  
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Figure 6: Timeline outlining the number of transplants performed each year in parallel to 
milestones in the field. By the 1980’s the number of transplants rose rapidly each year as the challenges 
posed by graft-versus-host-disease and pancytopenia were addressed. Reprinted with permission from the 
New England Journal of Medicine, Copyright Massachusetts Medical Society51. 
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Figure 7: Leukaemic cells are eradicated in CBA/H recipient’s that receive allogeneic, but not 
syngeneic, BMT. CBA/H mice were injected intraperitoneally with 106 leukaemic cells derived from a 
CBA/H mouse. 7 days later, recipients were lethally irradiated with 10 Gy and reconstituted with bone 
marrow from the femora of either CBA/H (syngeneic) or C57/H (allogeneic) mice on the same day. 7 days 
after transplant, mice that were transplanted with syngeneic bone marrow died from leukaemia. In mice 
that received bone marrow from a C57/H donor, a potent GVL effect was observed. All mice survived the 
initial tumour burden until they eventually succumbed to GVHD. This was the first observation of GVL in 
vivo, demonstrating the potent anti-leukaemic properties of cells from an allogeneic donor18. 
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Figure 8: The probability of relapse after allogeneic or syngeneic transplantation according to the 
type of graft and level of GVHD.  The onset of acute or chronic graft-versus-host-disease (GVHD) is 
associated with a decreased risk of relapse. Recipients that are transplanted with a graft from an identical 
twin (syngeneic) or receive an allogeneic depleted of T cells are at the greatest risk of relapse. Reprinted 
from Blood46. 
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1.2 Graft-versus-host-disease 
1.2.1 GVHD remains a major complication associated with allogeneic BMT 
Despite over 50 years of intensive research, the development of GVHD continues to be 
a significant cause of morbidity and mortality in the clinic, limiting the overall success of 
allogeneic BMT (Figure 3). The vast majority of allogeneic transplants in the clinic are 
directed at patients with haematological malignancies such ALL and AML. Central to 
the therapeutic benefit of allogeneic BMT is the role of donor T cells, which have been 
shown to play a significant role maintaining remission after transplant. Paradoxically, it 
is this population of donor cells that is tightly associated with the development of 
GVHD, a disorder where alloreactive donor T cells recognise host tissues as ‘non-self’ 
and mediate acute and chronic tissue injury. There have been significant improvements 
in our understanding of the pathophysiology, predisposition and treatment of GVHD. 
However, despite these advancements, the development of GVHD remains 
widespread. In a recent study reviewing the outcome of patients undergoing allogeneic 
transplants between 1993 to 1997 and 2003 to 2007, it was reported that the incidence 
of acute GVHD had only decreased by 6% (77% to 71%)52. However, the overall 
incidence of severe GVHD (Grade III-IV) showed the greatest decrease, falling from 
30% to 14%. 
First reported by Barnes and Loutit in 1957, it was a number of years later before 
Billingham outlined his three requirements for GVHD that still hold true today18,53: 
1. The graft must contain immunologically competent cells 
2. The recipient must express alloantigens that are not present in the donor 
3. The recipient must be incapable of mounting an immune response to eliminate 
the graft 
50 years later, we now know that alloreactive donor T cells are the immunologically 
competent cells mediating GVHD in recipients, with the number of donor T cells closely 
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correlating with the severity of GVHD that develops19,54. The third requirement 
stipulates that the recipient must be incapable of mounting an immune response to 
eliminate the graft. For allogeneic BMT, this is a consequence of the conditioning 
regime (chemotherapy and/or radiotherapy), which acts to enhance stem cell 
engraftment by eliminating the recipient’s haematopoietic system and treating the 
patient’s malignancy (if present)55. 
Perhaps the most important predictor of GVHD is the degree of histocompatibility 
between the donor and the recipient. In humans, differences in the highly polymorphic 
Class I and Class II HLA glycoproteins, responsible for antigen presentation, are 
directly related to the frequency and severity of GVHD56,57. Class I HLA (A, B and C), 
responsible for the presentation of endogenous antigens, are expressed on almost all 
nucleated cells. Class II HLA (DR, DQ and DP), responsible for the presentation of 
exogenous antigen, are predominantly expressed on B cells and antigen presenting 
cells (APC) such as macrophages and dendritic cells (DC). In the clinic, donors are 
typically matched at HLA-A, HLA-B, HLA-C and HLA-DRB1 (referred to as 8/8 match) 
before they are considered suitable56. This kind of high resolution HLA-typing is 
necessary as even a single mismatch can significantly impact the clinical outcome for a 
patient. In a study published in 2007, high resolution DNA typing showed that a single 
mismatch at either HLA-A, HLA-B, HLA-C or HLA-DRB1 (7/8 match) was associated 
with higher mortality with patients having a 1-year survival rate of 43% compared with 
52% for 8/8 matched pairs58. Certain HLA-mismatch combinations also carry a higher 
risk of developing GVHD than others, further complicating the process of finding a 
match59.  
Identifying a suitable donor begins in the family. The odds of finding a suitable HLA-
match between siblings are 1:4 and this can be severely limiting. However, with the 
development of high resolution DNA typing techniques, the differences in the clinical 
outcomes of HLA-matched sibling donors (MSD) versus unrelated donors (UD) has 
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narrowed significantly; with a recent article examining the differences between MSD 
and UD (8/8 match) reporting that the difference in the 1-year survival for patients with 
leukaemia has moved from 21% in favour of MSD in 1988 to just 9% in 20085. 
However, despite the majority of allogeneic transplants carried out coming from high 
resolution HLA-matched donor-recipient combinations, some level of GVHD requiring 
clinical intervention will develop in a large proportion of recipients. For recipients who 
receive grafts from HLA-matched sibling donors, around 40% of recipients will develop 
GVHD56. In this case, GVHD, and to an extent GVL, is driven by genetic differences 
between the donor and recipient in genes that are outside the HLA loci, encoding 
proteins that are referred to as minor H antigens56.  
Minor H antigens tend to be from highly polymorphic genes and can be derived from 
either autosomal chromosomes or the Y-chromosome. The disparities in minor H 
antigens between the donor and recipient can vary quite substantially. They can arise 
from polymorphisms that cause single or multiple changes in the amino acid sequence 
of a peptide. For example, the Smcy gene derived from the Y-chromosome differs from 
its homologue Smcx on the X-chromosome by more than 200 residues whereas the 
HA-1 and HA-2 allelic pairs differ by only a single amino acid residue55. These 
polymorphisms can have a profound effect on the immunogenicity of a peptide. They 
can alter the area where a T cell receptor (TCR) binds the peptide or interfere with the 
way the peptide is processed or post-translationally modified60–62. Minor H antigens can 
also arise from gene deletions, where the protein is expressed in the recipient but not 
the donor63. Thus, the immunodominance of minor H antigens can vary greatly. 
Unlike Class I HLA, which is ubiquitously expressed by all nucleated cells, the 
distribution of minor H antigens is highly variable and can be either broadly expressed 
in most tissues or restricted to haematopoietic cells56. Minor H antigens derived from 
the Y-chromosome tend to have a broad expression pattern and are found in most 
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tissues, including those commonly targeted by GVHD such as the skin, gut and liver64. 
Other minor H antigens, such as autosomal HA-1, HA-2 and ACC-1 protein, have a 
restricted expression pattern and are restricted to haematopoietic cells, including 
leukaemic cells64. This can have a profound effect on their ability to induce both GVHD 
and GVL. It is well established that male recipients of HLA-matched female grafts are 
at a greater risk of developing GVHD than male recipients of HLA-matched male 
grafts65. However, these recipients are also at a lower risk of relapse66. On the other 
hand, restricting minor H mismatches to antigens restricted to haematopoietic cells 
could enhance GVL while diminishing GVHD, with one promising study showing a HA-
1 specific CTL response inducing remission in patients with leukaemia after DLI67,68. 
The differential expression of minor H antigens between tissues and haematopoietic 
cells could also explain why GVL can occur without GVHD in some instances. 
Importantly, the presentation of minor H antigens is also MHC restricted. To elicit an 
immune response, they need to be processed and presented via Class I or Class II 
MHC the same as any other antigen. This changes the pathophysiology of GVHD in 
comparison to MHC-mismatch models, as alloreactive donor T cells can recognise 
peptides from minor H antigens coupled with MHC from both donor and recipient 
antigen presenting cells (APC)69. The pool of precursor T cells specific for minor H 
antigens is also much lower (estimated to be between 1 in 105 to 1 in 106) than those 
specific for MHC-mismatches (estimated to be between 1-10% of all T cells), which 
also influences the severity of the response69,70. 
Historically, GVHD has been classified into two types depending on the time after 
transplant it first develops. GVHD arising within the first 100 days of transplant is 
defined as acute GVHD with GVHD occurring after the first 100 days defined as 
chronic GVHD71. The arbitrary nature of this definition has made the classification 
somewhat controversial as features of acute GVHD can present after 100 days and 
features of chronic GVHD before 100 days due to the evolving nature of transplant 
 45 
regimes such as reduced intensity conditioning. However, for the remainder of this 
thesis I will focus on acute GVHD and the definition of acute and chronic GVHD is 
sufficient for the scope of this project.  
 46 
1.2.2 Clinical features of acute GVHD 
The incidence of acute GVHD after allogeneic BMT can vary significantly, from 10% to 
80%, depending on a number of risk factors72. Risk factors increasing the likelihood a 
patient will develop acute GVHD include HLA-disparity, sex mismatch between the 
donor and recipient (F→M), increasing age of the recipient (>40), recipient CMV status, 
stem cell source (PBSC>Bone Marrow>Cord Blood) and the conditioning regime (High 
intensity>Reduced intensity)73,74. 
Acute GVHD usually manifests within the first 100 days of transplant and 
predominantly affects the skin, liver and gastrointestinal (GI) tract. The skin is the most 
commonly affected tissue (81%), followed by the GI tract (54%) and the liver (50%)75. 
Epithelial cells are the main target in acute GVHD and the onset of the disease typically 
begins with the development of a diffuse maculopapular rash in the skin that is often 
painful and pruritic76. This can begin anywhere but usually develops around the hands, 
feet and ears before progressing around the rest of the body although the scalp is 
usually spared56. In severe cases, the skin can blister and ulcerate with the formation of 
bullae and show signs of desquamation in the epidermal layers (Grade IV)77. 
Histopathological features include dyskeratosis of epidermal keratinocytes, lymphocyte 
infiltration and apoptosis at the base of epidermal rete pegs56. 
In the GI tract, acute GVHD typically manifests with profuse secretory diarrhoea78. A 
combination of nausea, vomiting, anorexia, weight loss and abdominal pain can 
develop as the disease progresses78. The diarrhoea may become bloody due to 
mucosal ulceration and ileus may develop, which is indicative of a poor prognosis79. 
Histopathological features of the GI tract include patchy ulcerations, flattening of the 
surface epithelium, crypt ulceration and apoptotic bodies at crypt bases56,80. 
In the liver, the development of acute GVHD is characterised by jaundice as a result of 
hyperbilirubinemia81. The bile canaliculi are damaged leading to a cholestatic pattern of 
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liver damage with elevated levels of conjugated bilirubin, alkaline phosphatase and 
gamma-glutamyl-transpeptidase82. Histopathological features include lymphocyte 
infiltration of the portal areas, endothelialitis, bile duct apoptosis and pericholangitis80,82. 
Originally developed in 1974, an updated version of the Glucksberg classification is 
typically used to determine the severity of GVHD83. To grade GVHD, each organ 
commonly affected by acute GVHD is independently assessed and assigned a stage. 
The skin is assessed by the percentage surface area involved, the liver by the 
elevation of bilirubin and the GI tract by the amount of diarrhoea83. These stages are 
then used to divide patients with acute GVHD into one of four grades (I-mild, II-
moderate, III-severe, IV-very severe)83. The grade of GVHD has been shown to 
correlate with the overall survival and the development of severe GVHD (Grade III-IV) 
is associated with significant mortality, with only 25% of patients that develop Grade III 
GVHD and 5% of patients that develop Grade IV GVHD surviving longer than 5 
years84. 
For patients that develop Grade I GVHD, treatment is usually not necessary although 
topical steroids may be used to treat localised symptoms in the skin82. Calcineurin 
inhibitors, such as cyclosporine, are commonly used as a means of prophylaxis for 
GVHD. This inhibits the activation of interleukin 2 (IL-2), which leads to a reduction in 
the activity of T cells. Changing the dosage administered can increase the therapeutic 
benefit once symptoms begin to manifest. However, this can significantly impact the 
therapeutic benefits of GVL with one study showing a 50% reduction in the rate of 
relapse when the dose of cyclosporine A was reduced5. For patients that develop 
Grade II-IV GVHD, the use of anti-inflammatory steroids, such as corticosteroids, 
remains the benchmark for treating acute GVHD (Figure 9). This results in complete 
remission in less than half of patients, although their effectiveness is reduced as the 
severity of GVHD increases56,85. However, the continued use of steroids renders 
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immunosuppressed patients susceptible to developing serious infections, leading to a 
significant level of mortality in the clinic in itself with a TRM of 15%1. 
 
Stage Skin Liver (Bilirubin) GI Tract (Diarrhoea) 
1 Maculopapular rash <25% of body surface 2-3 mg/dl >500 ml 
2 Maculopapular rash 25-50% of body surface 3.1-6 mg/dl >100 ml 
3 Maculopapular rash >50% of body surface 6.1-15 mg/dl >1500 ml 
4 Generalised erythroderma with bullae formation and 
desquamation 
>15 mg/dl Severe abdominal pain 
with or without ileus 
Table 1: Acute graft-versus-host-disease staging83. 
 
Grade Skin Liver  GI Tract 
I Stage 1-2 Stage 0 Stage 0 
II Stage 3 or Stage 1 or Stage 1 
III - Stage 2-3 or Stage 2-4 
IV Stage 4 or Stage 4 - 
Table 2: 1994 Consensus Conference classification of acute graft-verus-host-disease83. 
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Figure 9: Summary of the strategy for the first line of treatment for acute graft-versus-host-disease. 
For Grade I-IV graft-versus-host-disease (GVHD), the levels of calcineurin inhibitors (Cyclosporine A) may 
be increased to therapeutic levels. The use of steroids remains the primary treatment for acute GVHD, 
ranging from IV>Oral>Topical administration depending on the severity of GVHD. Algorithm developed by 
a joint working group from the British Committee for Standards in Haematology and the British Society for 
Bone Marrow Transplantation. Reprinted with permission from the British Journal of Haematology82. 
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1.2.3 Pathogenesis of acute graft-versus-host-disease 
The precise pathophysiology of acute GVHD, which involves a complex cascade of 
humoral and cellular interactions between donor and host cells, remains incompletely 
understood86. However, to begin to understand some of the pathways involved, it is still 
useful to consider the development of GVHD as a three-step process in a model first 
proposed by Ferrara and Reddy (Figure 10)87. 
• Step 1: Tissue damage associated with conditioning activates recipient APC 
• Step 2: The activation, differentiation and migration of alloreactive donor T cells 
• Step 3: Development of clinical GVHD via target tissue apoptosis  
The first step in this process involves the activation of host APC by the release of pro-
inflammatory cytokines (TNF-α, IL-1) and damage-associated molecular patterns 
(DAMPs) such as adenosine-5’-triphosphate (ATP) as a result of tissue damage 
associated with the conditioning regime4. In secondary lymphoid tissues, activated host 
APC then present alloantigens and co-stimulatory signals to donor T cells infused as 
part of the graph promoting alloactivation and cytokine release86. Once primed, 
alloreactive T cells proliferate and differentiate into effector subsets before migrating to 
peripheral tissues such as the skin and GI tract where they drive acute GVHD via 
cellular (Cytotoxic T lymphocytes, NK cells) and inflammatory (TNF-α, IL-1) 
mediators88. The tissue damage associated with the effector phase is what underlies 
the clinical manifestations of acute GVHD. 
It is important to consider acute GVHD as a highly dysregulated immune response, 
where the initial ‘cytokine storm’ generated by the conditioning regime and ubiquitous 
availability of alloantigen, leads to a self-perpetuating immune response where tissue 
damage mediated by effector cells promotes the recruitment of more effector cells. A 
more detailed overview of each step leading to the development of acute GVHD 
including the humoral and cellular factors involved will be expanded upon below. 
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Figure 10: Pathogenesis of acute GVHD as proposed by Ferrara and Reddy. The development of 
acute GVHD is classically thought to occur in three sequential phases. 1. Tissue damage associated with 
the conditioning regime induces the release of danger/pattern-associated molecular patterns 
(DAMPs/PAMPs) and pro-inflammatory cytokines such as TNF-α, IL-1 and uric acid. This leads to the 
maturation of host APC and generates a pro-inflammatory environment for T cells in peripheral tissues. 2. 
Donor T cells are then primed by alloantigens in secondary lymphoid organs via donor and host APC and 
pro-inflammatory cytokines. T cells then differentiate and proliferate in response to pro-inflammatory 
molecules before migrating to peripheral tissues. 3. The combination of tissue damage associated with the 
conditioning regime and priming of T cells with alloantigens leads to a complex cascade where cellular 
(Cytotoxic T lymphocytes and NK cells) and inflammatory mediators (TNF-α and IL-1) are released which 
cause acute and chronic tissue injury in peripheral tissues such as the skin, GI tract and liver. Reprinted 
with permission from The Lancet56. 
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1.2.3.1 Step 1: Tissue damage associated with conditioning activates recipient APC 
To deplete the host haematopoietic system, promote stem cell engraftment and treat 
haematological malignancy, patients are myleosuppressed and immunosuppressed 
using chemotherapy and/or radiotherapy (γ–radiation). The cytotoxic effects of these 
treatments on both epithelial and endothelial cells in peripheral tissues leads to a 
significant degree of inflammation, which in turn supports the development of acute 
GVHD through the activation of APC89. This is widely known as the initiation phase. 
The initiation phase begins when endogenous danger signals, known as damage-
associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs) are released from damaged and dying cells following the conditioning regime. 
This leads to the secretion of pro-inflammatory cytokines like TNF-α, IL-1 and IL-6 in a 
process called the ‘cytokine storm’. This mediates profound changes to the tissue 
microenvironment causing an increase in the expression of adhesion molecules, co-
stimulatory molecules and antigens presented by MHC, as well as the development of 
chemokine gradients that promote the infiltration of immune effectors90–92. 
The release of DAMPs such as adenosine-5’-triphosphate (ATP), uric acid and high 
mobility group box 1 protein (HMGB1) activate the cellular components of the innate 
immune system through pattern recognition receptors (PRR) on the cell surface89. This 
converts professional APC from an immature phenotype, which specialise in the uptake 
of exogenous antigen and promote tolerance, to a mature phenotype, up-regulating 
MHC and co-stimulatory molecules on the cell surface, which in turn promote effector T 
cell responses93. 
ATP, a coenzyme responsible for energy transfer within cells, is an important example 
of a DAMP that has been shown to play a key role in the pathogenesis of GVHD94. 
Under physiological conditions, ATP is found at much lower concentrations in the 
extracellular space (10 nM) than the intracellular space (3-10 mM)95. However, 
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following tissue damage associated with the conditioning regime, the level of ATP is 
found to dramatically increase in the extracellular space of both humans and mice94. 
Once the extracellular concentration of ATP accumulates to levels indicative of cell 
stress, ATP binds the purinergic receptor P2X7 leading to a calcium efflux which 
promotes the assembly and activation of the protein 3 (Nlrp3) or cryopirin 
inflammasome. Activation of the Nlrp3 inflammasome leads to the secretion of the 
potent inflammatory cytokine IL-1β inducing APC to upregulate co-stimulatory 
molecules and produce pro-inflammatory cytokines promoting T cell expansion94,96,97. 
The immunomodulatory effects of IL-1β is particularly evident in the skin, where 
secretion has been shown to upregulate co-stimulatory molecules CD80 and CD86 on 
Langerhans cells (LC) and induce keratinocytes to express pro-inflammatory 
cytokines98,99.  
The P2X7 receptor (P2X7R) is an important pathway to the development of acute 
GVHD. Pharmaceutical blockade of the P2X7R was found to significantly reduce the 
severity of GVHD in mice. A similar decrease in the severity of GVHD was also 
observed when ATP was metabolised using apyrase94. 
ATP has also been shown to significantly influence the migration of APC, attracting 
them to sites of increased apoptosis and imparting tissue resident DC with an 
increased capacity to migrate to peripheral lymph nodes100,101. 
Another important DAMP released from dying cells is uric acid. Uric acid promotes the 
Nlrp-3 inflammasome mediated production of IL-1β and the enzymatic digestion of uric 
acid in the GI tract of mice was found to significantly reduce the severity of GVHD97. 
Thus, the depletion of specific DAMPs and therapies directly targeting the Nlrp3-
inflammasome remain attractive targets to reduce the severity of GVHD after 
transplantation. 
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In addition to the release of pro-inflammatory cytokines and DAMPs, the destruction of 
epithelial cells in tissues such as GI tract also leads to the loss of the epithelial barrier 
function. This enables both commensal and pathogenic bacteria that colonise the 
epithelial surface to translocate across the barrier, which further stimulates APC 
through the recognition of PAMPs. APC recognise these conserved structural moieties 
through PRR such as Toll-like receptors and the nucleotide binding oligomerisation 
domain (NOD)-like receptors (NLRs)102. Ligation of these receptors by PAMPs 
activates APC such as DC, increasing their expression of Class II MHC and promoting 
their subsequent migration back to secondary lymphoid tissues where they interact with 
T cells.  
The contribution of gut microbiota to GVHD has long been recognised. In experiments 
conducted by Van Bekkum in the 1970’s, decontamination of the GI tract using 
antibiotics was found to significantly reduce the severity of GVHD in the gut103. Similar 
observations were also made in humans that underwent gut decontamination104.  
The pathophysiology behind these observations became clearer when 
lipopolysaccharide (LPS) stimulation of TLR-4 was identified as a key driver of acute 
GVHD, generating a ‘cytokine storm’ that favours the development of GVHD90. In mice 
undergoing allogeneic BMT, treatment with either an LPS inhibitor or endotoxin 
neutralising antibodies was found to significantly reduce the severity of GVHD and 
increase the overall survival of mice105–107. Ferrara further clarified the importance of 
the LPS/TLR-4 pathway when mice transplanted with bone marrow from an LPS-
resistant donor developed significantly less GVHD than mice transplanted with bone 
marrow from an LPS-sensitive donor108. 
To summarise, as the intensity of the conditioning regime increases, the degree of 
tissue injury and inflammation is greater which in turn generates a ‘cytokine storm’ that 
favours the development of GVHD. The generation of inflammation in peripheral 
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tissues has two main effects. It activates recipient APC enhancing their ability to prime 
T cells in secondary lymphoid tissues and subsequently provides alloreactive primed T 
cells with the chemokine gradient and co-stimulation they need to mediate their 
cytotoxic effects109. The intensity of the conditioning regime can also effect the 
expression of immunosuppressant molecules, with a recent study demonstrating that 
sialic acid–binding immunoglobulin-like lectin-G (Siglec-G) is downregulated in 
response to radiation induced tissue damage, rendering the host even more 
susceptible to the effects of DAMPs110. Thus, the intensity of the conditioning regime 
plays a significant role in the development of acute GVHD.  
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Figure 11: Tissue damage associated with the conditioning regime leads to the activation of 
recipient antigen-presenting cells in the gastrointestinal tract. During the conditioning regime, 
epithelial cells become damaged leading to the release of pro-inflammatory cytokines and damage-
associated molecular patterns (DAMPs), which stimulate the maturation of antigen presenting cells (APC). 
In addition, bacteria can translocate the disrupted epithelial barrier and further stimulate pattern recognition 
receptors (PRR) on APC. These activated APC can then prime alloreactive donor T cells, which mediate 
acute and chronic tissue injury in peripheral tissues. Reprinted with permission from Frontiers in 
Immunology89.  
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1.2.3.2 Step 2: Activation and differentiation of donor T cells 
The second phase of GVHD involves the priming and subsequent differentiation of 
alloreactive donor T cells into effector cells capable of mounting an immune response. 
The site of this priming is predominantly, although not exclusively, in the spleen and 
secondary lymphoid tissues111. 
Central to this is the role of APC. Considered by many to be the ‘sensors’ of acute 
GVHD, APC are required to present alloantigen to donor T cells via the MHC molecule 
and provide critical co-stimulatory and cytokine signalling which strongly influence both 
the type and quality of the effector response112. 
There are several different types of APC capable of contributing to the development of 
GVHD. These include host haematopoietic APC that survive the conditioning regime, 
host non-haematopoietic APC and donor haematopoietic APC86. After transplantation, 
both host and donor haematopoietic APC are present in the secondary lymphoid 
organs91. However, MHC-disparity has significant influence on the role of host and 
donor APC in the development of acute GVHD69.  
In MHC-mismatched transplants, donor recognition of intact MHC molecules is the 
dominant mode of allorecognition and the MHC molecule itself contributes more to the 
TCR binding energy than the bound alloantigen4,113. In this setting, given that intact 
host MHC is the immunodominant antigen stimulating alloreactive T cells, antigen 
presentation is largely restricted to host APC, although donor APC may also contribute 
if they can acquire intact host MHC through a recently described phenomenon called 
cross-dressing69,114.  
Data supporting the importance of host APC (both haematopoietic and non-
haematopoietic) in initiating acute GVHD across MHC-mismatches first came from 
experiments where the alloresponse was directly measured in the thoracic duct lymph 
of irradiated mice receiving MHC-mismatched BMT115. Isolating donor T cells from the 
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thoracic duct lymph of irradiated recipients, donor T cells appeared as activated blasts 
as little as 3-5 days after transplant and were capable of initiating GVHD upon transfer 
into a newly irradiated recipient115. The rapid appearance of these activated blasts 
indicated that host APC were driving this response, as it was too early for any 
meaningful contribution from donor derived APC4. Direct evidence supporting an 
important role for host APC in the initiation of acute GVHD came when alloreactive 
donor NK cells from MHC-mismatched donors, transplanted as part of the graft, were 
able to protect mice from GVHD116. NK cells amplified the eradication of 
haematopoietic cells, including APC that were unable to signal the cells via MHC Class 
I. This protection was still conferred even if the dose of donor T cells given was 
increased to 100-fold greater than the dose that would normally be lethal without NK 
cells69. This was further supported by observations in humans where the incidence of 
GVHD was reduced in HLA-matched recipients where NK cell alloreactivity was 
predicted based on the HLA-B and HLA-C haplotypes of donors and recipients116.  
Direct evidence that host haematopoietic APC alone are sufficient to induce acute 
GVHD has also been shown in an MHC-mismatched, minor H matched model117. Using 
H2bm12 and H2b1 mice that lack MHC Class II-/- and MHC Class I-/-, respectively, 
Teshima et al. generated bone marrow chimeras using wild-type (WT) C57BL/6 (BL/6) 
as donors and H2bm12 and H2b1 mice as recipients. When these chimeras 
([BL/6→H2bm12] and [BL/6→H2bm12]) were established, antigen presentation was 
restricted to the haematopoietic system as haematopoietic APC would now be derived 
from donor WT BL/6 stem cells whereas non-haematopoietic APC would still be 
derived from H2bm12 and H2b1 mice. Teshima et al. was then able to show that host 
haematopoietic APC were sufficient to induce both CD4- and CD8-mediated GVHD 
when alloantigen presentation and expression was restricted to the haematopoietic 
system117. 
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In contrast to MHC-mismatched BMT, where the contribution of host APC which 
abundantly express MHC was not hard to predict, the contribution of both donor and 
host APC in MHC-matched, minor H mismatched is not as clear69. For many years, 
antigen presentation by host haematopoietic APC was considered essential for the 
induction of acute GVHD55. In the MHC-matched setting, peptide recognition of 
cognate antigen is the equivalent of pathogen peptide recognition and both host and 
donor APC are capable of presenting antigen4. Antigen can be directly presented, 
where antigen is derived from a protein synthesised in the cell, by host APC or it can 
be indirectly presented, where antigen is derived from an exogenous source, by both 
host and donor APC (Figure 12). In addition, antigen can also be cross-presented by 
both host and donor APC, a process where antigen derived from an exogenous source 
can be loaded in the MHC Class I processing pathway normally restricted to 
endogenous antigens (Figure 12). Another form of presentation has also been 
described in recent years, termed cross-dressing, where APC can acquire a peptide 
loaded MHC-molecule via ‘trogocytosis’118. This could have a significant impact on the 
role of donor APC in transplantation, with a recent report observing very high levels of 
recipient haematopoietic cell derived MHC Class I and Class II transfer to donor cells 
after BMT119. 
In CD8-mediated GVHD, where alloreactive CD8 T cells are primed by alloantigen 
presented via MHC Class I, a requirement for host haematopoietic APC to induce 
acute GVHD has been demonstrated in several studies, with donor haematopoietic 
APC augmenting this response120,121. Using β2-microglobulin (β2m) deficient mice, 
which lack MHC Class I-/-, Shlomchik generated bone marrow chimeras using BL/6 
mice as recipients and β2m mice as donors ([β2m →BL/6])55. In these chimeras, 
haematopoietic cells were deficient in MHC Class I and unable to present antigen to 
CD8 T cells. When the chimeras were subsequently retransplanted with C3H.SW BM 
supplemented with donor CD8 T cells, the chimeras were found to be highly resistant 
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to CD8-mediated GVHD55. Thus, demonstrating an important role for host 
haematopoietic APC in an MHC-matched, minor H mismatched model of GVHD. 
To address whether the failure was due to inefficiency in cross-presentation or an issue 
with the kinetics of engraftment, the experiments were repeated using [C3H.SW→BL/6] 
bone marrow chimeras4. These were also found to be resistant to GVHD, indicating 
that cross-priming is inefficient in the induction of acute GVHD, although the addition of 
donor CD4 T cells was found to improve the priming of CD8-mediated GVHD via cross-
presentation in another study122. Using the same MHC-matched, minor H mismatched 
model of BMT, Matte was able to demonstrate a role for donor haematopoietic APC in 
augmenting acute GVHD121. When BL/6 mice were transplanted with C3H.SW β2m-/- 
along with donor CD8 T cells from a WT C3H.SW donor, GVHD was still induced but 
the severity was significantly reduced121. 
In MHC-matched, minor H mismatched GVHD mediated by donor CD4 T cells, both 
host and donor haematopoietic APC have been show to be sufficient to induce 
GVHD69,123. To further delineate the role of both donor and host APC, Anderson et al. 
performed transplants using CD80/CD86-/- B6.C (H-2d) as donors and CD80/CD86-/- 
BALB/c (H-2d) as recipients124. Both strains of mice were deficient in the co-stimulatory 
molecules CD80 and CD86 and when transplanted (CD80/CD86-/- B6.C → 
CD80/CD86-/- BALB/c), acute GVHD failed to develop highlighting the absolute 
importance of co-stimulation for CD4-mediated GVHD. However, when either WT B6.C 
mice were used as donors (B6.C → CD80/CD86-/- BALB/c) or WT BALB/c mice as 
recipients (CD80/CD86-/- B6.C → BALB/c), GVHD still developed in the absence of the 
co-stimulatory molecules CD80/CD86 in either donor or host derived APC, indicating a 
non-redundant role124. Although it is worth noting that there was less skin GVHD when 
host APC were deficient of co-stimulatory molecules and less gut GVHD when donor 
APC were deficient, indicating non-overlapping roles. 
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The importance of host haematopoietic APC in priming acute GVHD make them 
attractive targets for immunotherapy. However, a number of recent studies have 
challenged this concept, as depletion of host DC, LC and B cells all failed to prevent 
the development of GVHD in mice125–127. The depletion of host macrophages was even 
seen to increase the severity of GVHD128. Therefore, it remains unclear whether any 
particular APC subset has a non-redundant role in the development of acute GVHD 
with a recent study suggesting that non-haematopoietic APCs, which are capable of 
expressing MHC Class II and stimulatory molecules, are the most potent inducers of 
GVHD by 100- to 1000- fold compared to host and donor haematopoietic APC129. 
Another study was able to demonstrate CD8-mediated GVHD in a MHC-matched, 
minor H mismatched model of GVHD when antigen presentation by host and donor 
haematopoietic APC were unable to present antigen130. However, the severity of GVHD 
was significantly less than that observed when both host and donor haematopoietic 
APC were capable of presenting antigen. 
The ligation of a TCR with its corresponding alloantigen presented by an APC alone is 
also insufficient to induce T cell activation131. T cells must also receive a ‘second signal’ 
mediated by co-stimulatory molecules on APC in order to proliferate, secrete cytokines 
and acquire effector functions91. This has been an area of intense research over the 
last two decades and co-stimulatory pathways from two main families are now known 
to deliver both positive and negative signals that are critical in the context of GVHD; the 
B7 family and the TNF receptor family56,132. The in vivo blockade of various positive co-
stimulatory molecules such as CD28, ICOS, CD40 and CD30 has been shown to 
mitigate GVHD in pre-clinical models while the blockade of inhibitory signals such as 
PD-1 and CTLA-4 exacerbated GVHD133–136. 
In MHC-matched, minor H antigen mismatched models of BMT, both CD4 and CD8 T 
cells can contribute to the development of acute GVHD in response to minor H 
antigens137. Once primed, alloreactive donor T cells rapidly proliferate and differentiate 
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into T-helper 1 (Th1), T-helper 2 (Th2), T-helper 17 (Th17) and CTL effector subsets56. 
The mechanisms behind the polarisation of T cell subsets in acute GVHD is not well 
understood, but it is believed to be largely dependent on the dominant cytokines 
produced at the time of activation in secondary lymphoid tissues136. For example, the 
development of Th1 type cells has been linked to IL-12 provided by APC whereas the 
development of Th2 type cells has been linked to IL-4138,139. However, the proliferation 
of donor T cell subsets is strongly linked to IL-2 secretion and many of the prophylactic 
inhibitors of GVHD, such as anti-calcineurin inhibitors, target this pathway109. Donor 
Th1 type cytokines (TNF-α, IFN-γ) are also strongly linked to the pathology associated 
with acute GVHD90. Interestingly, several studies in pre-clinical models have also 
shown that the development of acute GVHD is predominantly dependent on the 
priming of naïve (CD44low CD62Lhigh) rather than effector memory (CD44high CD62Llow) 
T cell subsets raising the possibility that depletion of naïve T cell subsets may mitigate 
GVHD without compromising immunity140,141. 
After undergoing a period of clonal expansion and differentiation, alloreactive donor T 
cells exit the secondary lymphoid tissues and traffic to peripheral organs through a 
combination of chemokine-receptor, selectin- and integrin-ligand interactions88,142. For 
example, activated CD8 T cells lose their expression of both CD62L and CCR7, which 
prevent them from entering lymph nodes, and upregulate their expression of P- and E- 
selectin ligands such as P-selectin glycoprotein ligand-1 (PSGL1) and CD44, enabling 
them to efficiently roll on inflamed endothelium expressing their counter-receptors P- 
and E-selectin143. The secondary lymphoid environment can also ‘imprint’ T cells, fine-
tuning their homing potential to a particular tissue143. CD8 T cells in the mesenteric 
lymph nodes preferentially migrate to the gut, upregulating their expression of α4β7 and 
CCR9, while CD8 T cells in the peripheral lymph nodes preferentially migrate to the 
skin, upregulating their expression of CCR10 and E-selectin ligand144,145.  
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In response to damage associated with the conditioning regime, chemokine gradients 
are established in peripheral tissues which mediate the arrest and subsequent 
migration of activated T cells into the tissue. In the skin, the IFN-γ inducible CXCL9 and 
CXCL10 are expressed in high levels in mice within the first week of transplant. The 
importance of this chemokine gradient for CD8 T cell infiltration into the skin has 
recently been described. In a model of cutaneous GVHD, CD8 T cells from CXCR3 
knockout (KO) mice were found to migrate in significantly fewer numbers to the skin 
than CD8 T cells from WT controls in response to CXCL9 and CXCL10 signalling, 
despite CD8 T cells from CXCR3KO mice retaining full activation and effector 
functions146. 
At the end of the activation phase, alloreactive donor T cells are primed, have 
undergone clonal expansion and have begun to infiltrate peripheral tissues such as the 
skin to begin the effector phase. For years, host APC were an attractive target for novel 
therapies due to their central role in the initiation of GVHD. However, their overall 
contribution has been called into question in recent years by a number of studies. Much 
of the research to date has focused on the role of APC in priming the T cell response. 
However, one area that is less clear is the role of infiltrating and tissue resident APC in 
the development of GVHD pathology. Such organ specific interactions with alloreactive 
donor T cells would make attractive targets for immunosuppression, as it may not 
interfere with the therapeutic benefits of GVL69.  
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Figure 12: Antigen presentation by professional antigen-presenting cells in MHC-matched, minor H 
mismatched GVHD. A. Endogenous proteins can be directly presented to donor CD8 T cells via MHC 
Class I after being degraded by the proteasome in recipient antigen-presenting cells (APC). The 
allopeptides are loaded onto MHC Class I molecules after being pumped into the endoplasmic reticulum 
by the transporter associated with antigen processing (TAP). The MHC Class I molecule coupled with 
allopeptide is then exported to the cell surface where they present antigen to donor CD8 T cells (Direct 
Presentation). Exogenous proteins are typically degraded by lysosomal proteolysis in endosomes before 
being loaded onto MHC Class II molecules. The MHC Class II coupled with peptide is loaded on to the 
surface ready for presentation to donor CD4 T cells (Indirect Presentation). Allopeptides derived from 
endogenous proteins may also be loaded onto MHC Class II molecules and presented to donor CD4 T 
cells (Direct Presentation). Recipient APC can also cross-present exogenously acquired antigens on MHC 
Class I molecules by retrotranslocation from phagosomes.  B. After the initiation phase, donor APCs can 
present exogenous alloantigens via MHC Class II (Indirect Presentation). Donor APC can also activate 
donor CD8 T cells by cross-presenting exogenous antigen (uptake of apoptotic recipient cells or shed 
proteins) via MHC Class I (Indirect Presentation). Reprinted with permission from Nature Reviews 
Immunology4. 
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1.2.3.3 Step 3: Development of acute GVHD via target tissue apoptosis 
The effector phase of acute GVHD begins with the development of end-organ damage 
in the skin, gut and liver mediated by a complex cascade of cellular effectors (CTLs, 
NK cells) and inflammatory cytokines (TNF-, IL-1, IL-6) that work synergistically to 
amplify the effects of one another56. Inflammatory cytokines can induce target tissue 
apoptosis without any cognate interaction, while cellular effectors require a cognate 
interaction (TCR:MHC Class I) to mediate killing4. Once fully initiated, acute GVHD is 
difficult to control as damage to host tissues perpetuates the disease, leading to further 
inflammation and the recruitment of even more effector cells that further augment the 
disease112. 
CTL are the main cellular effectors in acute GVHD, although NK cells can also 
contribute to the pathogenesis147. They require cognate interactions and mediate target 
cell apoptosis primarily via the perforin/granzyme and Fas/Fas Ligand (FasL) pathways 
(Figure 13)91,147–149. TNFR-like death receptors (DF), such as TNF-related apoptosis 
inducing ligand (TRAIL) and TNF-like weak inducers of apoptosis (TWEAK), can also 
play a role91. 
Using the granzyme/perforin pathway, CTLs secrete cytotoxic granules containing 
perforin and granzyme upon the cognate recognition of allopeptide bound to MHC 
Class I on a target cell. The secretion of perforin forms ‘pores’ on the membrane that 
facilitates the entry of granzyme into the cell, which mediates target cell apoptosis 
through the activation of a caspase signalling cascade147,150.  
The slower acting Fas/FasL pathway, involves the transmembrane protein FasL on 
CTLs binding the cell death surface receptor Fas on target cells. Upon binding FasL, 
the Fas receptor trimerises, leading to the formation of the death-inducing signalling-
complex (DISC), which mediates target cell apoptosis again through the activation of a 
caspase signalling cascade151,152. The expression of Fas is upregulated in GVHD target 
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organs by inflammatory cytokines such as IFN-γ and TNF-α and the Fas/FasL pathway 
is an important effector pathway in GVHD91,153. 
The involvement of each of these pathways has been studied extensively in pre-clinical 
models of GVHD using genetically modified donor CD8 T cells deficient in each 
pathway. CD8 CTLs preferentially use the fast-acting perforin/granzyme pathway 
although the Fas/FasL pathway is important for the development of GVHD in the liver 
where Fas is expressed in high levels by hepatocytes56,154,155. CD4 CTLs preferentially 
use the Fas/FasL pathway154. However, the development of acute GVHD is not 
dependant on any particular pathway. In both MHC-mismatched and MHC-matched, 
minor H mismatched models of GVHD, transfer of perforin deficient T cells following 
transplant induced lethal GVHD albeit with delayed kinetics156,157. Similarly, when FasL 
deficient T cells were transferred across MHC-matched, minor H antigen mismatched 
models, lethal GVHD was induced although the severity was reduced in both the skin 
and liver158. 
In synergy with the cytolytic effects of CTLs are inflammatory effectors such as TNF-α, 
IL-1, IL-6, IL-12 and nitric oxide (NO), which amplify the levels of target tissue 
destruction and do not require cell-to-cell contact to mediate killing91. The expression of 
TNF-α and IL-1 in particular, which can be expressed by an abundance of cells 
involved in both innate and adaptive immunity, are strongly linked with the development 
of the ‘cytokine storm’ and subsequent tissue injury associated with acute GVHD87. 
The involvement of TNF-α was first recognised almost 30 years ago when damaged 
tissue in the skin, gut and liver of mice receiving allogeneic BMT was found to express 
high levels of TNF-α mRNA159. Pharmaceutical blockade of the TNF-α pathway further 
highlighted the importance of this pathway in acute GVHD, when mice receiving either 
anti-TNF-α monoclonal antibodies (Ab) or soluble TNF-α receptor developed 
significantly less pathology91,160,161. In the clinic, genetic polymorphisms associated with 
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an increase in the production of TNF-α by donor cells or heightened response by 
recipient cells to TNF-α were also found to increase the risk of GVHD developing162,163. 
The release of TNF-α by Th1 T cells and activated monocytes/macrophages promotes 
the development of acute GVHD in a number of different ways. It promotes the 
maturation of APC such as tissue resident DC, enhancing antigen presentation and co-
stimulation of donor T cells164. It also promotes the expression of pro-inflammatory 
chemokines enhancing the recruitment of effector cells to the site of inflammation90. 
Finally, it can directly cause tissue damage by the induction of apoptosis and 
necrosis165. 
However, the precise effect of individual cytokines is difficult to predict as the timing, 
concentration and site of expression can either attenuate or amplify acute GVHD, as is 
the case with IFN-γ which appears to have a complex, dichotomous role in allogeneic 
BMT155,166,167. IFN-γ can be secreted by a wide variety of cells (Th1, CD8 CTLs, NK 
cells) and mediates a multitude of pro-inflammatory responses during the development 
of acute GHVD. However, the impact of IFN-γ appears to rely strongly on the timing of 
its production166. IFN-γ can have immunosuppressive effects immediately after 
transplant, but can also contribute to the pathogenesis of acute GVHD via its 
inflammatory properties at later stages112. In pre-clinical mouse models, the 
administration of high-dose IFN-γ or IL-12 (which stimulates the production of IFN-γ) 
immediately after BMT mediates a protective effect against acute GVHD168,169. 
However, the timing of this is critical as the administration of exogenous IFN-γ 3 days 
after transplant resulted in a substantial increase in GVHD-related mortality. 
Interestingly, transplanting lethally irradiated mice with T cells deficient in IFN-γ 
increased the severity of GVHD that developed, highlighting the complex role of 
cytokines in regulating acute GVHD170,171. 
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Other immune cells that have an involvement in the effector phase of acute GVHD 
include neutrophils, NK cells, macrophages and B cells. Macrophages, which are 
primed in response to IFN-γ signalling by Th1 and CTLs, co-localise with T cells and 
can contribute to acute GVHD by secreting NO, which can impair the repair of 
damaged epithelial tissues by inhibiting stem cell proliferation172. Macrophages can 
also secrete the pro-inflammatory cytokines TNF-α and IL-1 in response to a secondary 
stimulus such as LPS following the translocation of bacteria through the disrupted 
epithelial barrier in the gut lumen173,174. Neutrophils can also enhance the severity of 
GVHD and are rapidly recruited to peripheral tissues such as the gut where they 
promote inflammation and T cell activation in response to TLR-signalling by microbial 
flora86. In humans, the severity of GVHD in the intestine strongly correlated with the 
level of neutrophils in lesions175. The physical or genetic deletion of neutrophils was 
found to significantly reduce the GVHD-related mortality that developed in pre-clinical 
models175.  
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Figure 13: Mechanisms of tissue injury by alloreactive donor T cells in peripheral tissues. Activated 
alloreactive donor CD8 cytotoxic T lymphocytes (CTLs) require direct cognate interactions with MHC-Class 
I on non-haematopoietic cells in tissues such as skin, gut and liver to mediate damage. CTLs primarily kill 
target cells through one of two pathways. The Fas/Fas Ligand (CD95/CD95L) pathway involves the 
transmembrane protein FasL (CD95L) on CTLs binding the cell death surface receptor Fas (CD95) leading 
to the formation of the death-inducing signalling complex and apoptosis. In the perforin/granzyme pathway, 
CTLs secrete cytotoxic granules containing perforin and granzyme, which leads to the activation of a 
caspase-signalling cascade inducing apoptosis in target cells. In contrast, graft-versus-host-disease 
(GVHD) mediated by infiltrating CD4 T cells (Th1, Th2, Th17) does not require any cognate interaction 
with MHC-Class II on non-haematopoietic cells to induce target tissue apoptosis. The secretion of pro-
inflammatory cytokines such as TNF-α, IL-1 and IFN-γ by Th1 cells can amplify the inflammatory response 
and lead to the recruitment of more effector cells augmenting the GVHD. Reprinted with permission from 
Nature Reviews Immunology4. 
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1.2.4 Pre-clinical models of graft-versus-host-disease 
1.2.4.1 Advantages and disadvantages of the mouse as a pre-clinical model of GVHD 
Historically, the mouse has been an invaluable tool that has allowed many of the 
fundamental mechanisms of the human immune system to be elucidated. This is 
particularly true for BMT, where studies using mice led to the identification of the 
haematopoietic stem cell and the major histocompatibility complex, discoveries that 
underpin the biology behind transplants used in the clinic today7,8,176. GVHD was also 
demonstrated in mice first and the seminal studies by Korngold and Sprent were the 
first to confirm the dependence of GVHD on T cells18,177–179. 
The mouse remains the primary pre-clinical model used in the lab today to dissect the 
molecular mechanisms of GVHD, although the use of dogs has provided investigators 
with significant insights into the prevention and therapy of GVHD109,112,180,181. However, 
the mouse model has a number of advantages over other pre-clinical models109,112: 
1. Highly controlled background: Mice are highly inbred. The genetic background 
and degree of MHC-disparity, which drives the pathogenesis of GVHD, can be 
strictly controlled. The environmental conditions such as the conditioning 
regime and microflora in the gut can also be controlled enhancing the scientific 
rigor of experiments. 
2. High number of replicates: Mice have a short gestation period and large litters 
that can be housed in a relatively small amount of space. This allows 
researchers to conduct experiments using a high number of replicates, reducing 
the variance between observations. 
3. Genetically modified strains: There is a large number of genetically modified 
strains available which allows researchers to test the role of key immune 
molecules or specific cell subsets in various models of GVHD. For example, the 
role of dendritic cells such as LC can be tested using conditional depletion 
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models such as the Langerin-DTR mice. The short gestation period and large 
litter of mice also makes it easier to generate new transgenic lines than other 
pre-clinical models. 
4. Abundance of reagents and techniques: The extensive use of mice in the lab 
over the last 70 years has lead to a plethora of commercially available reagents. 
This can be extremely limiting in other pre-clinical models. For example, a quick 
search for anti-MHC Ab in the eBioscience catalogue (www.ebioscience.com) 
returns 64 anti-mouse Ab compared to just 2 anti-dog Ab. The immune 
response can also be imaged in real time using techniques such as intravital 
microscopy. 
5. Relatively low cost: Compared to the cost of other pre-clinical models such as 
primates and dogs, mice are relatively cheap. 
The main limitation of mouse models is their lack of genetic diversity109,180. Humans are 
genetically diverse and at the time of transplant vary in their age, disease state and 
range of immunomodulatory therapies they have received so far. This can have a 
fundamental impact on the type of GVHD that develops. Humans are also 
immunosuppressed after transplant using methotrexate and anti-calcineurin 
inhibitors182. These are rarely used in mouse models and the pathways involved in the 
pathogenesis of acute GVHD in mice may not be relevant in the clinical setting109. The 
development of mouse models of chronic GVHD that recapitulates all of the diverse 
characteristics associated with the disease has also proven difficult112.  
The majority of transplant models in the mouse also use TBI as the sole conditioning 
regime due to the difficultly in obtaining myeloablative chemotherapy drugs109,129. This 
contrasts the clinic where patients are predominantly treated with chemotherapy, with 
many transplant centres moving away from the use of TBI altogether109.  
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In addition, although mice and humans are similar on a genetic level (>95%), slight 
differences have emerged in their immune systems over 65 million years of 
evolution183. For example, endothelial cells in both mice and humans express MHC 
Class I. However, endothelial cells in humans also express MHC Class II whereas 
endothelial cells in mice do not184. Differences like these can confound findings that are 
translated from pre-clinical models into humans and the literature is littered with 
examples of promising drugs that showed therapeutic effects in animals but failed to 
show any in humans. It is worth considering these differences when translating any 
discovery from a pre-clinical model in the lab to the clinic.  
Nonetheless, the primary limitation of mouse models is also one of their strengths and 
as a reductionist model, the mouse remains an invaluable tool with many of the 
fundamental mechanisms in immunology largely conserved between the two 
species183. However, dogs remain an important pre-clinical model to validate the 
therapeutic efficacy of findings made in mice109. 
Mouse models of GVHD can be broadly subdivided into two categories based on the 
antigen driving the response; MHC-mismatched or MHC-matched, minor H antigen 
mismatched models of GVHD91. 
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1.2.4.2 MHC-mismatched and MHC-matched, minor H mismatched models of GVHD 
The majority of acute GVHD models in mice involve the transfer of T cell depleted 
(TCD) bone marrow from allogeneic donors supplemented with a defined number of 
donor T cells into lethally irradiated mice181. The bone marrow provides the stem cells 
required to reconstitute haematopoiesis after irradiation, preventing the mice from 
dying of bone marrow aplasia. T cells are normally depleted from the bone marrow 
graft in order to control the number and phenotype of donor T cells that are transferred. 
This can have a profound effect on the severity of acute GVHD, as the higher the 
number of donor T cells transferred, the greater the severity of GVHD that 
develops19,179. 
Mouse models of GVHD can be broadly subdivided into two categories based on the 
antigen driving the response; MHC-mismatched (Class I, Class II or both) or MHC-
matched, minor H antigen mismatched models of GVHD91. Disparity in MHC (referred 
to as H-2 in mice) molecules is a key determinant of the severity of the GVHD that 
develops181.  
In models that are fully MHC-mismatched, the GVHD that develops is primarily CD4 T 
cell dependant and characterised by cytokine dysregulation and Th1 differentiation, 
although CD8 T cells do contribute to the pathology of the disease91,117. One of the 
most commonly used models of acute GVHD is the BL/6 (H-2b) → BALB/c (H-2d) 
strain combination, where BL/6 mice act as the donor and BALB/c mice as the 
recipient. BALB/c mice are transplanted with a combination of TCD BM and 0.5-2.0 
x106 splenocytes derived from a BL/6 donor185. This is sufficient to induce system and 
lethal GVHD between 10 and 21 days after transplant depending on the number of 
splenocytes transplanted181. Incorporating transgenic strains such as B6.C-H2bm1 (MHC 
Class I-/-) and B6.C-H2Bm12 (MHC Class II-/-) into these models of acute GVHD has 
proven to be incredibly useful, enabling investigators to dissect the fundamental 
immunological mechanisms that underpin the pathogenesis of acute GVHD in vivo186.  
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In MHC-matched, minor H mismatched models of GVHD, either donor CD8 T cells, 
CD4 T cells or both can be involved depending on the strain combination involved91. 
Since the majority of transplants in the clinic are HLA-matched, these models more 
closely reflect what occurs in the clinic and are associated with less morbidity than 
MHC-mismatched models180,181. 
One of the limitations of MHC-matched, minor H antigen mismatched models of GVHD 
is that it is difficult to know which alloantigen donor T cells are responding to. To 
address this, many models now use transgenic T cells that have a TCR with a defined 
specificity, usually to a single peptide epitope. This reduces the effect of bystander T 
cell activation as a result of the conditioning regime and allows the response to specific 
antigen to be closely tracked in vivo181. Using TCR transgenic T cells, the role of 
antigen affinity during acute GVHD was characterised using 2C TCR Tg T cells and 
more recently the role of host haematopoietic APC during H-Y mismatched GVHD 
using CD8 MataHari Tg T cells, which recognise a Y-chromosome derived peptide from 
the Uty gene130,187–189. These models have also been used to induce organ specific 
GVHD, where OT-1 CD8 T cells, which bear a TCR specific for ovalbumin peptide, 
transferred into K14-mOVA transgenic mouse, where keratinocytes constitutively 
express ovalbumin (OVA) peptide, induces skin specific GVHD190. 
The severity of acute GVHD that develops in mice is also dependant on a number of 
other factors91,181:  
1. Radiation dose: The majority of models use TBI for conditioning. Several 
studies have now shown that the higher the dose of irradiation used the greater 
the degree of tissue damage that develops191,192. This results in a more intense 
‘cytokine storm’ which is directly related to the severity of acute GVHD that 
develops. As a general rule, models that receive a myeloablative dose greater 
than 11 Gy require a split dose in order to reduce the gut toxicity associated 
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with the conditioning regime181. Different strains are also more sensitive to 
radiation than others and the maximally tolerated TBI or the dose that is 
myeloablative differs between strains (BALB/c>C57BL/6)91. In addition, F1 
progeny are more resistant than parental strains (C57BL/6>F1)91. 
2. Dose and phenotype of donor T cells: The dose of donor T cells transferred into 
mice is directly proportional to the severity of GVHD that develops. In mice that 
receive TCD bone marrow alone, no acute GVHD will develop even across 
MHC-mismatches. The phenotype of T cells transferred into recipient mice is 
also important. In general, supplementing the bone marrow graft with 
alloreactive donor CD4 T cells will result in a higher GVHD-related mortality 
than that caused by the transfer of the equivalent number of alloreactive donor 
CD8 T cells130,186,193. The transfer of CD44high memory T cells or regulatory T 
cells (TReg) versus CD44low naïve T cells will also result in significantly less 
GVHD140,194,195. 
3. Environmental factors: The composition of the gut microflora can have a 
significant impact on the severity of GVHD. Mice kept under ‘germ-free’ 
conditions tend to be relatively resistant to acute GVHD, and gut 
decontamination using antibiotics can also reduce the severity of GVHD108,196. 
The difference in environmental pathogens between labs and suppliers can also 
introduce variance into acute GVHD models181,197.  
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1.3 The relationship between antigen presenting cells and T cells 
1.3.1 APC and T cell priming 
To initiate acute GVHD, alloreactive T cells need to be primed. This is no easy task, 
given that the estimated precursor frequency for donor T cells specific for minor H 
antigens is between 1 in 105 and 1 in 106 and a single T cell occupies only one 
hundred-trillionth of the volume of the human body70,198. Yet, these T cells are still 
sufficient to drive acute GVHD in around 70% of patients undergoing allogeneic BMT52. 
Central to the development of acute GVHD are APC, which stimulate T cells to 
proliferate and differentiate into the effector cell subsets responsible for the tissue 
damage associated with acute GVHD. 
APCs can be divided into two categories, haematopoietic and non-haematopoietic 
APC. Haematopoietic APC broadly include DC, macrophages, B cells and basophils69. 
Many of these cells are considered ‘professional APC’, cells that specialise in the 
uptake and presentation of exogenous antigen to lymphocytes via MHC Class I or 
Class II199. Non-haematopoietic APC include stromal cells in the lymphoid tissue and 
mesenchymal cells such as fibroblasts, myofibroblasts and pericytes found in the 
gut200. In response to inflammatory stimuli such as IFN-γ or TBI, these cells can 
upregulate their expression of MHC Class II and co-stimulatory molecules such as 
CD40, CD80 and CD86 and are capable of priming potent T cell responses to 
exogenous antigens129,200–202. 
Both haematopoietic and non-haematopoietic APC are capable of initiating acute 
GVHD. However, whether any specific population of APC has a non-redundant role in 
initiating GVHD remains controversial as depletion of DC, LC and B cells failed to 
prevent GVHD in pre-clinical models125–127. Non-haematopoietic APC can also replace 
the role of haematopoietic APC when antigen presentation is restricted in CD4-
mediated GVHD129.   
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To frame a discussion around the role of APC in GVHD, it is useful to consider their 
interactions with T cells from the perspective of a pathogen response. Among all APC 
subsets, DC are the most efficacious at priming naïve T cell responses in vivo164. 
Consistent with this and in the context of GVHD, in an MHC-mismatched transplant 
model where recipient mice were MHC Class II-/-, the infusion of WT splenic DC was 
sufficient to induce GVHD when other APC subsets were incapable of presenting 
antigen123. 
DC are a heterogeneous population of bone marrow derived cells involved in the 
induction and regulation of adaptive immune responses93. First described in 1868, the 
contribution of DC to immunity was not fully appreciated until 1973 when Steinman and 
Cohn demonstrated that splenic DC in mice are key activators of adaptive immunity203. 
The importance of DC to T cell responses has been further highlighted using mouse 
models where conventional DC (cDC) are constitutively absent or conditionally 
depleted. In the absence of cDC, mice show diminished anti-viral, anti-bacterial and 
anti-tumour immune responses204–206. 
Although there are many different subsets, all DC are efficient antigen presenting cells 
and there are three specialised features that drive their capacity to promote immune 
responses93. Firstly, DC are widely disseminated throughout the body with many 
tissues such as the lung, gut and skin seeded with distinct subsets of DC that can 
migrate to local lymphoid organs207–209. This elegant sampling system exposes the 
adaptive arm of the immune system (T and B cells) to a diverse array of antigen 
increasing the chances of a rare T-cell clone encountering its target antigen. 
Secondly, DC are equipped with a highly efficient endocytic system dedicated to the 
efficient capture, processing and presentation of antigen to lymphocytes210,211. In the 
steady state, “immature” DC in peripheral tissues specialise in the uptake of antigen via 
phagocytosis, macropinocytosis or adsorptive pinocytosis93. These antigens, usually in 
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the form of proteins, are enzymatically digested into immunogenic peptides and 
subsequently bound to MHC class I or class II molecules. Endogenous peptides are 
loaded onto MHC Class I promoting CD8+ T cell responses whereas exogenous 
peptides are loaded on to MHC Class II promoting CD4+ T cell responses (Figure 
12)212. Certain subsets of DC can also “cross-present” antigen, a process first 
described by Bevan, whereby antigen synthesised in one cell can be captured 
exogenously and processed via the MHC class I pathway213. The cross-presentation 
pathway involves transfer of exogenously acquired antigens from the endosome to the 
cytosol, where they are subsequently trimmed by the proteasome, transported into the 
endoplasmic reticulum through the TAP complex and loaded onto MHC Class I 
molecules, similar to endogenous antigens214. This is an essential pathway for inducing 
CTL responses to viruses and intracellular bacteria that do not normally infect APC215. 
However, this also appears to be a restricted process, with DC by far the most efficient 
APC subset in terms of cross-presentation capabilities. For instance, CD8+ DC appear 
to be especially efficient at the cross-presentation of antigen relative to CD8- DC, and 
are equipped with specialised machinery to control endosomal maturation and 
acidification that make them efficient at transporting antigens into the cytosol216–218. 
Thirdly, DC are equipped with a variety of pattern recognition receptors, including Toll-
like receptors (TLRs) and lectins, conferring DC with enormous functional plasticity219. 
DC differentiate and mature in response to a variety of stimuli to generate an 
appropriate and targeted immune response164. This is an important step as DC exist in 
two functionally and phenotypically distinct states in vivo. Immature DC, which 
specialise in the uptake of antigen, are unable to stimulate T cells in vitro and induce 
peripheral tolerance in vivo220. Upon stimulation, a number of significant functional 
changes promoting migration and lymphocyte activation occur within a DC (Figure 14). 
The pH within endocytic vacuoles is lowered, activating proteolysis and the number of 
peptide-MHC complexes on the cell surface increases210. Co-stimulatory molecules 
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from the B7, TNF and Notch families begin to be expressed on the cell surface and 
immunostimulatory cytokines such as IL-12 and type 1 interferons are 
synthesised164,221. These ‘secondary signals’ are critical to the generation of a robust T 
cell response. In the steady state, DC laden with self-peptide migrate at low rates back 
to the draining lymph where they induce the deletion of autoreactive T cells and expand 
Treg populations due to the lack of co-stimulatory molecules and pro-inflammatory 
cytokine production93,222. 
Upon maturation, tissue-resident DC also become more motile, acquiring a phenotype 
that encourages their egress from the site of antigen uptake to secondary lymphoid 
tissues where they can interact with T cells223. In the skin, LC downregulate their 
expression of E-cadherin, a molecule that mediates their adhesion to keratinocytes, 
and upregulate their expression of the chemokine receptor CCR7 that allows their 
active and passive translocation from the skin to the T cell zone of skin draining lymph 
nodes (LN)223–225. In essence, DC maturation links innate and adaptive immune 
responses together.  
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Figure 14: Overview of the dendritic cell maturation process. DC can be activated by a variety of 
stimuli via their pathogen-associated molecular pattern and danger-associated molecular pattern 
receptors. Following activation, DC undergo a maturation and differentiation process that switches their 
cellular machinery from antigen uptake to antigen presentation, promoting a phenotype that induces their 
active and passive migration to secondary lymphoid organs. Figure adapted from concepts proposed by 
Professor Steinman93,164.  
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1.3.2 The role of tissue-resident APC in the peripheral regulation of T cells in situ  
It is well established that T cells are essential for immunity against a wide array of 
pathogens and that DC are key activators of this response. To date, the role of DC in 
immunity has primarily been focused on the priming stage of the response. The 
paradigm follows that DC egress from the site of infection or inflammation following 
activation through their PRR and migrate to peripheral lymph nodes (pLN) in order to 
elicit an adaptive immune response164. DC then deliver antigen to the TCR of naïve T 
cells and provide them with the necessary co-stimulation and cytokines to prime them. 
Following activation, these T cells then undergo a programmed response of expansion 
and differentiation, upregulating effector molecules (perforin/granzyme) and cytokines 
before migrating to peripheral tissues where they aid in the clearance of a pathogen226.  
After this initial encounter in the draining LN (dLN), it is widely believed that T cells 
require no further interactions with DC to mediate their effector functions. However, 
several studies have now challenged this notion, advancing the idea that DC within 
peripheral tissues can significantly modulate the effector T cell (Teff) response in situ, 
shifting the balance away from regulation towards immunity226,227.  
Although maturation is typically associated with the migration of DC out of peripheral 
tissues, significant numbers do remain in infected and inflamed tissues228. In a mouse 
model of influenza A (IA), tissue-resident rDC were found to become refractory to 
migration signals after a period of transient migration to the lung dLN, leaving a 
significant population of respiratory DC (rDC) in the lungs228. This phenomenon is not 
isolated to the lungs with a significant population of LC remaining in the inflamed 
epidermis in a model of acute GVHD229.  In addition, DC precursors are rapidly 
recruited to inflamed tissues where they rapidly replenish DC that have migrated to 
dLN. In models of herpes simplex virus (HSV) infection in the skin or IA infection in the 
lungs of mice, the number of DC present in the skin or lung after infection can far 
exceed that found in the steady state230,231. 
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The development of murine models where DC can be conditionally depleted has 
enabled investigators to examine their role in vivo more closely and there is increasing 
evidence that tissue-resident and infiltrating DC populations can directly mediate 
changes in the activation, effector function, localisation and memory response of 
infiltrating Teff cells in situ at the site of infection or inflammation226,227. 
Depleting a specific cell type such as LC in vivo is a useful way of ascribing a function-
based definition to a cell type, when its precise contribution to an immune response is 
unknown. There are two approaches commonly used to deplete cells in vivo, 
constitutive and conditional approaches. Given the multifaceted nature of DC and 
possible importance during development, inducible systems, such as the Diphtheria 
toxin receptor-Diphtheria toxin (DTR-DT) system, of conditional cell ablation have 
become a popular tool used to dissect the function of cells in vivo. Diphtheria toxin (DT) 
is a protein produced by Corynebacterium diphtheria, which once internalised inhibits 
protein synthesis via ADP-ribosylation causing cell death232. Taking advantage of 
rodent cells insensitivity to DT, the engineered expression of a human or simian DT 
receptor (DTR) by a particular cell type will render that cell susceptible to depletion by 
DT. However, other unmanipulated cell types will be unaffected upon exposure to 
DT233. This system is capable of depleting both non-dividing and terminally 
differentiated cells and has the added advantage of inducing cell death via apoptosis. 
A critical role for DC in situ has been particularly well described in a model of IA 
infection in the lungs of mice. During infection, naïve CD8 T cells are primed in the dLN 
and subsequently traffic to the lung to clear the infection. Interestingly, these activated 
CD8 T cells rapidly proliferate upon entry into the lung in a way that directly correlates 
with the increased migration of DC to the lung234. Tissue-resident rDC were also found 
to promote rapid memory CD8 T cell responses in situ following reinfection235. 
Importantly, these tissue-resident memory CD8 T cells were maintained and activated 
by rDC even in the absence of secondary lymphoid organs236.  
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However, the most interesting observations came from depletion models. Depleting 
respiratory DC (rDC) that remain in the lung 48 hr after infection with IA, by 
administering clodronate liposomes intranasally (i.n.), was also found to profoundly 
impair the CD8 T cell response in situ, resulting in increased mortality and viral titers237. 
In the absence of rDC, pathogen specific CD8 T cells did not proliferate or survive in 
situ in the lung and died via apoptosis237. Interestingly, this phenotype could be rescued 
by reconstituting infected lungs with pulmonary DC i.n. in a direct, MHC Class I 
dependent manner that was antigen specific and required co-stimulatory molecules (IL-
15 and CD28)237–239. Thus, after their initial activation in the dLN, activated CD8 T cells 
require an antigen specific signal for a second time, provided here by rDC, for full 
effector function in the lung.  
This observation and the proposed “two-hit” hypothesis where Teff cells require a 
second signal at the site of infection or inflammation has many implications. This 
phenomenon is also not isolated to CD8 T cells or the lung226,227. A similar observation 
has also been made in the mucosal tract of the vagina infected with HSV-2, where 
infiltrating CD11b+ CD11c+ inflammatory DC were required to elicit IFN-γ production by 
infiltrating CD4 T cells to mediate viral clearance240. In a model of atherosclerosis, DC 
localised in lesions express CCL17 which limited the expansion of Treg cells, 
enhancing disease241. 
In the liver, infiltrating CD11b+ CD11c+ inflammatory DC were observed to co-localise 
with CD8 T cells and are directly responsible for their proliferation in situ following 
lymphocytic choriomeningitis virus (LCMV) or hepatitis B virus (HBV) infection242. In 
these models of infection, DC:T cell interactions also required co-stimulation as 
pharmacological blockade of CD80, CD86 and OX40L on the surface of inflammatory 
DC prevented CD8 T cell proliferation242. In an experimental model of autoimmunity, 
CD4 T cells were shown to interact with kidney DC in situ in the liver to produce 
cytokines and recruit autoreactive CD8 T cells243. 
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Similarly, in the skin, the depletion of CD11bhigh dermal DC (dDC) impaired CD4 Teff 
responses in the skin244. CD11bhigh dDC were required to present antigen to CD4 Teff 
directly in the skin for full effector function, promoting IFN-γ secretion by Th1 type cells 
that impaired the expansion of Tregs244.  
It is clear from the number of recent studies that the role of DC in mediating T cell 
responses extends far beyond the initial priming event in the dLN. Tissue-resident DC 
can modulate both CD4 and CD8 Teff responses in a wide variety of tissues, and 
contribute to the activation, survival and memory response of these T cells226,245. In the 
context of acute GVHD, the role of tissue-resident and infiltrating APC, such as DC, 
outside of the initial priming response remains an area less well investigated. 
  
 85 
1.4 Langerhans cells and T cell-mediated immunopathology in the skin 
1.4.1 Immunopathology in the skin 
The skin is the largest organ in the body by surface area and is the primary interface 
between the body and the environment. Acting as a barrier to a variety of chemical, 
microbial and physical challenges, the skin has evolved a highly sophisticated system 
of immune surveillance and defense that maintains a finely tuned equilibrium209,246. One 
such feature is the rich and complex network of DC found in both the epidermis and 
dermis. 
DC play a key role maintaining immune homeostasis in the skin, where they facilitate a 
rapid and protective immune response to infections when required. However, the 
regulation of these responses is also critical as inappropriate or misdirected activity can 
lead to a variety of inflammatory skin disorders such as atopic and contact dermatitis 
and psoriasis247–249. Therapies to disease have also led to the development of new 
autoimmune disorders of the skin, with cutaneous GVHD after allogeneic BMT a 
detrimental side effect of an otherwise life-saving therapy247. 
The contribution of dysfunctional DC responses to the pathogenesis of autoimmune 
disorders in the skin has long been recognised250. DC can directly prime autoreactive T 
cells, secrete cytokines to enhance innate and adaptive immune responses and more 
recently, have been recognised to interact with autoreactive T cells in situ to maintain 
this response. In psoriatic lesions in the skin, high numbers of infiltrating CD11c+ DC 
expressing the inflammatory mediators TNF-α and inducible nitric oxide synthase 
(iNOS) directly damage tissue251. The pathogenesis of this expression profile to 
psoriasis is highlighted by the effectiveness of TNF-α blockers in ameliorating 
disease252. Delineating the regulatory and functional mechanisms of DC in situ in the 
skin may bring about an important therapeutic step to the treatment of acute and 
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chronic autoimmune disorders or to the enhancement of pathogen and tumour 
clearance.  
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1.4.2 Immunosurveillance in the skin: Langerhans cells 
LC are a population of DC found in the skin that form a dense interlacing network within 
the epidermis253. The only DC population found within the epidermis, they are 
characterised by their expression of the C-type lectin, Langerin, and presence of 
Birbeck granules in the cytoplasm253. Originally thought to be similar to most other non-
lymphoid cDC, LC are well equipped to efficiently capture, process and present antigen 
via MHC and migrate to the skin dLN upon maturation254. However, LC are now known 
to have a number of unique features that distinguishes them from other cDC found in 
the skin (dermis). 
Unlike dermal DC (dDC), which arise from pre-DC precursors from the bone marrow 
and are dependent on fms-like tyrosine kinase 3 ligand (Flt3L), LC are derived from 
yolk sac derived precursors and fetal liver monocytes that seed the skin before birth 
and differentiate in response to IL-34 secreted by keratinocytes255–257. LC also have the 
unique ability to maintain themselves in the epidermis throughout life by proliferating in 
situ, without any further input from bone marrow derived precursors258. Furthermore, 
LC were also found to be radioresistant and remain of host origin in the epidermis after 
lethally irradiated mice are reconstituted with congenic bone marrow, unlike 
radiosensitive DC in the dermis258. Taken together, it is hypothesized that this mode of 
replenishment by LC may constitute a unique adaption to the epidermis, which lacks a 
vascular system of its own and is separated from dermal blood vessels by the 
basement membrane, making their environment quite distinct from other DC found in 
the dermis259. 
Despite extensive research, the precise role of LC in vivo remains elusive with 
evidence supporting a role for LC in a number of functions that are both immunogenic 
and tolerogenic259. The development of new mouse models has stimulated LC research 
somewhat and yielded a number of new insights. Adapting the inducible DTR-DT 
system of conditional depletion to the field of LC, a simian DTR and enhanced green 
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fluorescent protein (EGFP) cassette was integrated into the Langerin gene to create 
the Langerin-DTR mouse260. This new model enabled LC to be conditionally depleted 
at any time with a single injection of DT without any apparent side effects enabling 
investigators to specifically test the role of LC in vivo260. 
Accounting for around 3-5% of all nucleated cells in the epidermis of both humans and 
mice, LC are tightly associated with keratinocytes via E-cadherin and are the first APC 
to encounter antigen in the skin254,259. This lead to the widespread belief by many 
investigators that LC were immunogenic and pivotal to the development of cutaneous 
immunity (“The LC Paradigm”). Initial in vitro studies supported this hypothesis, as 
matured LCs from both humans and mice were found to be intrinsically potent inducers 
of naïve T cells261,262. However, with the development of cell depletion models, doubts 
surrounding the immunodominance of LC in initiating cutaneous immunity in vivo 
began to emerge. 
The first study questioning their role came from a mouse model of HSV infection, when 
LC failed to prime virus-specific CTL in the skin dLN263. Similar observations were also 
made in a model of murine Leishmaniasis, where LC again failed to prime an immune 
response to a pathogen invading the skin264. 
Several recent studies have now demonstrated that LC can have immunosuppressive 
functions, suggesting a role for LC as negative regulators of cutaneous immunity that 
can inhibit T cell responses elicited by other DC in the skin. In a murine model of 
contact hypersensitivity (CHS), the acute ablation of LC was found to increase CHS in 
response to the topical application of low doses of haptens265. Revisiting the murine 
model of Leishmaniasis, the selective depletion of LC attenuated the disease, with a 
reduction in Treg infiltration and an enhanced Th1 response266. In an experimental 
model of allergic contact dermatitis in mice, LC conferred protection from the 
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development of CHS, dampening the pathogenic allergen-specific CD8 T cell response 
and promoting the expansion of Treg267. 
However, the roles ascribed to LC in vivo have not been entirely tolerogenic. Using a 
Candida albicans infection model, direct presentation of antigen by LC was required to 
generate antigen-specific Th17 cells268. Similarly, LC that sampled antigen through 
keratinocyte tight junctions by extending their dendrites were able to elicit humoral 
immunity to staphylococcal antigens that had not yet penetrated the skin269.  Thus, the 
role of LC in the skin can no longer be thought of as purely immunogenic and 
substantial controversy remains as to their precise function in vivo. 
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Figure 15: Depletion of Langerhans cells via the DTR-DT system in mice. A. Mouse cells are 103 to 
105 times more resistant to DT mediated apoptosis than human or simian cells, due to a mutation in the 
receptor that binds the DT-B subunit. The injection of DT i.p. into a WT BL/6 mouse has no effect on LC or 
Langerin+ dermal DC in vivo. B. A high affinity simian DTR was knocked into the Langerin gene that is 
expressed in LC and Langerin+ dDC cells rendering both populations sensitive to DT-mediated apoptosis. 
This was found to have no effect on the natural development of LC or Langerin+ dermal DC in vivo. After a 
single injection of 400 ng of DT i.p., both LC and Langerin+ dDC are efficiently depleted within 24 hr. The 
DT-B subunit binds the high affinity simian receptor and facilitates the entry of the DT-A subunit into the 
cell that inhibits protein synthesis by ADP-ribosylation, inducing apoptosis. Reprinted with permission from 
Trends in Immunology270. 
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1.4.3 Immunosurveillance in the skin: Langerin+ dermal dendritic cells 
The remarkable heterogeneity and functional plasticity of DC has long been recognised 
and the skin is no different271. Finding a role for LC in vivo became even more complex 
with the discovery of a novel Langerin expressing DC population in the dermis of mice, 
the aptly named Langerin+ dDC272–274. An unexpected finding, Langerin+ were first 
identified when a Langerin+ population was seen to rapidly repopulate the dermis (<7 
days) shortly after LC depletion in the Langerin-DTR mouse275. This was an unusual 
observation as LC were not normally found in the skin less than 6 weeks after 
depletion. Once thought to be migrating LC, Langerin+ dDC are now known to be 
distinct subset of DC in mice. In contrast to LC, they develop independently of TGFβ1, 
exhibit differential expression of both EpCAM and CD11b, express CD103 and have 
dissimilar repopulation and migratory kinetics275,276. 
In terms of function, Langerin+ dDC appear to be highly immunogenic253,259. Refining 
the HSV-1 skin infection model, Langerin+ CD103+ dDC were the only migratory subset 
of DC from the skin to efficiently present HSV-1 antigens to naïve CD8 T cells, 
although all subsets presented HSV-1 antigens to CD4 T cells277. In the same study, 
Langerin+ CD103+ dDC were also shown to efficiently cross-present skin derived self-
antigens277. Similarly, using K5.mOVA mice that express OVA peptide in the epidermis, 
Langerin+ dDC excelled in the cross-presentation of antigen to OT-I T cells, irrespective 
of the presence or absence of LC276. Using a Candida albicans model, Langerin+ 
CD103+ dDC were also required for the generation of a Th1 type response and 
inhibited the ability of LC and other DC to promote Th17 type responses268. 
Langerin+ CD103+ dDC are now purported to be the main cross-presenting APC in the 
skin in terms of CD8 T cell immunity276,278. The potency of Langerin+ dDC in these 
responses is remarkable as they account for less than 5% of DC in the dermis254. A 
homologue to the Langerin+ dDC has now been found in the skin of humans and 
similar Langerin+ dDC like subsets of DC have now been found in the liver, lung and 
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kidney, yet their precise function remains poorly studied in vivo272,279,280. However, in 
the lung, a Langerin+ DC has been shown to be essential in the clearance of influenza 
in mice231.  
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1.5 Project Rationale 
1.5.1 A role for Langerhans cells in regulating cutaneous GVHD? 
LC are radioresistant in both humans and mice and have been found to persist in skin 
allografts years after transplant through continuous in situ proliferation258. In the context 
of allogeneic BMT, a recent study observed a significant delay in the engraftment of 
donor LC in patients that receive non-myeloablative conditioning compared to patients 
that receive myeloablative conditioning and full donor LC chimerism was only reached 
84 days after transplant281. Recipient LC were able to proliferate in situ, indicating they 
remained viable and capable of maturation for a significant period of time after non-
myeloablative transplant.  
This feature along with the immunogenic nature of host APC in the initiation of acute 
GVHD make LC of interest to transplant clinicians. Elegant bone marrow chimera 
experiments, exploiting LC radioresistance, have already shown that LC are capable of 
initiating GVHD-like lesions in the skin under circumstances where all other DC subsets 
in the skin are incapable of antigen presentation282. This suggested that host LC 
directly interacted with alloreactive donor T cells in the skin, dLN or both. However, in 
the presence of other DC subsets in the skin, LC were found to be redundant with 
systemic CD8- and CD4-mediated GVHD developing in a pre-clinical mouse model in 
the presence or absence of both donor and host LC126. 
An area less well investigated is the role of tissue-resident APC populations in GVHD 
target organs after alloreactive donor T cells are primed. Previous work in our lab 
showed that an inflammatory checkpoint operates in the skin that is critical to the 
recruitment and function of effector cells283. In this model, topical application of the TLR 
7-8 agonist Imiquimod to the skin of established MHC-mismatched mixed chimeras 
(where donor and host haematopoietic cells co-exist) at the time of allogeneic donor T 
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cell transfer, induces the recruitment of alloreactive CD8 T cells to the epidermis and 
development of localised cutaneous GVHD.  
To assess whether host LC have a role regulating this checkpoint when other DC 
populations are present, we adapted the model of localised cutaneous inflammation 
described above to Langerin-DTR mice, enabling us to specifically deplete host LC 
upon a single injection of DT229. Interestingly, in the absence of host LC, mice 
developed significantly less GVHD in the skin as evidenced by histopathological 
scoring229. The absence of host LC had no effect on the priming or number of 
alloreactive T cells found in skin draining lymph nodes, nor was the homing ability of 
CD8 T cells to the epidermis impaired. However, the capacity of CD8 T cells, recruited 
to the epidermis, to induce localised GVHD was impaired. When infiltrating T cells were 
purified from the epidermis, the expression of a number of key effector molecules such 
as IFN-γ, TNF-α and TRAIL were significantly reduced in the absence of host LC.  
This study described a new regulatory role for LC in the skin, where primed infiltrating 
CD8 T cells required a “second-hit” for full effector function229. Whether this interaction 
in situ has a role in the development of cutaneous GVHD in a model of acute GVHD 
remains to be determined. Haematopoietic APC subsets appear to be dispensable in 
the context of priming GVHD. However, given the number of recent reports expanding 
the role of DC beyond T cell priming in the dLN, it is worth investigating the role of 
tissue-resident APC in the development of organ specific pathology in pre-clinical 
models of acute GVHD. The identification of cell subsets that are critical for this 
response could lead to the development of novel targets for organ specific 
immunosuppression that may not interfere with the beneficial effects of systemic GVL. 
Hypothesis: Host Langerin+ DC are required for the development of cutaneous GVHD. 
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1.5.2 Aims & Objectives 
The primary aim of my project was to investigate the nature of DC:T cell interactions in 
the skin, using GVHD as a model of immune pathology. Dissecting the nature of these 
interactions could lead to the identification of novel skin-specific targets for 
immunosuppression without compromising the therapeutic benefits of GVL. To date, 
the role of LC in GVHD remains controversial and the contribution of other DC 
populations in the skin, such as Langerin+ dDC, remains unclear. To address these 
questions, I developed three objectives: 
1. The first objective of the project was to investigate the role of LC and Langerin+ 
dDC in an established MHC-mismatched model of BMT. Our lab has already 
identified a role for host LC in this model229, therefore I investigated whether 
host Langerin+ dDC were required for cutaneous GVHD in this model.  
2. The second objective of the project was to investigate the role of LC and 
Langerin+ dDC in a MHC-matched, minor H antigen mismatch model of GVHD. 
This type of model more accurately reflects what happens in the clinic as the 
majority of allogeneic transplants are HLA-matched. However, minor H antigens 
are still capable of inducing GVHD and recipients of sex-mismatched grafts are 
known to have a poorer outcome than those that receive grafts that are sex-
matched284. To accomplish this, I developed a minor H antigen-mismatched 
transplant model in the lab, using sex mismatched transplants (F→M) and 
transgenic (Tg) T cells specific for H-Y peptide to induce GVHD.  
3. The third objective of the project was to further explore the nature of LC and T 
cell interactions in the skin. To this end, I developed a model whereby LC could 
be locally depleted in situ to investigate whether LC were required directly in the 
skin for GVHD. I also sorted LC and T cells from the epidermis and dermis of 
transplanted mice (F→M) to investigate differences in gene expression in the 
presence or absence of host LC. 
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2 Materials and Methods 
2.1 Antibodies 
Anti-CD103 (M290), anti-CD11c (HL3), anti-CD45.2 (104) anti-CD8α (53-6.7), anti-
H2Dd (34-2-12), anti-H2Kb (AFC-88.5), anti-Vβ8.3 (1B3.3) and anti-IFNγ (XMG1.2) 
were purchased from BD Bioscience (USA). Anti-CD11b (M1/70), anti-CD24 (M1/69), 
anti-CD4 (GK1.5), anti-CD44 (IM7), andti-CD45.1 (A20) anti-CD62L (MEL-14), anti-
CD8β (H35-17.2), anti-EpCAM (G8.8), anti-MHCII (M5114.15.2), anti-Thy1.1 (HIS51) 
and anti-γδ (eBioGL3) were purchased from eBioscience (USA). Anti-CD86 (RMMP-1) 
was purchased from Immunotech (Beckman Coulter, USA). Detection of biotinylated 
antibodies was performed using APC, FITC, PE and PerCp-Cy.5.5 conjugated to 
streptavidin (BD Bioscience, Germany). More recently, eFluor450 conjugated to 
streptavidin was used (eBioscience, USA). Intracellular staining of Langerin (CD207) 
was performed using BD’s Cytofix/CytopermTM fixation/permeabilisation solution kit 
(BD Bioscience, Germany) in conjunction with an anti-CD207 PE (eBioL31) antibody 
purchased from eBioscience. 
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2.2 Animals 
C57BL/6 and BALB/c mice were purchased from Charles River Laboratories (Margate, 
UK) and bred in house by UCL Biological Services (Royal Free Hospital, UK). 
BALB/c.PL-ThyaCy (Thy1.1) mice were purchased from The Jackson Laboratory (Bay 
Harbour, USA) and bred in house. Langerin.DTREGFP (Langerin-DTR) mice were 
kindly provided by Bernard Malissen and Adrien Kissenpfennig (Université de la 
Mediterrannée, France) and bred in house. H-Y TCR transgenic MataHari mice were 
kindly provided by Jian Chai (Imperial College London, UK) and bred in house. Mice 
used as recipients for BMT were between 10 and 20 weeks old. Mice used as donors 
were between 8 and 20 weeks old. All procedures were conducted in accordance with 
the United Kingdom Home Office Animals (Scientific Procedure) Act of 1986. The 
present experiments were reviewed and approved by the Ethics and Welfare 
Committee of the Comparative Biology Unit, Royal Free and University College London 
Medical School, London. 
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2.3 Assessment of GVHD 
To evaluate the severity of GVHD both clinical and histological parameters were used 
to access mice. Clinical signs of GVHD were assessed using a six parameter scoring 
system. Mice were scored for ruffled fur, hunching, loss in activity, diarrhoea and eye 
opening (Table 3). Recipient mice were also weighed on the day of BMT and at least 
three times weekly thereafter to track weight loss relative to Day 0. Mice were culled for 
humane reasons if their cumulative score was ≥4. Upon death, specimens of GVHD 
target organs were collected, fixed in 4% formaldehyde, embedded in paraffin, cut into 
sections and stained with haematoxylin and eosin for examination.  
These histopathological sections were then scored single blinded using a severity 
scale, as reported previously283. The severity scale ranged from 0-4: 0, normal; 0.5, 
focal and rare; 1, focal and mild; 2, diffuse and mild; 3, diffuse and moderate; 4, diffuse 
and severe. Changes in the colon (crypt regeneration, crypt epithelial cell apoptosis, 
crypt loss, surface colonocyte attenuation, lamina propria inflammatory cell infiltrate, 
mucosal ulceration and thickness of the mucosa), liver (portal tract inflammatory cell 
infiltrate, lymphocytic infiltrate of bile ducts, bile duct epithelial cell apoptosis, vascular 
endothelialitis, parenchymal apoptosis, parenchymal microabcesses and parenchymal 
mitotic figures), lung (perivascular cell infiltrate, peribronchiolar cell infiltrate and 
alveolar/interstitial infiltrate) and skin (epidermal/dermal lymphocytic infiltrate, 
dyskeratotic epidermal keratinocytes and epidermal thickening) could then be 
assessed for signs of GVHD. 
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Table 3: Overview of the clinical scoring system used to assess GVHD in mice. 
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2.4 Bone Marrow Transplantation 
BMT was performed as described before with modifications285,286. The fluoroquinolone 
Baytril (0.15 mg/ml; Bayer, Germany) was added to the drinking water of all transplant 
recipients a week before transplant. In MHC-matched, minor H mismatch of model of 
GVHD, male BL/6 (or Langerin-DTR) recipients were lethally irradiated (11 GY, 0.55 
GY/min separated into 2 cycles over 48 hr) and reconstituted with mixture of 5 x106 
bone marrow cells and 2 x106 CD4 T cells derived from female WT BL/6 mice and 1 
x106 Mh CD8 T cells derived from female H-Y TCR transgenic MataHari mice injected 
intravenously (i.v.) in the tail vein 4 h later. The bone marrow was harvested by flushing 
the tibia and fibula with bone marrow medium (RPMI-1640, 10 mM HEPES, 10 µg 
Gentamycin). CD8+ and CD4+ T cells were isolated from the spleens of female 
MataHari and WT BL/6 mice respectively, by positive selection using anti-CD8α (Ly-2; 
Miltenyi, Germany) and anti-CD4 (L3T4; Miltenyi, Germany) magnetic-activated cell 
sorting (MACS) beads and LS columns (Miltenyi, Germany). Briefly, spleens were 
mashed, passed through a 40 µm cell strainer (BD, USA) and ACK lysed (Lonza, 
Switzerland), as per manufacturers instructions. The splenocytes were then washed in 
ice cold MACS buffer (PBS, 2% BSA, 2mM EDTA) and resuspended in 90 µL buffer 
per 1 x107 cells. 10 µL anti-CD8α- or anti-CD4 microbeads were added per 1 x107 cells 
and the suspension was incubated for 15 min at 4°C. Cell were washed by adding 1 ml 
of MACS buffer per 1 x107, resuspended in minimum of 500 µL per 1x108 cells and 
transferred to a rinsed LS column attached to a MidiMACS separator. The column was 
washed with 3 x 3ml of MACS buffer before being removed from the separator. The 
purified CD8+ and CD4+ T cells were then flushed from the LS column with 5 mL of 
MACS buffer using the plunger provided. Purity was confirmed by flow cytometry 
before Mh CD8 T cells, polyclonal CD4 T cells and BM were resuspended in PBS and 
stored on ice before infusion.   
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To generate [Langerin-DTR+BALB/c→BL/6] mixed chimeras (MC), recipient BL/6 mice 
were lethally irradiated (11 GY, 0.55 GY/min separated into 2 cycles over 48 hr) and 
reconstituted with 20 x106 TCD BM derived from the tibia and fibula of Langerin-DTR 
and BALB/c mice mixed at a 1:1 ratio injected i.v. in the tail vein 4 h later. The bone 
marrow was by TCD by negative selection using anti-CD3ε-biotin, anti-biotin 
microbeads and an LD column (Miltenyi, Germany), as per manufacturers instructions. 
T cell depletion was confirmed by flow cytometry before the BM mix was resuspended 
in PBS and infused into recipients. Mixed chimeras were allowed to recover for 8 
weeks before their chimerism was analysed. All mice are female unless otherwise 
stated. In GVHD experiments, DLI was administered to chimeras no less than 8 weeks 
after transplant. An allogeneic SC suspension of 30 x106 cells injected i.v. was used for 
DLI as described previously229. 4 mg Imiquimod (3M Pharmaceuticals, USA) was then 
applied to a shaved area of skin at the base of the tail on days 0, 5 and 10 after donor 
SC to induce cutaneous GVHD. 
To generate [Langerin-DTR→BL/6] chimeras, recipient male BL/6 mice were lethally 
irradiated (11 GY, 0.55 GY/min separated into 2 cycles over 48 hr) and reconstituted 
with 5 x106 TCD BM derived from the tibia and fibula of male Langerin-DTR mice 
injected i.v. in the tail vein 4 h later. TCD was carried out as described before. 
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2.5 Depletion of Langerin+ DC 
To systemically deplete Langerin+ DC, Langerin-DTR mice were injected i.p. with 400 
ng of DT in 200 µl sterile PBS. All experiments involving DT were controlled with the 
i.p. injection of 200 µl sterile PBS into littermates in parallel. 
To locally deplete Langerhans cells. Langerin-DTR mice were placed under general 
anaesthesia using an isoflurane machine. Briefly, mice were moved to an induction 
chamber and placed under general anaesthesia using 3-4% isoflurane with an oxygen 
flow rate of 1 l/min. Once asleep, anaesthesia was maintained using a nose cone while 
Langerin-DTR mice were injected with 25 ng of DT in 20 µl i.d. into the dorsal and 
ventral side of the left ear. Mice were placed under a heat source and observed until 
fully recovered.  
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2.6 Flow cytometry 
Homogenous single cell suspensions were incubated with 2.4 G2 antibody for 10 min 
at 4°C to block Fc receptors. Cells were washed using FACS buffer (PBS, 2% FBS, 
2mM EDTA) and subsequently incubated with flurochrome-conjugated primary 
antibodies in 75 µl at saturating concentrations for 15 min at 4°C. The samples were 
washed using FACS buffer and the cells were incubated with a secondary antibody if 
necessary. For intracellular staining, samples were incubated with BD Cytofix solution 
for 10 min at 4°C. Samples were washed with X1 BD Perm buffer. The fixed samples 
were incubated with intracellular antibody (IFN-γ or CD207) in X1 BD Perm buffer for at 
least 1 hr at 4°C and subsequently washed with X1 BD Perm buffer. All stained 
samples were re- suspended in FACS buffer before flow cytometry. 
Multiparamter flow cytometry was performed using BD LSRII, LSRFortessa and 
FACSCalibur systems (BD Bioscience, Germany). All samples were filtered using a 40 
µm cell strainer before acquisition. Propidium iodide (PI) was added to samples derived 
from the liver, lung and LP+PP at least 10 min before acquisition. Analysis was carried 
out using Tree Stars Flowjo software (v8.7). For each experiment appropriate single 
stain controls were used to compensate each channel. 
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2.7 Isolation of epidermal and dermal cells 
Skin tissue from the ears and/or body skin was excised and stored in HBSS on ice. The 
skin was processed in accordance with a published protocol with slight modifications276. 
The ears were split into dorsal and ventral sections. Samples were then incubated at 
4°C overnight or for 45 min at 36°C in a solution of HBSS containing 2.5 mg/ml 
Dispase II (Roche, Germany) and 2% FBS (Biosera Ltd, UK). The epidermis and 
dermis was carefully separated using a fine forceps. Epidermal sheets were transferred 
into a bijou containing PBS and 5% FBS. Bijou is vortexed repeatedly before the 
sample was passed through a 40 µm cell strainer (BD Bioscience, USA) into a 50 ml 
falcon tube washing with FACS buffer (PBS, 2% FBS, 2mM EDTA) to create a 
homogenous cell suspension. Dermal sheets were cut into small pieces and digested 
for 1 hour at 37°C in HBSS containing 2750 U/ml collagenase type IV (Worthington 
Biochemical Corporation, USA) and 5% FBS. 1mM EDTA was added and the samples 
incubated for 5 minutes at room temperature. The samples were then agitated and 
passed through a 40 µm nylon cell strainer into a 50 ml falcon tube washing with PBS 
to create a homogenous single cell suspension. 
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2.8 Isolation of lymphocytes from lymphoid and peripheral tissues 
To isolate SC, a cell strainer was placed in a mini petri dish in 1 ml of ACK lysis buffer. 
The spleen was added to the cell strainer and mechanically disassociated using the 
plunger from a syringe. The sample was swirled for 1 min before 9 ml of PBS was 
added. The sample was subsequently washed in FACS buffer.  
To isolate skin draining lymph nodes (axial, brachial, inguinal and cervical), samples 
were mechanically disassociated using the barrel of a 2ml syringe and passed through 
a 40 µm cell strainer before being washed and resuspended in FACS buffer.  
Lymphoid cells were counted using a haemocytometer under a light microscope. Cell 
viability was assessed using 0.1% trypan blue (Sigma, USA) in PBS. 
To isolate lymphocytes from the blood, 100 µl of blood was collected from the tail vein 
into an eppendorf containing 10 µl heparin. RBC were lysed using water shock 
treatment where 100 µl of blood was added to 9 ml of distilled H2O for 10 sec before 1 
ml of X10 PBS was added. Samples were subsequently washed in FACS buffer. 
To isolate lymphocytes from the lung, a needle was carefully inserted into the trachea 
post mortem and the lungs flushed with PBS. The lungs were excised, cut into small 
pieces and digested for 1 hour at 37°C in HBSS containing 2750 U/ml collagenase type 
IV and 5% FBS. Using the plunger from a 2 ml syringe the sample was mechanically 
disassociated passing it through a 40 µm cell strainer into a falcon tube, washing with 
FACS buffer. RBC were lysed using ACK lysis buffer and the cells were washed with 
FACS buffer. 
To isolate lymphocytes from the liver, a needle was carefully inserted into the portal 
tract vein post mortem and the liver perfused with PBS. The liver was excised, cut into 
small pieces and digested for 1 hour at 37°C in HBSS containing 2750 U/ml 
collagenase type IV and 5% FBS. Using the plunger from a 2 ml syringe the sample 
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was mechanically disassociated passing it through a 40 µm cell strainer into a falcon 
tube, washing with FACS buffer. RBC were lysed using ACK lysis buffer and the cells 
were washed with FACS buffer.  
To isolate lymphocytes from the lamina propria and peyer’s patches (LP+PP), two 5 cm 
of the small intestine were excised and flushed with PBS using a syringe and a forceps 
to remove faecal matter. LP+PP samples were cut longitudinally to increase surface 
area and incubated with HBSS containing 10 mM EDTA and 2% FBS in a bijou at 36°C 
with shaking (200 rpm) for 10 min. LP+PP samples were washed with HBSS and the 
process repeated twice more. LP+PP samples were cut into small pieces and digested 
for 1 hour at 37°C in HBSS containing 2750 U/ml collagenase type IV and 5% FBS. 
Using the plunger from a 2 ml syringe the sample was mechanically disassociated 
passing it through a 40 µm cell strainer into a falcon tube, washing with FACS buffer. 
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2.9 Isolation of primed MataHari T cells for secondary transfer 
Adapting a previously published protocol with slight modification, primed Mh T cells 
were isolated from the skin draining lymph nodes using nylon wool287. 0.5 g of nylon 
wool (G Kisker, Germany) was loaded into a 10 ml syringe up to the 5 ml mark. This 
was then autoclaved. The column was washed with 20 ml sterile CML-V medium 
(RPMI-1640, 2nM L-Glutamine, 100 µM β-mercaptoethanol, 100 units/ml Penicillin, 100 
µg/ml Streptomycin, 5% FCS, 10 mM HEPES), the syringe end capped and 2 ml of 
CML-V added. This is then incubated for 30 min at 37°C. The syringe was kept sterile, 
storing it in a 50 ml falcon tube.  
The skin draining lymph nodes are harvested from the transplanted recipient. Using the 
plunger from a 2 ml syringe the sample was mechanically disassociated passing it 
through a 40 µm cell strainer into a falcon tube, washing with warmed CML-V medium. 
The sample was resuspended in 2 ml warmed CML-V medium. 
The 2 ml of medium used to rinse the nylon wool was drained and the syringe end 
capped again. 2 ml of the lymph node suspension was added drip wise and more 2 ml 
of CML-V medium added on top. The sample was incubated for 45 min at 37°C and the 
suspension subsequently eluted using 10 ml of medium. The sample was washed 
three times with PBS and counted using a haemocytometer.   
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2.10 Langerin-DTR genotyping 
To genotype Langerin-DTR mice, a small excision of skin was taken from tail. To 
isolate genomic DNA, the tissue was placed in a 1.5 ml eppendorf with 75 µl of Buffer A 
(25 mM NaOH, 0.2 mM EDTA, pH12) and incubated for 15 min at 95°C. Sample was 
allowed to cool before 75 µl of Buffer B (40 mM Tris-HCL, pH 5.5) was added to 
neutralise the reaction288. 1 µl of the mix was then used for PCR. 
For PCR, 1 µl of genomic DNA was added to a master mix containing, 1 µl of each 
primer in Table 4, 5 µl 2X Phusion PCR Master Mix (New England BioLabs, USA) and 
1 µl H2O. Samples were run on a DNAEngine (BioRad, USA) thermal cycler according 
to the cycle specified in Table 4. All samples were run with positive and negative 
controls. 
Genomic DNA (10 µl) was then combined with 2 µl of X6 blue gel loading dye (NEB, 
USA) and loaded on to a 1.5% agarose gel containing SYBR safe (Life Technologies, 
USA) in X1 TAE buffer (Thermo Scientific, USA) and run at 100 V for 35 min. using Gel 
Doc XR system (BioRad, USA). Langerin-DTR band was 700 bp. WT BL/6 was 300 bp. 
Primer Oligonucleotide Sequence (5’ – 3’) 
WT Forward GAA TGA CAG ATC TGG CCT GAG CTC G 
DT Forward TTC CAG CAG CTA GCC CTC TCC GAA 
Common GTA GCT TTT ATA TGG TCA GCC AAG G 
Step Temp (°C) Time (min) 
1 94 5 
2 94 1 
3 60 1 
4 72 2 
5 Repeat steps 2-4 35 times 
6 72 3 
7 10 Hold 
Table 4: Langerin.DTREGFP primers and cycling protocol.  
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2.11 MataHari in vitro restimulation assay 
Spleens were harvested from transplanted recipients and female WT BL/6 donors and 
mashed through a 40 µm cell strainer (BD, USA) using sterile PBS (Lonza, USA) into a 
50 ml falcon tube. SC were centrifuged for 5 min at 1500 RPM using an Eppendorf 
5804 centrifuge (Eppendorf, Germany). SC were resuspended in ACK lysis buffer and 
allowed to stand for 1 min before 9 ml of sterile PBS was added. SC were washed 
twice by suspending the samples in PBS and centrifuging for 5 min at 1500 RPM. SC 
were counted using a haemocytometer and resuspended in CML-V medium (RPMI-
1640, 2nM L-Glutamine, 100 µM β-mercaptoethanol, 100 units/ml Penicillin, 100 µg/ml 
Streptomycin, 5% FCS, 10 mM HEPES) at a concentration of 1 x107 cells/ml. 100 µl of 
SC from transplanted recipients and female WT BL/6 donors were plated together in a 
96 well, round bottomed plate (Corning, USA). 5 µM of relevant (WMHHNMDLI) was 
added to SC and 5 µM of irrelevant (SIINFEKL) peptide added to another as a control. 
SC were incubated for 4 h before 10 µg/ml of Brefeldin A was added to each well. SC 
were incubated for another 4 h before SC were transferred to 96 well, v bottomed cell 
culture plate, resuspended in FACS buffer and stained using antibodies conjugated 
with fluorochromes as described before. 
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2.12 Statistical analysis 
Comparisons of absolute numbers, frequencies and histopathological scores for 
significance were made using a Mann-Whitney U test in GraphPads Prism (v6.0). A p-
value ≤0.05 was considered significant. 
For the gene level differential expression analysis, an absolute linear fold change (LFC) 
±2 and an Analysis of Variance (ANOVA) p-value ≤0.05 was considered significant. For 
the gene set enrichment analysis (GSEA), a false discovery rate (FDR) ≤0.25 was 
chosen as the cut off. 
  
 111 
2.13 Transcriptional profiling 
In collaboration with Professor Frederic Geissman and Dr Elisa Gomez Perdiguero, Mh 
T cells were flow sorted from the skin draining lymph nodes, dermis and epidermis 
directly into RLT lysis buffer containing 1µM β-mercaptoethanol using a BD FACSAria 
II. Mh T cells were identified in the skin based on their expression of CD45.2, CD45.1 
Thy1.1, Vβ8.3 and CD8. In parallel, host LC were flow sorted from the epidermis. In 
Langerin-DTR mice, LC were identified based on their expression of CD45.2, CD11b, 
GFP. In BL/6 mice, LC were identified based on their expression of CD45.2, CD11b, 
CD11c and CD24. A minimum of 5 x103 cells were collected per replicate with purity 
≥95%. 
Methods used for quantitative PCR (qPCR) have been described previously289,290. The 
samples were kindly amplified by Dr Terry Means at Massachusetts University Hospital 
using the primers listed in Table 5. mRNA quantification for each transcript was relative 
to expression of β2M. 
For the microarray study, RNA was purified using an RNeasy Micro Kit (Qiagen, 
Holland) as per the manufacturers protocol. Dr Simone Sharma subsequently 
processed RNA samples at a core facility in the Wolfson Institute for Biomedical 
Research, UCL. RNA purity was assessed using an RNA 6000 Pico Kit with an Agilent 
Bioanalsyer 2100 (Agilent, USA). cDNA was synthesised and labelled using the 
Oviation Pico WTA System V2 and Encore Biotin Module (NuGEN, USA). The 
amplified cDNA probes were then hybridised onto an Affymetrix GeneChip Mouse 
Gene 2.0 ST Array and scanned using a GeneChip Scanner 3000 7G (Affymetrix, 
USA). 
The microarray data was kindly analysed and annotated by Dr Pedro Ascensao Santos 
E Sousa in our lab using Affymetrix Expression Console Software (v1.3.1.187), 
applying the robust multi-array average (RMA) algorithm for probe-level normalisation 
 112 
and background correction. GenePattern software was used to perform a Principal 
Variance Component Analysis (PVCA) and unsupervised agglomerative cluster 
analysis on the dataset291. Affymetrix Transcriptome Analysis Console Software was 
used for a gene level differential expression analysis. A gene set enrichment analysis 
(GSEA) was performed using GSEA software and the Molecular Signatures Database 
Collection 2292. 
Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) 
β2M CCGAACATACTGAACTGCTACGTAA CCCGTTCTTCAGCATTTGGA 
IFN-γ  AACGCTACACACTGCATCTTGG GCCGTGGCAGTAACAGCC 
TNF-α  CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 
IL-10 TTTGAATTCCCTGGGTGAGAA GGAGAAATCGATGACAGCGC 
Perforin AACTCCCTAATGAGAGACGCC CCACACGCCAGTCGTTATTGA 
TRAIL ATGGTGATTTGCATAGTGCTCC GCAAGCAGGGTCTGTTCAAGA 
RANTES CAAGTGCTCCAATCTTGCAGTC TTCTCTGGGTTGGCACACAC 
Granzyme B CCCACAACATCAAAGAACAGGA CTCTTCAGCTTTAGCAGCATGA 
CCR2 ATCCACGGCATACTATCAACATC CAAGGCTCACCATCATCGTAG 
CCR4 TCCTGACGGACGTGTACCT CAGACCTAGTCCAAAAACCCAC 
CCR5 TGGATTTTCAAGGGTCAGTTCC GAGCCGCAATTTGTTTCACA 
CCR10 TCAATCCGGTGCTTTATGCC AGCAGCCTCCGCAGGTC 
CX3CR1 ACCGGTACCTTGCCATCGT ACACCGTGCTGCACTGTCC 
Ki67 AACTCAGCGCCTTGTTCCAG GGCCAGAGCAAGTCTGTTCG 
BCL-xL GACAAGGAGATGCAGGTATTGG TCCCGTAGAGATCCACAAAAGT 
FasL TCCGTGAGTTCACCAACCAAA GGGGGTTCCCTGTTAAATGGG 
Table 5: Primers used for qPCR study. 
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3 Langerin+ dermal DC are not required for cutaneous GVHD 
The first objective of my project was to investigate the role of Langerin+ dDC in an 
established MHC-mismatched model of localised cutaneous GVHD, where we have 
already shown a role for host LC.  
This required new protocols to identify DC populations in the skin to be developed in 
the lab, as Langerin+ dDC in the dermis are present in relatively low frequencies. Once 
established, I investigated the chimerism of LC and Langerin+ dDC in the skin of 
established MC, where LC were expected to be of host origin and Langerin+ dDC were 
expected to be donor derived. This was important as I needed to confirm that host 
Langerin+ dDC were radiosensitive in order to deplete them in our MHC-mismatched 
model of localised cutaneous GVHD. 
In the last part of this chapter, I investigated the role of Langerin+ dDC in the 
development of acute GVHD. Langerin+ dDC are potent stimulators of CD8 T cell 
immunity, yet their role in GVHD remains uncharacterised. Adapting the transgenic 
Langerin-DTR mouse to our established model of localised cutaneous GVHD, I was 
able to generate MC where host Langerin+ dDC but not LC could be depleted. Thus, 
enabling me to investigate the role of host Langerin+ dDC in a model of localised 
cutaneous GVHD when other host APC populations were capable of presenting 
antigen. 
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3.1 Characterising dendritic cells in the skin 
3.1.1 Characterising cutaneous DC in the steady state 
To investigate the function of specific DC populations in the skin, protocols to 
consistently identify DC by flow cytometry were developed. Staining protocols were 
adapted from two recently published papers to identify DC in both the epidermis and 
dermis275,276. Firstly, the epidermis and dermis were separated by treating ears and/or 
whole body skin in trypsin, a serine protease, for 45 min at 37°C. The dermis was 
subsequently digested using a mixture containing collagenase IV. Varying the 
concentration and incubation time of collagenase IV with the dermis was found to have 
no effect on the viability of the sample (Figure 16, A). Therefore, the lowest 
concentration and incubation time (2750 U/ml for 1 hr) was used in future experiments. 
Fetal bovine serum (FBS) was subsequently added to the collagenase digestion in 
order to improve dermal cell viability (Figure 16, B)293.  
This protocol proved ineffective, with inconsistent staining of the dermis a common 
problem. An alternative protocol using dispase II, a protease that cleaves leucine-
phenyalanine bonds, instead of trypsin was subsequently used. Skin samples were 
incubated with a mixture of dispase II (2.5 mg/ml) and FBS overnight at 4°C or for 45 
min at 37°C. Dispase has low cytotoxicity and remains active in the presence of 
serum294. The dermis was subsequently digested using a mixture containing 
collagenase IV and FBS as described before. This protocol yielded a much more 
consistent staining pattern within the dermal compartment and was used to stain for 
DC and T cells in the skin moving forward. 
To identify cutaneous DC by flow cytometry, a staining panel of 5-6 antibodies, usually 
CD45, MHCII, CD207 (Langerin), CD11b, EpCAM and CD24 was used based on 
phenotypes described in previously published studies (Table 6)275,276,295. After an initial 
gate excluding low FSC cells, which tend to be apoptotic296, and low SSC cells which 
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tend to be γδ T cells, MHCII+ cells were gated and analysed for the expression of 
CD207, EpCAM and CD11b. 
DC Subset MHCII CD11c CD11b CD24 CD207 EpCAM CD103 
LC + + inter/high + + + - 
Langerin+ dDC + + -/low + + - -/+ 
CD11b+ dDC + + + - - - - 
CD11b- dDC + + -/low - - - - 
Table 6: Phenotype of DC subsets found in the skin of mice. 
 
In Figure 17, the gating strategies employed to identify DC in the epidermis and dermis 
is illustrated. Analysing MHCII+ cells in the epidermis for the expression of CD207 and 
EpCAM, the majority of DC found are LC in accordance with the literature276. In 
contrast, using the same strategy in the dermis, three distinct populations of DC can be 
clearly identified; migrating LC, Langerin+ dDC and conventional dDC. Conventional 
dDC can be further subdivided into two subpopulations based on their expression of 
CD11b.  
Overall, the relative frequencies of DC observed in the skin showed good concordance 
with previously published observations (Table 7)276. 
Tissue DC Subset Frequency 
Epidermis LC 89.9 ± 2.7 
Dermis Migrating LC 6.8 ± 3.7 
 Langerin+ dDC 4.8 ± 2.2 
 CD11b+ dDC 55.5 ± 11.8 
 CD11b- dDC 29.2 ± 10 
Table 7: Frequency ± SD of DC subsets in the epidermis and dermis among MHC+ cells. Data is 
representative of 12 samples from 7 independent experiments. 
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Figure 16: The addition of FBS improved the viability of collagenase treated dermal samples. A 
Left- A suspension of dermal cells taken from the skin of a BL/6 mouse and incubated with either 2750 or 
4000 U/ml of Collagenase IV for 1, 1.5 or 2 h. Varying the concentration and incubation time had no effect 
on the viability of dermal cells. No difference in the frequency of PI- was observed between samples. 
Right- Single stain controls. Dermal samples incubated with 2750 U/ml of Collagenase IV for 1 h stained 
with either PI or FACS buffer. B Dermal suspension incubated with 2750 U/ml of Collagenase IV for 1 h 
and 2.5% FBS stained with PI. The frequency of PI- cells increased with the addition of FBS compared to 
dermal samples incubated with Collagenase IV alone. 
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Figure 17: Overview of cutaneous dendritic cells and the depletion of Langerin+ DC in Langerin-
DTR mice. Representative dot and contour plots of the epidermis and dermis taken from Langerin-DTR 
mice injected with either 400 ng of DT or PBS i.p. 24 h earlier. In the epidermis, following a broad DC gate, 
the majority of MHCII+ cells were found to be LC (GFP+, EpCAM+, CD207+ and CD11b+). In the dermis, 
four populations of DC could be identified from MHCII+ cells. In addition to migrating LC, Langerin+ dDC 
(GFP+, CD11b- and EpCAM-) could be identified as an addition DC subset expressing Langerin in the skin. 
Following exposure to DT, both LC and Langerin+ dDC are depleted within 24 h as evidenced in the dot 
and contour plots above. 
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3.1.2 LC and Langerin+ dDC are depleted in Langerin-DTR mice 
To investigate the role of Langerin+ DC in cutaneous GVHD, the knock-in Langerin-
DTR mouse was used. Upon a single injection of 400 ng of DT i.p., both LC and 
Langerin+ dDC in the epidermis and dermis were efficiently depleted within 24 h 
compared to PBS controls (Figure 17). Langerin+ dDC repopulate the skin much more 
rapidly than LC upon depletion275,276. This was confirmed when DT treated Langerin-
DTR mouse were culled 20 days post DT treatment where Langerin+ dDC were found 
to have fully repopulated the dermis while LC remained depleted in the epidermis and 
dermis (Figure 18). The LC compartment was fully reconstituted when the epidermis of 
Langerin-DTR mice was examined 22 weeks after DT treatment (Figure 18).  
The effect of the pro-inflammatory TLR 7-8 agonist Imiquimod (Imiq) on Langerin-DTR 
mice was then investigated297. This was of interest as depletion of DC in the skin of 
CD11c-DTR mice, where cells expressing the integrin CD11c are conditionally 
depleted in the presence of DT, was found to be inefficient when Imiquimod is painted 
on to the skin. CD11c+ DC in the epidermis of Imiquimod treated mice failed to deplete 
when mice were injected with DT 24 h later in contrast to untreated controls (Figure 
19). 
In Langerin-DTR mice, CD11b+ cells in the epidermis, the majority of which are LC, 
were found to increase their expression of MHCII and the co-stimulatory molecule 
CD86 in the presence of Imiquimod (Figure 20), indicating LC maturation93,298. 
However, the inflammation generated by Imiquimod had no significant effect on the 
depletion of both LC and Langerin+ dDC in Langerin-DTR mice treated with DT 24 h 
after Imiquimod application (Figure 21 and Figure 22). 
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Figure 18: Langerin+ dDC repopulate the skin more rapidly than Langerhans cells upon depletion 
with DT. Representative dot plots of the epidermis and dermis taken from Langerin-DTR mice injected 
with either 400 ng of DT or PBS i.p., culled either 20 days or 22 weeks post DT/PBS treatment. 20 days 
post DT, LC remain depleted in both the epidermis and dermis. However, the Langerin+ dDC have 
repopulated the dermis. 22 weeks post DT, LC have fully repopulated the epidermis of DT treated 
Langerin-DTR mice and are similar to PBS controls. 
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Figure 19: CD11c+ cells in the epidermis are inefficiently depleted in CD11c-DTR mice in the 
presence of Imiquimod. Dot plots of the epidermis taken from the ears of CD11c-DTR mice injected with 
100 ng of DT or PBS i.p. and painted with or without 4 mg of Imiquimod 24 h earlier. DC were identified by 
the expression of GFP (CD11c). In the absence of Imiquimod, GFP+ cells were depleted upon injection of 
DT. In the presence of Imiquimod, GFP+ DC were inefficiently depleted upon injection of DT. 
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Figure 20: Imiquimod activates dendritic cells in the skin. Dot and contour plots of the epidermis taken 
from mice painted with or without the TLR agonist Imiquimod 24 h earlier. Following exposure to 
Imiquimod, CD11b+ cells in the epidermis exhibited an increase in both the expression of MHCII and CD86 
compared to untreated ears. 
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Figure 21: Langerhans cells and Langerin+ dDC are depleted in the presence of Imiquimod in 
Langerin-DTR mice. Representative dot and contour plots of the epidermis and dermis from the ears of 
Langerin-DTR mice injected with 400 ng of DT or PBS i.p. and painted with or without 4 mg of Imiquimod 
24 hr earlier. In the presence of Imiquimod, both LC and Langerin+ dDC were efficiently depleted in the 
epidermis and dermis of mice. 
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Figure 22: Langerin+ DC are efficiently depleted in the presence or absence of Imiquimod in 
Langerin-DTR mice. Summary data showing the percentage of gated MHChigh cells that were either LC or 
Langerin+ dDC (n=5-6 per group, data pooled from 3 independent experiments, analysed using a Mann-
Whitney test. The mean ±SD is indicated by the horizontal bar.). Top- In the epidermis, there was a 
significant reduction in the frequency of LC in mice treated with DT and Imiq+DT compared to controls. 
Bottom left- In the dermis, there was a significant reduction in the frequency of migrating LC in mice 
treated with DT and Imiq+DT compared to controls.  Bottom right- There was a significant reduction in the 
frequency of Langerin+ dDC in mice treated with DT and Imiq+DT compared to controls. 
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3.2 Host Langerhans cells are radioresistant but donor Langerhans cells were 
observed in established mixed chimeras 
3.2.1 LC derived from donor MHC-mismatched BM co-populate the epidermis of 
established MC with host LC 
Previous studies have shown that LC are radioresistant and can self-renew and 
proliferate in situ in the steady state independently of precursor cells from the blood 
and bone marrow258,299. Exploiting theses unique characteristics, we adapted an 
established model of localised cutaneous GVHD using MC to the Langerin-DTR 
system (Figure 23, A)229,283. This enabled us to selectively deplete host LC and 
investigate the role of LC in the development of cutaneous GVHD (Figure 23, B).  
Briefly, Langerin-DTR (H-2b) mice were lethally irradiated with a split dose of 11 Gy 
and reconstituted with 20 x106 TCD BM from MHC-matched BL/6 (H-2b) and MHC-
mismatched BALB/c (H-2d) mice mixed at a 1:1 ratio (Figure 23, A). The mice were 
allowed to recover for at least 8 weeks and their chimerism was subsequently checked. 
In the haematopoietic system, myeloid, T and B cells were mixed between donor BL/6 
(H-2b) and BALB/c (H-2d) derived cells as expected229. The chimerism of LCs in the 
MC ([BL/6+BALB/c] → Langerin-DTR) was then examined to confirm host origin 
(Langerin-DTR). MHCII+ and CD11b+ in the epidermis were gated and analysed for the 
expression of H-2Kb (Langerin-DTR and BL/6) and H2-Dd (BALB/c). Two populations 
of LC were found (Figure 24): H-2Kb+ H2Dd- and H-2Kb- H2Dd+ LCs, contrary to what 
was expected from previously published data where all LC were derived from the 
host258. Both populations were then analysed for their expression of GFP (LC from 
Langerin-DTR mice are GFP+). LCs that were H-2Kb+ H2Dd- were entirely GFP+ and 
therefore of host origin (Langerin-DTR, H-2b) whereas H-2Kb- H2Dd+ LCs were GFP- 
and derived from donor (BALB/c, H-2d) origin (Figure 24). Interestingly, within the H-
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2Kb+ H-2Dd- population of LC, virtually none were derived from donor BL/6 (MHC-
matched, H-2b) BM despite a large proportion of LC in the epidermis being derived 
from infiltrating donor BALB/c (MHC-mismatched, H-2d) precursors (Figure 24).  
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Figure 23: [BL/6 + BALB/c] →  Langerin-DTR allogeneic mixed chimera model. A. Langerin-DTR (H-
2b) mice are lethally irradiated with a split dose of 11 GY and reconstituted with a 1:1 mix of TCD MHC-
matched BL/6 (H-2b) and MHC-mismatched BALB/c (H-2d) BM and allowed to recover for 8 weeks. B. 
Overview of the expected chimerism of DC in MC based on current literature. In the epidermis, LC are 
radioresistant and expected to be entirely of host (Langerin-DTR) origin. In the dermis, Langerin+ dDC, 
CD11b+ and CD11b- dDC are expected to be donor derived, a mix between BL/6 and BALB/c derived 
cells. 
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Figure 24: Langerhans cells in allogeneic mixed chimeras are both host and donor in origin. Dot 
plots from the epidermis of a [BL/6 + BALB/c] → Langerin-DTR MC that was culled 12 weeks after 
transplant. LC characterised here as MHCII+ and CD11b+ cells, were analysed for the expression of the 
MHCI molecules H2-Dd and H-2Kb. Interestingly, the population of LC in the epidermis was mixed 
between H2-Dd+ and H-2Kb+ LC. H2-Dd+ LC were GFP- and derived from donor MHC-mismatched 
BALB/c (H-2d) BM. H-2Kb+ LC were GFP+ and entirely of host (Langerin-DTR, H-2b) origin with no LC 
derived from donor MHC-matched BL/6 (H-2b, GFP-) BM detected. 
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3.2.2 LC derived from donor MHC-matched BM did not repopulate the epidermis 
when host LC were present but DC derived from MHC-matched BM did 
repopulate the dermis 
In 5 independent experiments, the LC compartment was primarily derived from two cell 
subsets, with host (Langerin-DTR) cells comprising the majority of LC found in the 
epidermis (Figure 25, Left~). However, Langerin+ dDC in the dermis, which are not 
radioresistant like LC, were found to be entirely of donor origin and mixed equally 
between BL/6 and BALB/c derived cells as expected (Figure 25, Right~). 
To explore whether this finding would be reproducible in another strain background 
independent of the Langerin-DTR system, a 1:1 mix of MHC-matched BL/6 
(CD45.2.CD45.1 heterozygotes, H-2b) and MHC-mismatched B62DF1 (CD45.2, H-
2db) TCD BM was used to reconstitute lethally irradiated BL/6 mice (CD45.1, H-2b). In 
these MC, the chimerism of each cutaneous DC population could be easily tracked in 
vivo due to the differential expression of the congenic markers CD45.1 and CD45.2 
between host and donor cells. 
The majority of LC in the epidermis were again derived from host (BL/6, CD45.1, H-2b) 
and donor cells from MHC-mismatched B62DF1 (CD45.2, H-2db) BM, consistent with 
what was observed using Langerin-DTR mice (Figure 26, A). Virtually, no LC were 
derived from donor cells from MHC-matched BL/6 (CD45.2.CD45.1, H-2b) BM.  
In the dermis, migrating LC were again split between host (BL/6, CD45.1, H-2b) and 
donor cells derived from MHC-mismatched B62DF1 (CD45.2, H-2db) BM but 
Langerin+, CD11b+ and CD11b- dDC were entirely derived from donor cells and mixed 
equally between DC derived from MHC-matched BL/6 (CD45.2.CD45.1, H-2b) and 
MHC-mismatched B62DF1 (CD45.2, H-2db) BM (Figure 26, A).  
The chimerism of epidermal γδ T cells in [BL/6(CD45.2.CD45.1)+B62DF1(CD45.2)] → 
BL/6(CD45.1) MC was also examined. Cells that were γδ TCR+ were gated and 
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analysed for the expression of CD45.1 and CD45.2. Interestingly, in contrast to LC, the 
majority of γδ T cells were derived from host (BL/6, CD45.1, H-2b) and donor cells 
derived from MHC-matched BL/6 (CD45.2.CD45.1, H-2b) BM (Figure 26, B). This was 
consistent across the three mice analysed from 1 independent experiment. 
To investigate whether the infiltration of donor LC into the epidermis could be skewed 
towards syngeneic precursors, the ratio of donor MHC-matched (BL/6, H-2b) to MHC-
mismatched (BALB/c, H-2d) BM transplanted into irradiated Langerin-DTR (H-2b) 
recipients was altered from 1:1 to 3:1 and the subsequent chimerism of cutaneous DC 
investigated.  
In the epidermis, LC were again split between host (Langerin-DTR, H-2b) and donor 
cells derived from MHC-mismatched BALB/c (H-2d) BM (Figure 27). Increasing the 
ratio of MHC-matched BL/6 (H-2b) to MHC-mismatched BALB/c (H-2d) BM had no 
effect on the chimerism of LC (Figure 27). In the dermis, dDC were again entirely 
derived from donor cells derived from MHC-matched BL/6 (H-2b) and MHC-
mismatched BALB/c (H-2d) BM.  
However, increasing the ratio of MHC-matched BL/6 (H-2b) to MHC-mismatched 
BALB/c (H-2d) BM did have a noticeable effect on the chimerism of DC in the dermis, 
with an increase in the frequency of donor dDC derived from MHC-matched BM 
observed for all dDC populations in the dermis compared to controls (Figure 27).  
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Figure 25: Langerhans cells are mixed between donor and host whereas Langerin+ dDC are entirely 
donor in origin. Left- Summary data showing the percentage of LC in the epidermis that were either host 
BL/6 (H-2b), donor BL/6 (MHC-matched, H-2b) or donor BALB/c (MHC-mismatched, H-2d) in origin. Host 
BL/6 (H-2b) derived LC comprised the majority of LC in MC, followed by donor BALB/c (MHC-mismatched, 
H-2d) derived LC. Virtually no donor BL/6 (MHC-matched, H-2b) derived LC were detected (n=9 per group, 
data pooled from 5 independent experiments >12 weeks after transplant, analysed using a Mann-Whitney 
test. The mean ±SD is indicated by the horizontal bar.). Right- Summary data showing the percentage of 
Langerin+ dDC that were either host BL/6 (H-2b), donor BL/6 (MHC-matched, H-2b) or donor BALB/c 
(MHC-mismatched, H-2d) in origin. Langerin+ dDC were entirely of donor origin and there was no 
significant difference between the proportion of BL/6 and BALB/c derived cells (n=6 per group, data pooled 
from 3 independent experiments >12 weeks after transplant, analysed using a Mann-Whitney test. The 
mean ±SD is indicated by the horizontal bar.). 
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Figure 26: Dermal dendritic cells are derived from donor cells while epidermal γδ T cells are mixed 
between host and donor cells. A. Representative dot plots of the epidermis and dermis from [BL/6 
(CD45.1.CD45.2) + B62DF1 (CD45.2)] → BL/6 (CD45.1) MC culled 22 weeks after transplant. In the 
epidermis, LC were derived from host (BL/6, CD45.1, H-2b) and donor cells derived from MHC-
mismatched B62DF1 (CD45.2, H-2db) BM. In the dermis, Langerin+, CD11b+ and CD11b- dDC were 
derived entirely from a mixture of donor cells (BL/6 (CD45.1.CD45.2, H-2b) and B62DF1 (CD45.2, H-2db)). 
B. γδ T cells were dervied from both host (BL/6 (CD45.1) and donor (BL/6 (CD45.1.CD45.2, H-2b) + 
B62DF1 (CD45.2, H-2db)) cells. In contrast to LC, the majority of donor derived γδ T cells were from MHC-
matched donor BL/6 (CD45.1 x CD45.2, H-2b) BM.  
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Figure 27: Increasing the ratio of donor BL/6(H-2b):BALB/c(H-2d) BM transplanted had no effect on 
the chimerism of Langerhans cells in mixed chimeras. Representative dot plots of the epidermis and 
dermis from [BL/6 + BALB/c] → Langerin-DTR MC culled 14 weeks after transplant. In the epidermis, LC 
were derived from host (Langerin-DTR, H-2b) and donor cells derived from MHC-mismatched BALB/c (H-
2d) BM. Increasing the ratio of donor MHC-matched BL/6 (H-2b) to MHC-mismatched BALB/c (H-2d) BM 
from 1:1 to 3:1 had no effect on the chimerism of LC in the epidermis of lethally irradiated Langerin-DTR 
(H-2b) recipients. In the dermis, Langerin+ dDC, CD11b+ and CD11b- dDC were derived from a mixture of 
donor cells (BL/6 and BALB/c). Increasing the ratio of donor MHC-matched BL/6 (H-2b) to MHC-
mismatched BALB/c (H-2d) BM led to a minor increase in the proportion dDC dervied from donor MHC-
matched BL/6 BM. 
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3.3 Host Langerin+ dDC are not required for cutaneous GVHD 
3.3.1 Generating [BALB/c+Langerin-DTR] → BL/6 MC and the induction of GVHD 
By modifying our MC model of localised cutaneous GVHD described previously229,283, I 
established a model where host Langerin+ dDC but not host LC could be conditionally 
depleted (Figure 28, A). This allowed a role for host Langerin+ dDC in the development 
of localised cutaneous GVHD to be investigated. Briefly, BL/6 (H-2b) mice were lethally 
irradiated and reconstituted with TCD BM from MHC-matched Langerin-DTR (H-2b) 
and MHC-mismatched BALB/c (H-2d) mice mixed at a 1:1 ratio. TCD was confirmed by 
flow cytometry before each transplant (Figure 29, A). In these MC, Langerin+ dDC are 
mixed between donor Langerin-DTR (MHC-matched, H2-b) and BALB/c (MHC-
mismatched, H2-d) derived cells. Injecting these MCs with DT will only deplete 
Langerin+ dDC derived from Langerin-DTR mice (Figure 28, B). LC in these MC will be 
mixed between host (BL/6, H-2b) and donor cells derived from MHC-mismatched 
(BALB/c, H-2d) BM and are not depleted, unlike the [BL/6+BALB/c] → Langerin-DTR 
MC discussed in the previous section. 
After transplant, the MC were allowed to recover for at least 8 weeks and their 
chimerism was subsequently checked (Figure 30, A). Gating for lymphocytes, both 
CD8+ and B220+ cells were examined for their expression of H2-Dd. Both populations 
were mixed and derived equally from both Langerin-DTR and BALB/c donor cells. 
However, when granulocytes were gated based on their higher SSC properties300, and 
CD11b+ granulocytes examined for the expression of H2-Dd (BALB/c), there was a 
significant skewing towards BALB/c derived cells (Figure 30, B). This phenomenon had 
been noted in [BL/6+BALB/c] → Langerin-DTR MCs and had no effect on the 
chimerism of Langerin+ dDC (Figure 26, A).  
To induce localised cutaneous GVHD, I transferred 30 x106 Thy1.1+ BALB/c 
splenocytes as DLI into established [BALB/c+Langerin-DTR] → B6 MC that received 
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either DT or PBS 2 days previously (Figure 29, B). A shaved area at the base of the tail 
was then painted with the TLR 7-8 agonist Imiquimod or PBS 0, 5 and 10 days after 
DLI, as described elsewhere, to induce inflammation. MC were subsequently injected 
with DT or PBS 1, 4, 7, 10, and 13 days post-transplant to ensure continual depletion of 
host-type (Langerin-DTR, H-2b) Langerin+ dDC. 
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Figure 28: [Langerin-DTR + BALB/c] →  BL/6 allogeneic mixed chimera model. A. BL/6 (H-2b) mice 
were lethally irradiated with a split dose of 11 GY and reconstituted with a 1:1 mix of the TCD MHC-
matched Langerin-DTR (H-2b) and BALB/c (H-2d) BM and allowed to recover for 8 weeks. The MC were 
injected with 400 ng of DT or PBS i.p. on days -2, +1, +4, +7, +10, +13 following the infusion of 3 x107 
BALB/c (H-2d) SC. MC were treated topically with or without Imiquimod on days 0, 5 and 10 following 
donor SC infusion. B. Overview of the chimerism of cutaneous DC in [Langerin-DTR + BALB/c] → BL/6 
allogeneic MC. LC are mixed between host (BL/6, H-2b) and donor cells derived from MHC-mismatched 
BALB/c (H-2d) BM. Dermal DC are mixed between both types donor (Langerin-DTR and BALB/c) cells. 
When 400 ng of DT is injected i.p. only donor Langerin+ dDC derived from Langerin-DTR (H-2b) BM will be 
depleted.  
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Figure 29: T cells were efficiently depleted from the bone marrow before transplant. A. 
Representative dot plots of bone marrows cell pre- and post-T cell depletion. Bone marrow harvested from 
Langerin-DTR and BALB/c mice was processed and depleted of T cells using anti- CD4 and CD8 
microbeads (Miltenyi, Germany). T cell depletion was confirmed through FACS and depleted BM used for 
transplant. B. Representative dot plots of splenocytes harvested from a Thy1.1 BALB/c donor. 
Splenocytes were confirmed to be Thy1.1+ before being used for DLI. 
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Figure 30: The haematopoietic system of mixed chimeras is mixed between donor Langerin-DTR 
and BALB/c cells. A. Representative dot plots of RBC lysed blood samples taken from a MC >8 weeks 
after being transplanted with 1:1 mix of Langerin-DTR and BALB/c BM.  Granulocytes were gated and 
CD11b+ cells examined for their expression of H2-Dd. Lymphocytes were gated and CD8+ or B220+ cells 
were examined for their expression of H2-Dd. B. Percentage of gated CD4/CD8 T cells, B cells and 
granulocytes in blood samples from MC that were either H2-Dd- (Langerin-DTR) or H2-Dd+ (BALB/c). 
There was no difference in the frequency of Langerin-DTR and BALB/c derivied CD4/CD8 T and B cell 
populations. The CD11b+ granulocyte population was skewed towards BALB/c derived cells (n=19, data 
pooled from 2 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is indicated 
by the horizontal bars.).  
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3.3.2 Host Langerin+ dDC are not required for the accumulation and activation of     
alloreactive T cells 
The MCs were tracked for changes in weight and clinical observation scores, key 
indicators of GVHD, and culled 14 days after receiving DLI (Figure 31, A). In the 
spleen, after a broad gate excluding low FSC cells, the congenic T cell marker Thy1.1 
was used to track allogeneic donor T lymphocytes in vivo (Figure 31, B). As shown in 
Figure 31 C, the depletion of host-type Langerin+ dDC (H-2b) had no effect on the 
absolute number of either Thy1.1+ CD8 or CD4 donor T cells in the spleens of MCs 
treated with Imiquimod. 
In the skin draining lymph nodes, Thy1.1+ CD8 donor T cells were gated and analysed 
for their expression of the T cell effector/memory markers CD44 and CD62L (Figure 31, 
A). There was no significant difference in either the effector phenotype or absolute 
number of either Thy1.1+ CD8 donor T cells in Imiquimod treated mice in the presence 
or absence of host Langerin+ dDC (Figure 32, B+C). There also appeared to be no 
difference in the frequency of donor Thy1.1+ CD8+ T cells expressing E-selectin ligand, 
indicating similar skin homing potential in both populations (Figure 32, D). 
Taken together, these data shows that host-type Langerin+ dDC are not required during 
the initial clonal expansion and priming phase of the allogeneic response.  
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Figure 31: The depletion of host Langerin+ dDC had no effect on the systemic expansion of 
alloreactive donor T cells. A. Clincal score and weight loss plots (n=2-5, data pooled from 3 independent 
experiments.). There was no diferrence in the level of systemic GVHD that developed in Imiquimod treated 
mice with or without host Langerin+ dDC. B. Representative dot plots of the spleen of Imiq+PBS and 
Imiq+DT treated MC on day +14 post donor SC infusion. C. Absolute numbers of Thy1.1+ CD8 and CD4 T 
cells in the spleen of MC on day +14 (n=2-5, data pooled from 3 independent experiments, analysed using 
a Mann-Whitney test, the mean ±SD is indicated by the horizontal bars.). There was no significant 
difference in the absolute number of either CD4 or CD8 donor T cells in MC with or without host Langerin+ 
dDC.  
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Figure 32: Depletion of host Langerin+ dDC had no effect on the activation and expansion of donor 
T cells in the skin draining lymph nodes. A. Representative dot plots of the skin draining LN of 
Imiq+PBS and Imiq+DT treated MC on day +14 post donor SC infusion. B. Percentage of gated Thy1.1+ 
CD8+ T cells that were CD44high CD62Llow (n=5, data pooled from 3 independent experiments, analysed 
using a Mann-Whitney test, the mean ±SD is indicated by the horizontal bars.). There was no difference in 
the frequency of CD8 T effector memory cells in the presence or absence of host Langerin+ dDC. C. 
Absolute numbers of Thy1.1+ CD8 and CD4 T cells in the skin draining LN of MC on day +14 (n=2-5, data 
pooled from 3 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is indicated 
by the horizontal bars.). There was no significant difference in the absolute number of either CD4 or CD8 
donor T cells in MC with or without host Langerin+ dDC. D.  Dot plots of the skin draining LN of Imiq+PBS 
and Imiq+DT treated MC on day +14 post donor SC infusion. There appeared to be no difference in the 
frequency of donor Thy1.1+ CD8+ expressing E-selectin ligand. 
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3.3.3 Host Langerin+ dDC are not required for the development of cutaneous GVHD 
In accordance with previous findings229,283, topical application of Imiquimod initiated the 
recruitment of effector CTLs into the epidermis inducing localised cutaneous GVHD. 
After an initial lymphocyte gate, GFP- were gated to exclude any autofluorescence and 
examined for their expression of Thy1.1 (Figure 33, A). The depletion of host-type 
Langerin+ dDC had no significant effect on the frequency of Thy1.1+ donor T cells 
recruited to the epidermis compared to Imiquimod treated controls (Figure 33, B). 
Sections of skin were also H&E stained and examined for histopathological signs of 
cutaneous GVHD, which includes epidermal thickening, dyskeratosis and inflammatory 
cell infiltrate. In MCs treated with Imiquimod, evidence of skin pathology was observed 
indicating that these MCs had developed cutaneous GVHD (Figure 34, A). In the 
absence of inflammation, no signs of cutaneous GVHD were present (Figure 34, A+B). 
The depletion of host Langerin+ dDC was found to have no effect on the severity of 
GVHD observed (Figure 34, B). 
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Figure 33: Depletion of host Langerin+ dDC has no effect on the infiltration of donor T cells into the 
epidermis. A. Representative dot plots of the epidermis of Imiquimod+PBS and Imiquimod+DT treated 
MC on day +14 post donor SC infusion. After an initial lymphocyte gate, autofluorescent cells were gated 
out and the sample analysed for the frequency of donor Thy1.1+ T cells. B. Summary data showing the 
accumulation of donor Thy1.1+ T cells as a percentage of the initial FSC-H, SSC-H lymphocyte gate (n=2-
5, data pooled from 3 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is 
indicated by the horizontal bars.). There was no difference in the accumulation of donor Thy1.1+ T cells 
when host Langerin+ dDC were depleted. 
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Figure 34: The depletion of host Langerin+ dDC had no effect on the severity of cutaneous GVHD. 
A. Histological sections of back skin on day +14 post donor SC infusion. Images captured at X20 
magnification using a Leica DMD108 light microscope. B. Summary data of histological GVHD score as 
evaluated single blind (n=2-5, data pooled from 3 independent experiments, analysed using a Mann-
Whitney test, the mean ±SD is indicated by the horizontal bars.). There was no difference in the severity 
between MC that received Imiquimod and Imiquimod+DT. Mice that received no Imiquimod showed no 
histological signs of cutaneous GVHD. 
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3.4 Discussion 
3.4.1 Flow cytometry staining of the skin and the Langerin-DTR model 
In the first part of this project, I adapted and developed new protocols in the laboratory 
to consistently identify DC in the skin of mice using flow cytometry. This was important 
as future experiments relied on my ability to confirm depletion of Langerin+ DC in the 
skin. Initially, samples exhibited poor viability, as evidenced by the PI staining in Figure 
16, and inconsistent staining patterns. Switching to Dispase II, the addition of EDTA to 
FACS buffer and FBS to the dispase and collagenase steps yielded much more 
consistent staining patterns in line with published observations276. 
To investigate the role of Langerin+ DC in cutaneous GVHD, we have adopted the 
inducible Langerin-DTR mouse in our models of GVHD. Incorporating a high-affinity 
simian DTR and EGFP cassette downstream of the internal stop codon of the Langerin 
gene, LC and Langerin+ dDC can be selectively depleted via apoptosis upon exposure 
to DT. LC and Langerin+ dDC develop normally and there are no known side effects 
associated with the construct. Using the newly established flow cytometry staining 
protocols in the lab I determined that a single injection of 400 ng was sufficient to 
deplete both LC and Langerin+ dDC within 24 h. The injection of PBS i.p. as a control 
had no discernable effects. In line with literature, Langerin+ dDC were found to 
repopulate the skin more rapidly than host LC. Langerin+ dDC repopulate the dermis by 
7 days whereas LC take 6 weeks plus to fully repopulate the epidermis upon 
depletion275. 
The effect of Imiquimod on the depletion of Langerin+ DC in Langerin-DTR was then 
examined. In the CD11c-DTR mouse, a transgenic line where the expression of 
integrin, alpha x (CD11c) is linked to a high affinity diphtheria toxin receptor204, we 
noticed that the topical application of Imiquimod reduced the efficiency of DC depletion 
in the skin. To ensure inflammation induced by Imiquimod did not interfere with the 
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depletion of Langerin+ DC in my models I administered 4 mg of Imiquimod to a cohort 
of mice 24 h before DT/PBS. This was found to have no effect on the depletion of LC or 
Langerin+ dDC. When using Tg lines of mice it is important to investigate any potential 
anomalies in the system as meaningful biological observations may be misconstrued. 
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3.4.2 Investigating the role of host LC in cutaneous GVHD using MCs 
The development of GVHD remains a significant clinical burden associated with 
allogeneic transplantation. The skin is the most commonly affected organ, with 
cutaneous GVHD developing in 81% of patients with acute GVHD75. In MHC-
mismatched models of GVHD, recipient APCs that survive the conditioning are 
essential in the development of GVHD55. The skin contains a number of phenotypically 
distinct dendritic cell populations, including LC and Langerin+ dermal DC. Host LC are 
of potential interest due to their radioresistance, ability to persist post transplant and 
immunogenicity of host APC. 
Exploiting theses unique characteristics, elegant BM chimera experiments have shown 
that LC are capable of inducing GVHD-like lesions in the skin when presentation of 
relevant antigen in the skin is restricted to LC282,301. We decided to investigate whether 
LC were required in the presence of other host-type (BL/6 derived) cutaneous DCs that 
are capable of presenting relevant antigen. In [BL/6+BALB/c] → Langerin-DTR MCs, it 
was hypothesised based on the literature that the LC compartment would remain of 
host (Langerin-DTR) origin (Figure 23, B). LC could therefore be depleted using DT 
allowing us to investigate the role of host LC in cutaneous GVHD. 
However, when the chimerism of LC in established [BL/6+BALB/c] → Langerin-DTR 
MCs was examined, two populations of LC derived from host and donor cells derived 
from MHC-mismatched BM were observed. Although the majority of LC in the 
epidermis were host derived (Langerin-DTR) LC, BALB/c derived LC constituted 
around ~38% of the total population.  
This was an unexpected observation based on the literature and is the first time donor 
infiltration of LC into the epidermis in mice that have received TCD BM has been 
reported. Research conducted by Merad et al. has shown that LC in BL/6 mice which 
expressed the CD45.2 allele were lethally irradiated and reconstituted with CD45.1 
 147 
congenic donor BM, were found to be of host origin up to 18 months after transplant258. 
In addition, when lethally irradiated BALB/c (H-2d) mice were reconstituted with MHC-
mismatched allogeneic TCD BM from a BL/6 (H-2b) donor, LC again remained of host 
origin for at least 12 months after transplantation282. However, when BALB/c recipients 
were reconstituted with whole BM which contained around ~2% T cells, host LC were 
largely replaced with donor derived LC, suggesting alloreactive T cells are required for 
donor conversion282. In the [BL/6+BALB/c] → Langerin-DTR MC, the depletion of T 
cells in donor BM was confirmed before transplant.  
Interestingly, despite the presence of donor BALB/c (H-2d) derived LC, virtually no 
donor BL/6 (H-2b) derived LCs were observed. However, Langerin+ dDC in the dermis 
were mixed and derived equally from donor BL/6 (H-2b) and BALB/c (H-2d) bone 
marrow. This indicated that BM precursors from donor BL/6 mice were able to access 
the skin. The ratio of BL/6:BALB/c BM was then changed from 1:1 to 3:1. Increasing 
the number of donor BL/6 BM precursors had no effect on the chimerism of LC in the 
epidermis. In the dermis, the chimerism of dermal DC was altered and skewed towards 
donor BL/6 derived cells. Taken together, these data suggests there is an active 
mechanism preventing donor BL/6 precursors establishing LCs in the epidermis. 
To account for any inherent strain variation, [BL/6(CD45.2.CD45.1)+B6D2F1(CD45.2)] 
→ BL/6(CD45.1) MCs were generated. In these MC, dermal DC were donor derived 
and again equally mixed between BL/6 (H-2b) and B62DF1 (H-2db) cells. In the 
epidermis, no donor BL/6 (H-2b) derived LC were observed. However, when the 
chimerism of epidermal γδ T cells was examined, the population was split between 
donor and host BL/6 derived cells with very few donor B62DF1 derived cells detected. 
This was the converse of what was observed in LC and indicated that BM precursors 
were in fact able to access the epidermis as well as the dermis. γδ T cells colocalise 
with LC in the epidermis and have also shown reactivity to self-MHC independent of 
the antigen302,303. Using Tcrdtm1Mom knockout mice (H-2b), in which epidermal γδ T cells 
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are constitutively absent, one possible experiment to test the role of γδ T cells in the 
repopulation of host-type LC would be to generate [γδ-/-+BALB/c→ γδ-/-] mixed 
chimeras. In this model, host-type γδ T cells would be constitutively depleted and 
therefore unable to influence the repopulation of host-type LC. However, due to time 
constraints, dissecting the precise mechanism behind this observation was outside the 
scope of this project.  
This is an important observation as MCs are commonly used in the field to dissect the 
function of cells and genes alike. It appears there is an active, yet to be described 
mechanism, which prevents LC precursors derived from host-type BL/6 precursors 
from seeding the epidermis in the presence of host LC. Increasing the number of BL/6 
precursors had no effect on LC chimerism despite increasing the frequency of BL/6 
derived DC in the dermis. This mechanism also appears to be dependant on the MHC 
haplotype of donor cells rather than the genetic background of mice. Similar 
populations of donor derived LC were observed using both BALB/c (H2-d) and B62DF1 
(H2-db) as allogeneic donors.  
Despite the presence of donor BALB/c derived LC, the depletion of host LC was found 
to significantly decrease the severity of cutaneous GVHD in MC229. This would indicate 
that a direct interaction of host LC with T cells or another immunomodulatory cell type 
is important. Inflammation mediated by the TLR 7-8 agonist Imiquimod would have the 
same effect on donor and host derived LC in the epidermis. The cytokines and/or 
chemokines released by LC in specific response to Imiquimod could be compensated 
for by BALB/c derived LC when host LC have been depleted using DT. 
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3.4.3 Host Langerin+ dDC are not required for cutaneous GVHD 
Finding a precise role for LC in vivo became even more complex with the discovery of 
Langerin+ dDC. Modifying the MC model we used to deplete host LC, I was able to 
generate MCs where host-type (H2-b) Langerin+ dDC but not host LC could be 
depleted. This was important, as many of the immunological functions ascribed to LC in 
the past have now been attributed to the newly discovered Langerin+ dDC263,304.  
To date, a role for Langerin+ dDC in cutaneous GVHD has never been investigated. In 
our MC model of localised cutaneous GVHD, host Langerin+ dDC in contrast to host LC 
had no effect on the severity of GVHD that developed in the skin229. Other host-type 
DC subsets present in the skin such as LC and conventional dDC likely compensated 
for the depletion of host Langerin+ dDC. However, as Langerin+ dDC are efficient at 
cross-presenting self-antigens, BALB/c-derived Langerin+ dDC, which will not be 
depleted by DT, may be able to compensate for the depletion of host Langerin+ dDC. 
To definitively rule out a non-redundant role for Langerin+ dDC in the development of 
cutaneous GVHD, a model where all other DC are present except Langerin+ dDC 
would need to be developed. 
The MC model is a reductionist system and the use of the TLR 7-8 agonist Imiquimod 
stimulates a potent response in the skin of the MC. Any contribution of host Langerin+ 
dDC may also be masked by the potent inflammatory response mediated by 
Imiquimod. Another technical difficulty using the MC model was identifying host 
Langerin+ dDC during the allogeneic response. To analyse the cells in this series of 
experiments, I used the FACSCalibur (BD) flow cytometry system, which permitted a 
maximum staining panel of 4 separate flurophores. Langerin+ dDC account for around 
~4.8% of DC found in the dermis (Table 7), further separating this population into 
Langerin-DTR and BALB/c derived cells using 4 flurophores proved challenging. In 
future experiments, the LSRFortessa (BD) and a minimum staining panel of 5 
antibodies was used to characterise DC. 
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4 The depletion of host Langerhans cells significantly 
reduced the severity of cutaneous GVHD 
In the previous chapter, I developed protocols to consistently identify DC in the skin 
and investigated the role of host Langerin+ dDC in a model of localised cutaneous 
GVHD. Previous work in our lab using this model has already established a role for 
host LC in the skin during inflammation. However, the role of host haematopoietic APC 
such as DC in the development of acute GVHD remains controversial, with a number of 
studies reporting that host non-haematopoietic APC are sufficient to induce both CD4- 
and CD8-mediated GVHD129,130. 
To investigate whether host LC had a role in the development of GVHD in a more 
clinically relevant pre-clinical model of acute systemic GVHD, a MHC-matched, minor 
H antigen mismatched model of GVHD was developed. This model represents 
transplants in the clinic more closely than MHC-mismatched models, as MHC-
mismatched transplants are not commonly performed in humans. This model was then 
adapted to the Langerin-DTR mouse to investigate whether the conditional depletion of 
host LC and/or Langerin+ dDC had any influence on the development of either systemic 
or cutaneous GVHD. 
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4.1 MataHari minor H mismatch model of acute GVHD 
4.1.1 1 x106 MataHari CD8 T cells and 2 x106 polyclonal CD4 T cells is sufficient to 
induce GVHD 
In the clinic, male recipients of female MHC-matched BMT (F→M) are at greater risk of 
developing GVHD than other sex combinations and show strong alloresponses to H-Y 
derived minor histocompatibility antigens (H)66,305,306. Using MataHari (Mh) Tg CD8 T 
cells to initiate GVHD, a F→M, MHC-matched, minor H mismatch model of acute 
GVHD was developed. 
Mh CD8 T cells are monoclonal and bear a TCR specific for the ubiquitous male 
antigen (H-Y) derived peptide WMHHNMDLI (from the Uty gene), combined with the 
MHC class I molecule H-2Db189. To investigate whether Mh T cells were capable of 
initiating systemic GVHD, male BL/6 mice were lethally irradiated with a split dose of 11 
Gy and transplanted with a mixture of 1 x106 Mh T cells and 5 x106 BM, derived from a 
female BL/6 donor. In some models of CD8 T cell mediated GVHD, CD4 “help” can 
enhance the severity of GVHD188,307. Therefore, an additional cohort of recipients was 
injected with 2 x106 polyclonal CD4 T cells, derived from a female BL/6 donor, along 
with the BM and Mh T cell mixture. An exact outline of model is illustrated in Figure 
35A. 
Male BL/6 recipients were tracked for changes in weight and clinical observation score, 
key indicators of clinical GVHD, and culled 7 and 14 days after transplant. All recipients 
survived until the day of takedown but recipients that received 1x106 Mh T cells 
developed clinical GVHD as indicated by observation scores and weight loss compared 
to BM controls (Figure 35, B). However, the clinical score and weight loss observed 
was higher in recipients that received Mh+CD4 T cells than Mh T cells alone (Figure 
35, B). 
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In the spleen, Vβ8.3+ CD8+ Mh T cells were gated and analysed for their expression of 
CD44 and CD62L. A dose of 1 x106 Mh T cells was sufficient for Mh T cells to engraft 
and expand in vivo in the presence or absence of 2 x106 polyclonal CD4 T cells (Figure 
36, A). However, there was an increase in the absolute number of Mh T cells in the 
spleen by day 7 when Mh T cells were transplanted with polyclonal CD4 T cells (Figure 
36, B). There was no difference in the absolute number of Mh T cells by day 14. In 
controls, which received BM alone, a small frequency of Vβ8.3+ and CD8+ was 
identified. These represent endogenous donor CD8 T cells derived from the donor BM. 
To definitively track and characterise Mh T cells in future experiments a specific 
congenic marker, such as Thy1.1, was used. 
A dose 1 x106 cells was also sufficient for Mh T cells to infiltrate and accumulate in the 
skin 7 days after transplant (Figure 37, A). After an initial live cell gate, followed by a 
lymphocyte gate, Mh T cells were gated based on their expression of VB8.3+ CD45.2+ 
and CD8+. Mh T cells in the skin were both Vβ8.3+ CD45.2+. However, the expression 
of CD8 was inconsistent, with a large frequency of cells CD8- (Figure 37, A). This 
indicated that either Mh T cells down-regulate their expression of CD8 or an enzymatic 
step during processing was interfering with staining. Similar to the spleen, there was an 
increase in the frequency of Mh T cells in recipients that received Mh+CD4 T cells 
versus Mh T cells alone by day 7. However, there was no difference in the frequency of 
Mh T cells by day 14. 
Due to the increase of clinical GVHD and higher numbers/frequency of Mh T cells in 
both the spleen and epidermis 7 days after transplant, future experiments using the Mh 
minor H mismatch model will use 1 x106 Mh T cells and 2 x106 female polyclonal CD4 
T cells to induce GVHD. This dose was sufficient to induce acute GVHD in lethally 
irradiated male recipients, with GVHD like-pathology developing in GVHD target organs 
such as the skin and gut as evidenced by histological sections (Figure 38).  
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Figure 35: MataHari minor H mismatch model of GVHD. A. Male BL/6 mice (H-2b) were lethally 
irradiated with a split dose of 11 Gy and transplanted with a mixture of 1x106 Mh CD8 T cells and 5 x106 
BM, derived from a female BL/6 donor. Another cohort of recipients received 2 x106 polyclonal CD4 T 
cells, derived from a female BL/6 donor, along with BM and Mh T cells. The mice were culled 7 and 14 
days post transplant. B. Clinical score and weight loss plots (n=4-8, data pooled from 2 independent 
experiments, each data points represents the mean). Male BL/6 recipients that received Mh+CD4 T cells 
developed higher levels of clinical GVHD than recipients that received Mh T cells alone. 
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Figure 36: A dose of 1 x106 cell is sufficient for MataHari T cells to engraft and expand in vivo. A. 
Representative dot plots of SC taken from male BL/6 recipients 7 days after transplant. After an initial live 
gate, followed by a lymphocyte gate, Mh T cells were identified based on their expression of Vβ8.3 and 
CD8. The activation profile of Mh T cells was also analysed using CD44 and CD62L. In the spleen of 
recipients that were transplanted with Mh and Mh+CD4 T cells, 1 x106 Mh T cells was sufficient for Mh T 
cells to engraft and expand in vivo. B. Absolute numbers of Vβ8.3+ CD8+ Mh T cells in the spleen of male 
BL/6 recipients 7 and 14 days after transplant (n=2-4, data pooled from 2 independent experiments, 
horizontal bars indicate the mean±SD). There was a small increase in the number of Mh T cells in the 
spleen of recipients that received Mh+CD4 T cells compared to Mh T cells alone by day +7 after 
transplant. There was difference in the number of Mh T cells in the spleen by day +14 after transplant.  
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Figure 37: A dose of 1 x106 cells is sufficient for MataHari T cells to accumulate in the skin 7 days 
after transplant. A. Representative dot plots of the epidermis taken from male BL/6 recipients 14 days 
after transplant. After an initial live cell gate, followed by a lymphocyte gate, Mh T cells were identified 
based on their expression of Vβ8.3, CD45.2 and CD8β. In the epidermis of recipients that were 
transplanted with Mh and Mh+CD4 T cells, 1 x106 Mh T cells was sufficient for Mh T cells to accumulate in 
the skin. However, the expression of CD8β on Mh T cells was inconsistent. B. Summary data showing the 
accumulation of Vβ8.3+ CD45.2+ Mh T cells in the epidermis of male BL/6 recipients 7 and 14 days after 
transplant as a percentage of the initial FSC-H, SSC-H lymphocyte gate (n=2-4, data pooled from 2 
independent experiments, horizontal bars indicate the mean±SD). There was a small increase in the 
number of Mh T cells in the epidermis of recipients that received Mh+CD4 T cells compared to Mh T cells 
alone by day 7. There was no difference by day 14. In controls that received BM alone, no Mh T cell 
accumulated in the skin.  
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Figure 38: 1 x106 MataHari T cells is sufficient to induce GVHD 7 days after transplant. Histological 
sections of back skin and the colon of male recipients 7 days post transplant. Images captured at x10 
magnification using a Leica DMD108 light microscope. Evidence of histological GVHD can be observed in 
both the skin and colon of recipients that received Mh+CD4 T cells. In the skin, significant levels of 
epidermal thickening, dyskeratosis and lymphocyte infiltration was present in recipients that received 
Mh+CD4 T cells compared to BM controls. In the colon, significant levels of lamina propria inflammatory 
cell infiltrate, crypt epithelial cell apoptosis and crypt loss was present in recipients that received Mh+CD4 
T cells compared to BM controls.  
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4.1.2 Incubating SC with Dispase II impedes the staining of Mh T cells with CD8 
The expression of CD8β on Mh T cells in the skin was inconsistent. It has previously 
been shown that Dispase II can interfere with the expression of CD8 on 
lymphocytes308. To investigate whether Dispase II interfered with the staining of Mh T 
cells with anti-CD8 antibodies, SC were harvested from BL/6 recipients 7 days after 
transplant with Thy1.1+ Mh T cells, 2 x106 CD4 T cells and 5 x106 BM. SC were 
incubated at 36 °C and 2.5 mg/ml Dispase II added for 0, 30, 60 and 90 min. The 
samples were then stained for Mh T cells and the expression of CD8 examined.  
After 30 min with Dispase II, the expression of CD8α on Mh T cells was undetectable 
(Figure 39). Mh T cells remained CD8β+ until SC samples were incubated with Dispase 
II for 90 min (Figure 39). However, the expression of CD8β was reduced compared to 
controls the longer samples were incubated with Dispase II. In controls, which were 
incubated for 90 min without Dispase II, Mh T cells expressed both CD8α and CD8β 
(Figure 39). Therefore, the use of anti-CD8α or anit-CD8β as an antibody to identify Mh 
T cells in Dispase II treated samples was discontinued. 
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Figure 39: Incubating splenocytes with Dispase II restricts the identification of T cells using CD8. 
Representative dot plots of SC samples treated with or without 2.5 mg/ml Dispase II taken from a BL/6 
mouse 7 days after BMT with 1x106 Mh T cells, 2 x106 CD4 T cells and 5 x106 BM. After a lymphocyte 
gate based on FSC-A, SSC-A, donor Mh T cells were identified based on their expression of Vβ8.3 and 
Thy1.1. Mh T cells were CD8α+ and CD8β+ in untreated controls. In SC samples incubated with Dispase II 
for 30, 60, 90 min, the expression of CD8α on Mh T cells was undetectable. The expression of CD8β was 
detectable until samples were incubated with Dispase II for 90 min. However, the expression was reduced 
compared to controls in all samples treated with Dispase II. 
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4.2 The depletion of host Langerhans Cells reduced the severity of cutaneous 
GVHD 
4.2.1 Depletion of host Langerin+ DC has no effect on systemic GVHD 
The MataHari minor H mismatch model was then adapted to Langerin-DTR mice, 
enabling us to investigate the role of host Langerin+ DC in a more clinically relevant 
model of GVHD. 
Male Langerin-DTR mice were lethally irradiated and reconstituted with a mixture of 1 
x106 Thy1.1+ Mh T cells along with 5 x106 BM and 2 x106 CD4 T cells, derived from a 
female WT BL/6 donor. To deplete host Langerin+ DC, Langerin-DTR mice were 
injected on day -2, 1, 4 and 7 days post transplant with 400 ng of DT. This was 
sufficient to deplete both host LC and Langerin+ dDC during the development of acute 
GVHD mediated by Mh T cells. As a control, another cohort of Langerin-DTR recipients 
were treated with PBS (Figure 40, A). 
Langerin-DTR recipients were tracked for changes in weight and clinical observation 
scores blinded, 3 times a week for 7 weeks (Figure 40, B). Langerin-DTR recipients 
that received Mh T cells developed clinical GVHD, with a number of recipients 
sacrificed for humane reasons when either the percentage weight loss exceeded 20% 
from original weight recorded at day 0 or clinical observations score exceeded 4. This 
contrasted recipients that were transplanted with BM alone, which had a 100% survival 
rate. However, there was no significant difference in the severity of acute GVHD that 
developed in Langerin-DTR recipients in the presence or absence of host Langerin+ 
DC as evidenced by weight loss and survival, two key indicators of clinical GVHD 
(Figure 40, B).  
The depletion of Langerin+ DC had no effect on the expansion and activation of 
circulating Mh T cells in the blood 14 days after transplant. After an initial lymphocyte 
gate, Vβ8.3+ and CD8+ Mh T cells were analysed for their expression of CD44 and 
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CD62L (Figure 41, A). There was no significant difference in either the frequency of Mh 
T cells or frequency of CD44high CD62Llow effector Mh T cells circulating in the blood in 
the presence or absence of host Langerin+ DC (Figure 41, B).  
Focusing on weight loss and survival of Langerin-DTR recipients, clinical GVHD 
appeared to peak 26 days after transplant (Figure 40, B). Langerin-DTR recipients 
were then culled either 7 days, during the initial cytokine storm phase, or 26 days after 
transplant to investigate whether Langerin+ DC have a role in the development of 
GVHD. In the spleen, the depletion of Langerin+ DC had no effect on the expansion, 
activation or function of donor T cells 7 and 26 days after transplant. After a lymphocyte 
gate, Vβ8.3+ Thy1.1+ CD8+ Mh T cells and CD4+ T cells were analysed for their 
expression of CD44 and CD62L (Figure 42, A). There was no significant difference in 
either the absolute number of Mh and CD4 T cells or frequency of CD44high CD62Llow 
effector Mh and CD4 T cells in the presence or absence of host Langerin+ DC at both 
time points (Figure 42, B). In BM controls, no evidence of Mh T cells was detected. 
Mh T cells were then taken from the spleen of Langerin-DTR recipients 7 days after 
transplant and restimulated for 8 h with 5 µm of relevant (WMH) or irrelevant 
(SIINFEKL) peptide in vitro. After a lymphocyte gate, Vβ8.3+ Thy1.1+ Mh T cells were 
analysed for their expression of the type II interferon, IFN-γ, a potent cytokine which 
shows a strong correlation with GVHD (Figure 43, A)309. After 8 h, Mh T cells stimulated 
with relevant peptide expressed IFN-γ. However, there was no significant difference in 
the expression of IFN-γ by Mh T cells from recipients with or without host Langerin+ DC 
(Figure 43, B). IFN-γ expression was also antigen specific, as Mh T cell in controls 
stimulated with irrelevant peptide did not express IFN-γ after restimulation. 
In the skin draining LN, defined in this study as the axial, brachial, cervical and inguinal 
LN, the depletion of Langerin+ DC again had no effect on either the expansion or 
activation of Mh T cells 7 and 26 days after transplant. After a lymphocyte gate, Mh T 
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Vβ8.3+ Thy1.1+ and CD8+ Mh T cells and CD4+ T cells were analysed for their 
expression of CD44 and CD62L (Figure 44). There was no significant difference in 
either the absolute number of Mh T cells or frequency of CD44high CD62Llow effector Mh 
T cells in the presence or absence of host Langerin+ DC 7 and 26 days after transplant 
(Figure 45). There was also no significant difference in either the absolute number of 
CD4 T cells or frequency of CD44high CD62Llow effector CD4 T cells in the presence or 
absence of host Langerin+ DC 26 days after transplant. No data for CD4 T cells was 
recorded 7 days after transplant. 
Taken together, these data shows that the depletion of host Langerin+ DC has no effect 
on the severity of GVHD that develops in this model. 
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Figure 40: The depletion of host Langerin+ DC had no effect on the development of acute GVHD. A. 
Male Langerin-DTR mice were lethally irradiated with a split dose of 11 Gy and reconstituted with a 
mixture of 1 x106 Thy1.1+ Mh T cells, 2 x106 CD4 T cells and 5 x 106 BM. To deplete host Langerin+ DC, 
Langerin-DTR recipients were injected i.p. with 400 ng of DT on day -2, 1, 4 and 7 post transplant. 
Controls were treated with PBS. Langerin-DTR recipients were tracked for changes in weight and clinical 
score and culled 7 weeks later. B. Clinical score, weight loss and survival plots (n=3-8, data pooled from 2 
independent experiments, each data point represents the mean, survival curve analysed using a log-rank 
(Mantel-Cox) test). The depletion of Langerin+ DC had no effect on the severity of GVHD that developed. 
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Figure 41: The depletion of host Langerin+ DC had no effect on the frequency of Mh T cells in the 
blood. A. Representative dot plots of blood taken from Langerin-DTR recipients 14 days after transplant. 
After a lymphocyte gate based on FSC-A, SSC-A, Mh T cells were identified based on their expression of 
Vβ8.3, CD45.1 and CD8. The activation profile of Mh T cells was also analysed using CD44 and CD62L. 
Mh T cells were circulating in the blood in the presence or absence of host Langerin+ DC. In BM controls, 
no Mh T cells were detected. B. Left- Summary data showing the frequency of Mh T cells as a percentage 
of the initial lymphocyte gate 14 days after transplant (n=11-12, data pooled from 3 independent 
experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney test). Right- 
Summary data showing the frequency of CD44high CD62Llow effector Mh T cells as a percentage of Mh 
cells gated 14 days after transplant (n=11-12, data pooled from 3 independent experiments, horizontal 
lines represent the mean±SD, data analysed using a Mann-Whitney test). The depletion of host Langerin+ 
DC had no effect on the expansion or activation of circulating Mh T cells. 
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Figure 42: The depletion of host Langerin+ DC had no effect on the expansion and activation of 
donor T cells in the spleen. A. Representative dot plots of SC taken from Langerin-DTR recipients 7 and 
26 days after transplant. After an initial anti-apoptotic cell gate followed by a lymphocyte gate, Mh T cells 
were identified based on their expression of Vβ8.3, Thy1.1 and CD8. The activation profile of Mh T cells 
was also analysed using CD44 and CD62L. Mh T cells expanded in the spleen in the presence or absence 
of host Langerin+ DC. In BM controls, no Mh T cells were detected. B. Left- Absolute number of Vβ8.3+ 
Thy1.1+ Mh and CD4+ T cells in the spleen 7 and 26 days after transplant (n=6-8, data pooled from 3 
independent experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney 
test). Right- Summary data showing the frequency of CD44high CD62Llow effector Mh T cells as a 
percentage of Mh and CD4 T cells gated (n=6-8, data pooled from 3 independent experiments, horizontal 
lines represent the mean±SD, data analysed using a Mann-Whitney test). The depletion of host Langerin+ 
DC had no effect on the expansion or activation of donor T cells in the spleen. 
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Figure 43: The depletion of Langerin+ DC had no effect on the function of Mh T cells in the spleen. 
A. Representative dot plots of SC taken from Langerin-DTR recipients 7 days after transplant, restimulated 
with 5 µm of WMH or SIINFEKL peptide for 8 h. After an initial lymphocyte gate, Mh T cells were identified 
based on their expression of Vβ8.3, Thy1.1. The expression of IFN-γ by Mh T cells was then examined. Mh 
T cells from the spleen restimulated with relevant antigen expressed IFN-γ in the presence or absence of 
host Langerin+ DC. In SIINFEKL controls, no IFN-γ expression was detected. B. Summary data showing 
the frequency of IFN-γ+ Vβ8.3+ Thy1.1+ Mh T cells after 8 h restimulation with peptide as a percentage of 
Mh T cells gated (n=6, data pooled from 2 independent experiments, horizontal lines represent the 
mean±SD, data analysed using a Mann-Whitney test). The depletion of host Langerin+ DC had no 
significant effect on the function of Mh T cells in the spleen.  
 166 
 
Figure 44: Gating strategy used to identify MataHari T cells in the skin draining lymph nodes. 
Representative dot plots from the skin draining LN taken from Langerin-DTR recipients 7 and 26 days after 
transplant. After an initial live cell gate followed by a lymphocyte gate, Mh T cells were identified based on 
their expression of Vβ8.3, Thy1.1 and CD8. The activation profile of Mh T cells was also analysed using 
CD44 and CD62L. Mh T cells expanded in the skin draining LN in the presence or absence of host 
Langerin+ DC. In BM controls, no Mh T cells were detected. 
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Figure 45: The depletion of host Langerin+ DC had no effect on the expansion and activation of 
donor T cells in the skin draining LN. Left- Absolute number of Vβ8.3+ Thy1.1+ Mh and CD4+ T cells in 
the spleen 7 and 26 days after transplant (n=5-8, data pooled from 3 independent experiments, horizontal 
lines represent the mean±SD, data analysed using a Mann-Whitney test). Right- Summary data showing 
the frequency of CD44high CD62Llow effector T cells as a percentage of Mh and CD4 T cells gated (n=5-8, 
data pooled from 3 independent experiments, horizontal lines represent the mean±SD, data analysed 
using a Mann-Whitney test). The depletion of host Langerin+ DC had no effect on the expansion or 
activation of donor T cells in the skin draining LN. 
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4.2.2 The majority of host Langerin+ DC are depleted 26 days after transplant 
Treating Langerin-DTR recipients with DT on days -2, 1, 4 and 7 post transplant was 
highly effective at depleting host Langerin+ DC for the duration of the experiment. 7 
days after transplant, no LC were detected in the skin of Langerin-DTR recipients 
treated with DT (Figure 46). In both PBS treated recipients of Mh T cells and BM 
controls, host LC (GFP+) remained in the epidermis (Figure 48). 
A different pattern emerged 26 days after transplant. In the presence of donor Mh T 
cells, the majority of host Langerin+ DC were depleted. After an initial live cell gate 
followed by a DC gate, LC were identified based on their expression of MHCII, CD11b, 
CD24, CD45.2 and GFP (Figure 47).  LC were now present in the epidermis of both 
PBS and DT treated Langerin-DTR recipients. However, the majority of LC in the skin 
of PBS treated mice were now GFP- CD45.2- donor derived LC (Figure 48). This 
contrasted the epidermis of BM controls, where the majority of LC remained host 
derived (Figure 48). Both donor and host LC populations could be distinguished from 
one another as CD45.2+ Langerin-DTR recipients were transplanted with congenically 
marked CD45.1+ BM from a female WT BL/6 donor (Figure 47). 
Of note, there remained significantly more LC in the epidermis of PBS versus DT 
treated recipients 26 days after transplant, despite the majority of these cells being 
GFP- CD45.2- donor derived LC. There were also significantly more MHCII+ CD11b+ 
cells in PBS versus DT treated recipients 26 days after transplant with alloreactive 
donor T cells, the majority of which were not LC (Figure 49).  
Taken together, DT efficiently depletes Langerin+ DC. In contrast to BM controls, the 
majority of host derived Langerin+, including radio-resistant LC, are depleted in PBS 
treated recipients 26 days after transplant with alloreactive Mh T cells. Interestingly, the 
frequency of MHCII+ CD11b+ cells in the epidermis is higher in PBS versus DT treated 
recipients by day 26 despite the majority of cells in both recipients being donor derived. 
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The presence of Langerin+ DC at the time of transplant increases the frequency of 
MHCII+ CD11b+ cells that infiltrate the epidermis.  
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Figure 46: Host Langerhans cells are depleted in Langerin-DTR recipients 7 days after transplant. 
Representative dot plots of the epidermis from Langerin-DTR recipients 7 days after transplant. After an 
initial live cell gate, followed by FSC-W versus FSC-A gate to eliminate doublets and a broad DC gate 
based on FSC-A, SSC-A, LC were identified based on their expression of EpCAM, CD11b and GFP.  Host 
LC were efficiently depleted in Langerin-DTR recipients treated with DT. Host LC persisted in both PBS 
treated recipients and BM controls 7 days after transplant. 
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Figure 47: Langerhans cells remain depleted in DT treated Langerin-DTR recipients 26 days after 
transplant with Mh T cells are donor derived. A. Representative dot plots of the epidermis from 
Langerin-DTR recipients 26 days after transplant. After an initial live cell gate, followed by a DC gate, LC 
were identified based on their expression of MHCII, CD11b, CD24, CD45.2 and GFP.  In Langerin-DTR 
recipients transplanted with Mh T cells the majority of LC were donor derived (CD45.2- GFP-). In contrast, 
the majority of LC in BM controls were host derived. Donor derived LC were observed in DT treated 
recipients. However, the frequency of donor derived LC was higher in PBS versus DT treated recipients. 
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Figure 48: The majority of Langerhans cells in the epidermis 26 days after transplant with Mh T 
cells are donor derived. Top left- Summary data showing the frequency of EpCAM+ CD11b+ LC as a 
percentage of the initial DC gate 7 days after transplant (n=2-6, data pooled from 2 independent 
experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney test). LC were 
efficiently depleted in Langerin-DTR recipients treated with DT 7 days after transplant. Top right- Summary 
data showing the frequency of CD45.2+ GFP+ LC as a percentage of LC gated 7 days after transplant 
(n=2-6, data pooled from 2 independent experiments, horizontal lines represent the mean±SD). The 
majority of LC in Langerin-DTR recipients 7 days after transplant are CD45.2+ GFP+ host derived. Bottom 
left- Summary data showing the frequency of MHCII+ CD11b+ CD24+ LC as a percentage of the initial DC 
gate 26 days after transplant (n=2-8, data pooled from 3 independent experiments, horizontal lines 
represent the mean±SD, data analysed using a Mann-Whitney test). LC were observed in both PBS and 
DT treated Langerin-DTR recipients of Mh T cells 26 days after transplant. However, there was 
significantly more LC in PBS versus DT treated recipients. Bottom right- Summary data showing the 
frequency of CD45.2+ GFP+ LC as a percentage of the LC gated 26 days after transplant (n=2-8, data 
pooled from 3 independent experiments, horizontal lines represent the mean±SD, data analysed using a 
Mann-Whitney test). The majority of LC in PBS treated Langerin-DTR recipients were donor derived LC 
(CD45.2- GFP-) 26 days after transplant. In BM controls, the majority of LC remained of host origin 
(CD45.2+ GFP+). 
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Figure 49: The depletion of host Langerin+ DC influences the repopulation kinetics of donor 
dendritic cells in the skin. Top left- Summary data showing the frequency of CD11b+ cells as a 
percentage of the initial DC gate 7 days after transplant (n=2-6, data pooled from 2 independent 
experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney test). There 
were significantly more CD11b+ cells in the PBS versus DT recipients that were transplanted with Mh T 
cells. Top right- Summary data showing the frequency of EpCAM+ GFP+ LC as a percentage of CD11b 
cells gated 26 days after transplant (n=2-6, data pooled from 2 independent experiments, horizontal lines 
represent the mean±SD). The majority of CD11b+ in Langerin-DTR recipients 7 days after are CD45.2+ 
GFP+ host derived LC, but there is a significant infiltration of other CD11b+ cells. Bottom left- Summary 
data showing the frequency of MHCII+ CD11b+ DC as a percentage of the initial DC gate 26 days after 
transplant (n=2-8, data pooled from 3 independent experiments, horizontal lines represent the mean±SD, 
data analysed using a Mann-Whitney test). There were significantly more cells expressing a DC-like 
phenotype in PBS versus DT treated Langerin-DTR recipients of Mh T cells 26 days after transplant. The 
depletion of host Langerin+ DC significantly reduced the infiltration of donor DC into the epidermis. Bottom 
right- Summary data showing the frequency of CD24+ LC as a percentage of the MHCII+ CD11b+ cells 
gated (n=2-8, data pooled from 3 independent experiments, horizontal lines represent the mean±SD). The 
majority of DC gated were not LC 26 days after transplant. 
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4.2.3 Depletion of host Langerin+ DC reduced the accumulation of MataHari CD8 T 
cells in the skin 
 
To determine the role of Langerin+ DC in the development of cutaneous GVHD, the 
infiltration and accumulation of donor T cells in the skin of Langerin-DTR recipients, 
treated with either PBS or DT, was assessed 7 and 26 days after transplant with Mh T 
cells. 
After an initial live cell gate, followed by a lymphocyte gate, Mh T cells were identified 
based on their expression of Vβ8.3 and Thy1.1. The epidermis and dermis were 
separated using dispase II, therefore the use of anti-CD8 antibodies for staining was 
precluded. CD4 T cells were identified using CD4 and CD45.2 (Figure 50).  
Both Mh and CD4 T cells could be easily identified in the epidermis and dermis of 
Langerin-DTR recipients transplanted with Mh T cells. Interestingly, the depletion of 
host Langerin+ DC significantly reduced the accumulation of Mh T cells in the epidermis 
7 and 26 days after transplant (Figure 51). In the dermis, there was a strong trend 
towards a lower frequency of Mh T cells in the absence of Langerin+ DC but this was 
not significant (p=0.0584) 7 days after transplant. By day 26 post transplant, there was 
a highly significant reduction in the frequency of Mh T cells in the dermis (Figure 51). 
The frequency of CD4 T cells in the epidermis was not affected by the depletion of 
Langerin+ DC 7 days after transplant. However, by day 26, there was a strong trend 
towards there being less CD4 T cells in the epidermis of Langerin-DTR recipients 
treated with DT, but this was not significant (p=0.0514). The frequency of CD4 T cells 
in the dermis was unaffected by the depletion of host Langerin+ DC depletion (Figure 
51). Unlike the lymphoid tissues, the depletion of host Langerin+ DC had a profound 
effect on the frequency of Mh T cells in the skin, indicating a possible reduction the 
degree of cutaneous GVHD that developed.  
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Figure 50: The depletion of host Langerin+ DC reduces the accumulation of donor T cells in the 
skin 26 days after transplant. Representative dot plots of the epidermis and dermis from Langerin-DTR 
recipients 26 days after transplant. After an initial live cell gate followed by a lymphocyte gate, Mh T cells 
were identified based on their expression of Vβ8.3 and Thy1.1. CD4 T cells were identified based on their 
expression of CD4 and CD45.2. In both the epidermis and dermis, the frequency of both Mh and CD4 T 
cells was reduced in DT versus PBS treated Langerin-DTR recipients 26 days after transplant. In BM 
controls, a small frequency of CD4 T cells but no Mh T cells were detected. 
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Figure 51: The depletion of host Langerin+ DC significantly reduces the accumulation of MataHari T 
cells in the skin by day 7. Top & Bottom Left- Summary data showing the frequency of Vβ8.3+ Thy1.1+ 
Mh T cells in the epidermis and dermis as a percentage of lymphocytes gated 7 and 26 days after 
transplant (n=5-8, data pooled from 3 independent experiments, horizontal lines represent the mean±SD, 
data analysed using a Mann-Whitney test). The accumulation of Mh T cells was significantly reduced in the 
absence of host Langerin+ DC in both the epidermis and dermis 7 and 26 days after transplant. Top & 
Bottom Right- Summary data showing the frequency of CD45.2+ CD4+ T cells in the epidermis and dermis 
as a percentage of lymphocytes gated 7 and 26 days after transplant (n=3-5, data pooled from 1-2 
independent experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney 
test). There was no difference in the accumulation of CD4 T cells in the epidermis by day 7. However, 
there was a significant reduction in the absence of host Langerin+ DC in the epidermis 26 days after 
transplant. There was no difference in the dermis, although there was a trend towards there being less 
CD4 T cells in the absence of host Langerin+ DC. 
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4.2.4 The depletion of host LC, but not Langerin+ dDC, reduced the severity of 
cutaneous GVHD 
GVHD experiments using Langerin-DTR recipients have so far depleted both LC and 
Langerin+ dDC. As both populations are migratory DC, each is capable of presenting 
host antigen to donor T cells. To determine whether the reduction in the frequency and 
of Mh T cells in the skin is dependent on the depletion of either host LC or Langerin+ 
dDC, a series of experiments were designed taking advantage of the unique 
characteristics of each population. This enabled us to investigate whether a similar Mh 
T cell phenotype was observed in the skin when either host LC were depleted but not 
Langerin+ dDC or vice versa. 
Taking advantage of the repopulation kinetics of Langerin+ dDC, which fully 
reconstitute its dermal niche 7 days after acute depletion, Langerin-DTR recipients 
were injected with DT 20 days before transplant to deplete host LC but not Langerin+ 
dDC (Figure 52)275. At Day 0 (time of transplant), host LC but not Langerin+ dDC would 
be depleted in the skin of DT treated Langerin-DTR recipients. This was confirmed 
through flow cytometry of epidermal and dermal samples of Langerin-DTR mice treated 
with DT 20 days earlier (Figure 53). After an initial live cell gate followed by a DC gate, 
LC and Langerin+ dDC were identified based on their expression of MHCII, CD45.2, 
CD11b, CD207 and GFP. In the epidermis, LC were efficiently depleted. However, 
CD11b-/low GFP+ Langerin+ dDC had reconstituted the dermis as expected. 
To deplete host Langerin+ dDC but not LC, male WT BL/6 mice were lethally irradiated 
and reconstituted with 5 x106 TCD BM cells from male Langerin-DTR mice (Figure 54). 
The [Langerin-DTR → BL/6] chimeras were allowed to recover for 8 weeks before 
being subsequently transplanted with Mh T cells and female BM + CD4 T cells derived 
from a WT BL/6 donor. To deplete host Langerin+ dDC but not LC, the [Langerin-DTR 
→ BL/6] chimeras were treated on days -2, 1, 4 and 7 days post transplant with DT. LC 
are radioresistant and in [Langerin-DTR → BL/6] chimeras, LC are derived from WT 
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BL/6 and resistant to depletion via DT. This was confirmed by flow cytometry when LC 
were not depleted in the epidermis of DT treated chimeras 7 days after transplant 
(Figure 55). Langerin+ dDC are not radioresistant and will be derived from Langerin-
DTR BM and thus be susceptible to depletion via DT. This was highlighted in previous 
chapter where host LC in MC were derived from host and donor cells whereas 
Langerin+ dDC were derived entirely of donor cells. 
The accumulation of donor T cells in the skin when either host LC or Langerin+ dDC 
were depleted was then investigated. The same gating strategy was applied to both 
data sets so the frequencies of T cells could be directly compared (Figure 56). Mh T 
cells were identified based on their expression of Vβ8.3 and Thy1.1. CD4 T cells on 
their expression of CD4 and CD45.2. 
The depletion of host LC, but not Langerin+ dDC, significantly reduced the 
accumulation of Mh T cells in the epidermis (Figure 57). The magnitude of this 
reduction was similar to that seen when Langerin+ DC were depleted. There was no 
significant difference in the frequency of CD4 T cells in the epidermis. However, similar 
to when Langerin+ DC were depleted, there was a trend towards there being less CD4 
T cells when host LC were depleted. A similar pattern to the epidermis for both Mh and 
CD4 T cells was observed in the dermis (Figure 58). 
In contrast, the depletion of host Langerin+ dDC, but not LC, in chimeras 20 days after 
transplant had no effect on the accumulation of Mh T cells in the epidermis (Figure 57). 
The frequency of Mh T cells in the epidermis of both PBS and DT treated chimeras was 
similar to that of PBS treated Langerin-DTR recipients culled 26 days after transplant. 
There was also no difference in the frequency of CD4 T cells although the frequency in 
chimeras was lower than that of Langerin-DTR recipients (Figure 57). A similar pattern 
to the epidermis was again observed in the dermis (Figure 58). Combining these 
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results together, it is clear that host LC, but not Langerin+ dDC, are responsible for the 
phenotype that has been described so far. 
Histological sections of skin were also collected from the ears of Langerin-DTR 
recipients 26 days after transplant, where only host LC had or had not been depleted 
(Figure 59, A). Sections were evaluated single blind for evidence of histopathological 
GVHD (dyskeratosis, epidermal thickening and lymphocyte infiltration). In the absence 
of host LC, there was a highly significant reduction in the severity of pathology that 
developed in the skin (Figure 59, B). This reduction was consistent across all three 
independent experiments and no evidence of cutaneous GVHD was observed in a BM 
control. Thus, the depletion of host LC, but not Langerin+ dDC, is responsible for a 
significant reduction both in the accumulation of alloreactive Mh T cells in the skin and 
the severity of cutaneous GVHD that develops. 
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Figure 52: The depletion of host Langerhans cells but not Langerin+ dDC in the MataHari minor H 
mismatch model. A. Male Langerin-DTR mice were lethally irradiated with a split dose of 11 Gy and 
reconstituted with a mixture of 1 x106 Thy1.1+ Mh T cells, 2 x106 CD4 T cells and 5 x 106 BM. To deplete 
host LC but not Langerin+ dDC, Langerin-DTR recipients were injected i.p. with 400 ng of DT on day -20 
before transplant. Controls were injected PBS. B. Overview of the DC populations 1 and 20 days post DT 
based on data in the previous chapter. After 1 day, both host LC and Langerin+ dDC are depleted. 
However, by day 20, host Langerin+ dDC have repopulated the dermis while host LC remain depleted in 
the epidermis. 
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Figure 53: Langerin+ dDC repopulate the dermis of Langerin-DTR mice 20 days after exposure to 
DT. Representative dot plots of the epidermis and dermis from Langerin-DTR mouse 20 days after 
treatment with 400 ng of DT. After an initial anti-apoptotic cell gate, followed by a DC gate, LC and 
Langerin+ dDC were identified based on their expression of MHCII, CD45.2, CD207 and GFP. LC 
remained depleted 20 days after exposure to DT. However, Langerin+ dDC had repopulated the dermis 20 
days after DT treatment. 
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Figure 54: The depletion of host Langerin+ dDC but not Langerhans cells in the MataHari minor H 
mismatch model. A. Male BL/6 mice were lethally irradiated with a split dose of 11 Gy and reconstituted 
with 5 x106 BM derived from male Langerin-DTR mice. After 8 weeks, [Langerin-DTR → BL/6] chimeras 
were lethally irradiated and transplanted with a mixture of 1 x106 Thy1.1+ Mh T cells, 2 x106 CD4 T cells 
and 5 x 106 BM. To deplete host Langerin+ dDC [Langerin-DTR → BL/6] recipients were injected i.p. with 
400 ng of DT on days -2, 1, 4 and 7 before transplant. Controls were injected PBS. B. Overview of the DC 
populations in the skin of WT BL/6 mice and [Langerin-DTR → BL/6] chimeras based on data in Chapter 1 
and the literature. In WT BL/6 mice, treatment with DT has no effect on DC populations in the skin. LC are 
radioresistant. In [Langerin-DTR → BL/6] chimeras, LC are derived from BL/6 mice and will not be 
depleted by DT. However, Langerin+ dDC will be entirely derived from Langerin-DTR BM and susceptible 
to depletion via DT. Therefore, treating [Langerin-DTR → BL/6] chimeras with DT will deplete host 
Langerin+ dDC but not LC. 
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Figure 55: Host Langerhans cells are not depleted by DT in [Langerin-DTR →  BL/6] chimeras. 
Representative dot plots of the epidermis from [Langerin-DTR → BL/6] chimeras 7 days after transplant. 
After an initial live cell gate, followed by a DC gate, LC were identified based on their expression of CD11c, 
CD11b, CD24 and CD45.2. In the epidermis, LC were not depleted by DT. 
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Figure 56: Gating strategy used to identify MataHari and CD4 T cells in the skin. Representative dot 
plots of the epidermis Langerin-DTR and [Langerin-DTR → BL/6] recipients 26 and 20 days after 
transplant respectively. After a live cell gate followed by a lymphocyte gate, Mh T cells were identified 
based on their expression of Vβ8.3 and Thy1.1. CD4 T cells were identified based on their expression of 
CD4 and CD45.2. The depletion of host LC reduced the accumulation of Mh T cells in the epidermis. 
However, the depletion of host Langerin+ dDC had no effect on the accumulation of Mh T cells in the 
epidermis. 
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Figure 57: The depletion host Langerhans cells but not Langerin+ dDC reduced the accumulation of 
MataHari T cells in the epidermis. Summary data showing the accumulation of Vβ8.3+ Thy1.1+ Mh and 
CD45.2+ CD4+ T cells in the epidermis as a percentage of the initial lymphocyte gate (n=5-9, data pooled 
from 2-3 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is indicated by the 
horizontal bars). There was a significant reduction in the accumulation of Mh T cells 26 days after 
transplant when host LC were depleted. However, there was no reduction in the accumulation of Mh T 
cells 20 days after transplant when host Langerin+ dDC were depleted. There was no significant difference 
in the accumulation of CD4 T cells. However there was a trends towards there being less in recipients 
depleted of host LC only. Thus, the depletion of host LC are responsible for the reduction in Mh T cells 
observed in the epidermis.  
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Figure 58: The depletion host Langerhans cells but not Langerin+ dDC reduced the accumulation of 
MataHari T cells in the dermis. Summary data showing the accumulation of Vβ8.3+ Thy1.1+ Mh and 
CD45.2+ CD4+ T cells in the dermis as a percentage of the initial lymphocyte gate (n=5-9, data pooled from 
2-3 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is indicated by the 
horizontal bars). A similar pattern to the epidermis emerged. There was a significant reduction in the 
accumulation of Mh T cells 26 days after transplant when host LC were depleted. However, there was no 
reduction in the accumulation of Mh T cells 20 days after transplant when host Langerin+ dDC were 
depleted. There was no difference in the accumulation of CD4 T cells. However there was a trends 
towards there being less in recipients depleted of host LC only. Thus, the depletion of host LC are 
responsible for the reduction in Mh T cells observed in the skin. 
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Figure 59: The severity of GVHD is significantly reduced in the absence of host Langerhans cells. 
A. Histological sections of ear skin taken from Langerin-DTR recipeints 26 days after transplant. Only host 
LC were depleted in DT samples. Images captured at X20 magnification using a Leica DMD108 light 
microscope. B. Summary data of histological GVHD score as evaluated single blind (n=1-9, data pooled 
from 1-3 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is indicated by the 
horizontal bars.). There was a significant reduction in the severity of cutaneous GVHD between DT versus 
PBS treated recipients. 
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4.2.5 The depletion of host LC and Langerin+ dDC had no effect on the severity of 
acute GVHD in the lung, liver or gut 
The depletion of host LC but not Langerin+ dDC resulted in a highly significant 
reduction of cutaneous GVHD. Whether the depletion of host LC or Langerin+ dDC had 
any influence on the development of GVHD in other tissues commonly affected was 
also investigated. 
In the previous section, the effect of host LC or Langerin+ dDC on the accumulation of 
donor T cells in the skin was evaluated. In parallel, the liver, lamina propria + peyer’s 
patches (LP+PP) and lung were also harvested from these recipients and the 
accumulation of donor T cells and pathology of GVHD analysed. 
For the liver, cells were stained for propidium iodide (PI), an intercalating agent that 
binds nucleic acid, to eliminate dead cells and PI+ were first gated out. After a live cell 
gate followed by a lymphocyte were gate, Mh T cells were identified based on their 
expression of Vβ8.3 and Thy1.1. CD4 T cells were identified based on their expression 
of CD4 and CD45.2 (Figure 60). A similar gating strategy was later used to analyse 
both the LP+PP and lung. Mh and CD4 T cells were easily identified in the liver. The 
depletion of either host LC or Langerin+ dDC had no significant effect on the frequency 
of either Mh or CD4 T cells in the liver (Figure 60). The frequency of both Mh and CD4 
T cells between the livers of Langerin-DTR recipients and [Langerin-DTR BL/6] 
chimeras was also similar. The depletion of host LC was also found to have no 
significant effect on the severity of GVHD that developed in the liver, as evidenced by 
histological sections evaluated single blind, although the degree of pathology that 
developed in this tissue was relatively mild overall (Figure 61). 
In the LP+PP, a similar phenotype to the liver developed. The depletion of either host 
LC or Langerin+ dDC had no effect on the frequency of both Mh and CD4 T cells in the 
LP+PP (Figure 62). The frequency of donor T cells infiltrating the LP+PP was again 
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similar between Langerin-DTR recipients and [Langerin-DTR BL/6] chimeras. Of note, 
the degree of pathology that developed in this tissue was markedly more severe than 
the liver, although the depletion of host LC had no effect on the level of GVHD that 
developed (Figure 63).  
In the lung, there again was no difference in the frequency of either Mh or CD4 T cells 
when host LC or Langerin+ dDC were depleted and donor T cells again infiltrated both 
sets of recipients equally (Figure 64). However, there was a significant reduction in the 
severity of GVHD in the lung when host LC were depleted, although the magnitude of 
this reduction was much lower than that observed in the skin (Figure 65). Combining 
the data from the skin together with the tissues analysed here, the response of Mh T 
cells to the depletion of host LC is restricted mostly to the skin. 
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Figure 60: The depletion of host Langerin+ DC had no effect on the accumulation of donor T cells in 
the liver. A. Representative dot plots of the liver taken from Langerin-DTR recipients 26 days after 
transplant. PI- cells were gated to eliminate dead cells. After a live cell gate followed by a lymphocyte gate, 
Mh T cells were identified based on their expression of Thy1.1 and CD8. CD4 T cells were identified based 
on their expression of CD4. This gating strategy was applied to all samples analysed. B. Left- Summary 
data showing the frequency of Mh T cells in the liver as a percentage of the initial lymphocyte gate 26 (LC 
depletion) and 20 (Langerin+ dDC) days after transplant (n=5-9, data pooled from 2-3 independent 
experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney test). There 
was no difference in the accumulation of Mh T cells when either population of Langerin+ DC was depleted. 
Right- Summary data showing the frequency of CD4 T cells as a percentage of the initial lymphocyte gate 
26 (LC depletion) and 20 (Langerin+ dDC) days after transplant (n=5-9, data pooled from 2-3 independent 
experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney test). There 
was no difference in the accumulation of CD4 T cells when either population of Langerin+ DC was 
depleted.  
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Figure 61: The depletion of host Langerhans cells had no effect on the severity of GVHD in the 
liver. A. Histological sections of liver taken from Langerin-DTR recipeints 26 days after transplant. Only 
host LC were depleted in DT treated samples. Images captured at X20 magnification using a Leica 
DMD108 light microscope. B. Summary data of histological GVHD score as evaluated single blind (n=1-9, 
data pooled from 3 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is 
indicated by the horizontal bars.). The liver developed mild GVHD in this model and there was no 
significant reduction in the severity of GVHD in the liver when host LC were depleted.  
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Figure 62: The depletion of host Langerin+ DC had no effect on the accumulation of donor T cells in 
the LP+PP. A. Representative dot plots of the LP+PP taken from Langerin-DTR recipients 26 days after 
transplant. PI- cells were gated to eliminate dead cells. After a live cell gate followed by a lymphocyte gate, 
Mh T cells were identified based on their expression of Thy1.1 and CD8. CD4 T cells were identified based 
on their expression of CD4. This gating strategy was applied to all samples analysed. B. Left- Summary 
data showing the frequency of Mh T cells in the LP+PP as a percentage of the initial lymphocyte gate 26 
(LC depletion) and 20 (Langerin+ dDC) days after transplant (n=5-9, data pooled from 2-3 independent 
experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney test). There 
was no difference in the accumulation of Mh T cells when either population of Langerin+ DC was depleted. 
Right- Summary data showing the frequency of CD4 T cells in the LP+PP as a percentage of the initial 
lymphocyte gate 26 (LC depletion) and 20 (Langerin+ dDC) days after transplant (n=5-9, data pooled from 
2-3 independent experiments, horizontal lines represent the mean±SD, data analysed using a Mann-
Whitney test). There was no difference in the accumulation of CD4 T cells when either population of 
Langerin+ DC were depleted.  
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Figure 63: The depletion of host Langerhans cells had no effect on the severity of GVHD in the 
colon. A. Histological sections of the colon taken from Langerin-DTR recipeints 26 days after transplant. 
Only host LC were depleted in DT treated samples. Images captured at X20 magnification using a Leica 
DMD108 light microscope. B. Summary data of histological GVHD score as evaluated single blind (n=1-9, 
data pooled from 3 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is 
indicated by the horizontal bars.). There was no significant reduction in the severity of GVHD in the colon 
when host LC were depleted.  
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Figure 64: The depletion of host Langerin+ DC had no effect on the accumulation of donor T cells in 
the lung. A. Representative dot plots of the lung taken from Langerin-DTR recipients 26 days after 
transplant. PI- cells were gated to eliminate dead cells. After a live cell gate followed by a lymphocyte gate, 
Mh T cells were identified based on their expression of Thy1.1 and CD8. CD4 T cells were identified based 
on their expression of CD4. This gating strategy was applied to all samples analysed in B. B. Left- 
Summary data showing the frequency of Mh T cells in the lung as a percentage of the initial lymphocyte 
gate 26 (LC depletion) and 20 (Langerin+ dDC) days after transplant (n=5-9, data pooled from 2-3 
independent experiments, horizontal lines represent the mean±SD, data analysed using a Mann-Whitney 
test). There was no difference in the accumulation of Mh T cells when either population of Langerin+ DC 
was depleted. Right- Summary data showing the frequency of CD4 T cells in the lung as a percentage of 
the initial lymphocyte gate 26 (LC depletion) and 20 (Langerin+ dDC) days after transplant (n=5-9, data 
pooled from 2-3 independent experiments, horizontal lines represent the mean±SD, data analysed using a 
Mann-Whitney test). There was no difference in the accumulation of CD4 T cells when either population of 
Langerin+ DC were depleted.  
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Figure 65: The depletion of host Langerhans cells had no effect on the severity of GVHD in the 
lung. A. Histological sections of the lung taken from Langerin-DTR recipeints 26 days after transplant. 
Only host LC were depleted in DT treated samples. Images captured at X20 magnification using a Leica 
DMD108 light microscope. B. Summary data of histological GVHD score as evaluated single blind (n=1-9, 
data pooled from 3 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is 
indicated by the horizontal bars.). There was a significant reduction in the severity of GVHD in the lung 
when host LC were depleted. However, the magnitude of the difference was lower than that seen in the 
skin. 
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4.2.6 Mh T cells accumulate in the skin 6 days after transplant 
In all allogeneic BMT experiments involving Mh T cells to date, the earliest time point 
investigated post transplant was 7 days. This was sufficient for Mh T cells to have 
markedly expanded in the lymphoid tissues and also to infiltrate tissues commonly 
affected by GVHD such as the skin, liver, lung and LP+PP. 
To investigate the kinetics of Mh T cell infiltration in the aforementioned tissues, 
Langerin-DTR recipients, treated with or without DT 20 days before transplant to 
deplete host LC, were culled 3, 4, 5 and 6 days after transplant and the frequency of 
Mh T cells in each organ analysed. 
In the liver, lung and LP+PP, Mh T cells were gated using the strategy outlined in 
Figure 66. Mh T cells were detected in all three tissues 3 days after transplant, 
although the frequency of cells in the LP+PP at this time point was very low. The 
frequency of Mh T cells in each tissue increased steadily until day 6 post transplant. 
However, 26 days after transplant, the frequency of MataHari T cells was markedly 
decreased in all 3 tissues versus day 6 (Figure 68). 
In the skin, a different pattern was observed (Figure 67). In the epidermis, no Mh T 
cells were detected until day 6 post transplant and there was a significant reduction in 
the frequency of Mh T cells in the absence of host LC at this timepoint. In contrast to 
the liver, lung and LP+PP, the frequency of Mh T cells increased from day 6 to day 26 
post transplant. In the dermis, a very low frequency of Mh T cells was detected by day 
5 post transplant, which increased steadily by day 6. There was no difference in the 
accumulation of Mh T cells in the dermis in the absence of host LC by day 6. The 
frequency of Mh T cells also increased in the dermis between day 6 and day 26. Taken 
together, these data highlights the site-specific differences of a T cell response 
targeting the same antigen between tissues, and was the first step at identifying the 
mechanism of the phenotype mediated by host LC.  
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Figure 66: MataHari T cells have infiltrated the lung by day 3 post-transplant. Representative dot 
plots of the lung taken from Langerin-DTR recipients 3, 4, 5 and 6 days after transplant with Mh T cells. 
After a PI- gate followed by a lymphocyte gate, Mh T cells were identified based on their expression of 
Vβ8.3 and Thy1.1. This gating strategy was used for liver and LP+PP samples. Mh T cells had infiltrated 
the lung 3 days after transplant, with the frequency of cells in the lung increasing over the next few days. 
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Figure 67: MataHari T cells infiltrate the epidermis by day 6 post-transplant. Representative dot plots 
of the epidermis taken from Langerin-DTR recipients 3, 4, 5 and 6 days after transplant with Mh T cells. 
After a PI- AnV- gate, to eliminate dead and apoptotic cells, followed by a lymphocyte gate, Mh T cells 
were identified based on their expression of Vβ8.3 and Thy1.1. Interestingly, no Mh T cells were detected 
in the epidermis 3, 4 and 5 days post transplant. On day 6, Mh T cells accumulated in the epidermis. In 
recipients depleted of host LC, there was a reduction in the frequency of Mh T cells detected. 
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Figure 68: The infiltration of Mh T cells into the skin is distinct from other GVHD target organs. A. 
Summary data showing the frequency of Vβ8.3+ Thy1.1+ Mh T cells as a percentage the initial lymphocyte 
gate versus time after transplant in tissues indicated (day 3: n=1, day 4: n=2, day 5: n=5, day 6: n=6, day 
26: n=6, data pooled from 1-4 independent experiments, horizontal lines represent the mean). Mh T cells 
accumulated the liver and lung by day 3 post transplant. Mh T cells were detected on day 3 at very low 
frequencies, but increased steadily in the days afterwards. In all 3 tissues, there was a reduction in the 
frequency of Mh T cells at day 26 versus day 6. B. Top- Summary data showing the frequency of Vβ8.3+ 
Thy1.1+ Mh T cells as a percentage the initial lymphocyte gate versus time after transplant in the epidermis 
(day 3: n=1, day 4: n=2, day 5: n=5, day 6: n=6, day 26: n=9, data pooled from 1-4 independent 
experiments, horizontal lines represent the mean). Unlike other tissues affected by GVHD, Mh T cells were 
not detected in the epidermis until day 6 post transplant. The frequency of Mh T cells in the epidermis was 
lower on day 6 when host LC were depleted. The frequency of Mh T cells also increased between day 6 
and day 26, unlike other tissues investigated. Bottom- Summary data showing the frequency of Vβ8.3+ 
Thy1.1+ Mh T cells as a percentage the initial lymphocyte gate versus time after transplant in the dermis 
(day 3: n=1, day 4: n=2, day 5: n=5, day 6: n=6, day 26: n=9, data pooled from 1-4 independent 
experiments, horizontal lines represent the mean). In contrast to the epidermis, a very small frequency of 
Mh T cell was detected in the dermis by day 6 post transplant. The depletion of host LC had no effect on 
the frequency of Mh T cells by day 6. The frequency of Mh T cells also increased between day 6 and day 
26. 
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4.3 Discussion 
4.3.1 MHC-matched, minor H mismatch model of acute GVHD 
In the previous chapter, the role of host Langerin+ dDC was explored using an MHC-
mismatched model of localised cutaneous GVHD. Previous work in our lab using this 
model has shown a role for host LC in the development of cutaneous GVHD. However, 
the MC model is a highly reductionist system that has no clear clinical correlate. 
To further explore the role of host LC and Langerin+ dDC in the development of 
cutaneous GVHD, I developed a more clinically relevant model of acute systemic 
GVHD, where either host LC or Langerin+ dDC could be conditionally depleted. In the 
clinic, male recipients of female BM (F→M) are at a greater risk of developing GVHD 
and show H-Y specific alloresponses306. Adapting this observation to mice, I developed 
a F→M, MHC-matched, minor H mismatch model of acute GVHD using Mh Tg CD8 T 
cells, which bear a TCR specific for a ubiquitous male antigen, to initiate GVHD.  
This model had a number of advantages over the MC model. Firstly, MHC-matched, 
minor H antigen mismatched models represent transplants in the clinic more closely 
than MHC-mismatched models, as MHC-mismatched transplants are not commonly 
performed in humans. Secondly, the GVHD that developed in this model was systemic. 
Histopathological GVHD developed in both the skin and gut 7 days after transplant with 
Mh T cells, organs that are commonly affected by acute GVHD in the clinic. Thirdly, the 
inflammation in this model is also generated by the conditioning regime, which more 
closely resembles the type of inflammation that initiates acute GVHD in the clinic rather 
than the application of the TLR agonist Imiquimod in the MC model. 
Using a monoclonal Tg T cell population to initiate GVHD also had advantages. A 
major limitation of MHC-matched, minor H antigen mismatched models that use 
polyclonal T cells is the difficultly in determining which alloantigens donor T cells are 
responding to. Differences in the TCR-repertoire may also have a significant influence 
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on the development of GVHD in a particular tissue. Using monoclonal Mh T cells, the 
dose of alloreactive T cells can be tightly controlled and easily traced in vivo using 
Vβ8.3 and Thy1.1, making the model highly tractable. The TCR is also ‘fixed’ and 
recognises the same antigen at every site, thus any changes in the development of 
GVHD in the skin when Langerin+ DC are depleted are TCR-repertoire independent. 
To initiate GVHD, I initially infused lethally irradiated BL/6 male mice with 1 x106 Mh T 
cells from the spleen of female Mh donors and 5 x106 BM cells derived from female 
BL/6 donor 4 h after the final dose of irradiation. This dosage was sufficient for Mh T 
cells to engraft and rapidly expand in vivo. By day 7 post transplant, Mh T cells had 
expanded in the spleen, with the majority of cells exhibiting a CD44high CD62Llow 
effector phenotype. This dosage was also sufficient for Mh T cells to infiltrate and 
accumulate in the skin 7 days after transplant.  
The addition of polyclonal CD4 T cells from a female donor appeared to enhance the 
Mh T cell response in vivo. There was an increase in both the absolute number of Mh T 
cells in the spleen and the frequency of infiltrating cells in the epidermis 7 days after 
transplant. In addition, recipients that received both Mh and CD4 T cells developed 
slightly more severe clinical GVHD, as evidenced by an increased weight loss and 
higher clinical scores, key indicators of GVHD. This was not unexpected, as the 
addition of CD4 ‘help’ has been shown to enhance the CD8 T cells response in other 
MHC-matched, minor H mismatch models193. Therefore, a dose of 2 x106 polyclonal 
CD4 T cells derived from the spleen of female WT BL/6 donors was added to the 
transplant mixture in all future experiments. This was sufficient to induce acute and 
systemic GVHD as evidenced by the development of histopathological GVHD in both 
the skin and gut 7 days after transplant, pathology that was absent in recipients that 
received BM alone.  
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In the skin, the expression of CD8 in Mh T cells was inconsistent, with a large 
frequency of cells infiltrating the epidermis negative for CD8. This was unexpected and 
indicated that either Mh T cells were downregulating their expression of CD8 or an 
enzymatic step during processing was interfering with staining. To test the latter 
hypothesis, I incubated SC harvested from male BL/6 recipients 7 days after transplant 
with donor Mh T cells with 2.5 mg/ml Dispase II for 0, 30, 60 and 90 min at 37°C. This 
had a profound effect on the expression of both CD8α and CD8β on VB8.3 and Thy1.1 
Mh T cells in line with a previously published report on the effects of Dispase II308. 
Therefore, the use of anti-CD8 antibodies to detect Mh T cells in the skin was 
discontinued in future experiments. 
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4.3.2 The depletion of host LC, but not Langerin+ dDC, significantly reduces the 
severity of cutaneous GVHD 
To evaluate the role host Langerin+ DC in the development of acute GVHD, male 
Langerin-DTR mice were used as recipients in the MataHari minor H mismatch model I 
developed at the beginning of the chapter. To deplete both host LC and Langerin+ 
dDC, Langerin-DTR recipients were injected on day -2, 1, 4 and 7 days post transplant 
with 400 ng of DT. This was sufficient to deplete both host LC and Langerin+ dDC 
during the initiation phase of acute GVHD and was based on the premise that the 
majority of infused donor Mh T cells would be primed by day 7 post transplant. As a 
control for any potential side effects associated with repeated i.p. injections, another 
cohort of Langerin-DTR recipients were treated with a similar volume PBS in parallel. 
This was important due to the frequency of injections at such an early stage after lethal 
irradiation, as it may have increased morbidity and mortality. 
Langerin-DTR recipients were subsequently tracked for 7 weeks after transplant for 
changes in survival and clinical GVHD. Langerin-DTR recipients that received Mh T 
cells developed moderate to severe clinical GVHD, with over 50% of recipients in both 
cohorts sacrificed for humane reasons before 7 weeks. This contrasted recipients that 
were transplanted with BM alone, which had a 100% survival rate. Langerin-DTR 
recipients of Mh T cells lost weight, appeared hunched, showed reduced activity and 
fur ruffling (key indicators of clinical GVHD in mice). The depletion of host Langerin+ 
DC had no significant effect on the survival, degree of weight loss and clinical score 
compared to PBS treated controls. Thus, host Langerin+ DC are not required for the 
initiation of acute GVHD in this model. The severity of GVHD that developed in this 
model appeared to be less severe than that published by another group using a similar 
dose of Mh T cells. However, it is well established in the field that differences in 
protocols and environmental pathogens between labs can significantly influence the 
degree of GVHD that develops181. For instance, in our model we add the antibiotic 
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Baytril to the drinking water a week before transplant, which may account for some of 
the differences observed between models. 
Focusing on the degree of weight loss in recipients, a double dip pattern emerged 
where recipients rapidly lost weight immediately after transplant before subsequently 
recovering for a few days, followed by another period of rapid weight loss, which was 
associated with the highest rate of mortality. This is a pattern commonly seen in other 
pre-clinical models, where mice initially lose weight due to the ‘cytokine storm’ 
associated with the conditioning regime before rapidly losing again due to the effector 
functions of alloreactive donor T cells. To assess the donor T cell response in vivo, 
Langerin-DTR recipients were culled at day 7 and 26 post transplant, where clinical 
GVHD appeared to peak in recipients around day 26.  
The depletion of host Langerin+ DC had no effect on the activation or expansion of 
donor Mh or CD4 T cells in the lymphoid tissue at day 7 or day 26 post transplant. In 
the spleen, the absolute number and frequency of effector CD44high CD62Llow Mh and 
CD4 T cells was similar in both cohorts. However, the absolute number of Mh T cells 
was significantly reduced in both cohorts by day 26 compared to day 7. This may be a 
result of either trafficking or activation induced cell death. The function of Mh T cells 
derived from the spleen of Langerin-DTR recipients 7 days after transplant was also 
assessed using an in vitro restimulation assay. There was no significant difference in 
the expression of IFN-γ in Mh T cells derived from Langerin-DTR recipients depleted of 
host Langerin+ DC compared to PBS treated controls.  
In the skin draining lymph nodes, which in this project refer to the inguinal, axial, 
brachial and cervical lymph nodes, a similar pattern emerged. The depletion of host 
Langerin+ DC had no effect on the activation or expansion of donor Mh T cells in the 
skin draining lymph nodes at day 7 or day 26 post transplant. The activation and 
expansion of donor CD4 T cells was not assessed on day 7 post transplant due to 
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efforts to stain T cells with E-selectin ligand, which were unsuccessfully due to 
technical reasons. However, there was no significant difference in the activation and 
expansion of donor CD4 T cells between cohorts after 26 days. The frequency of 
circulating donor Mh T cells was also assessed by tail bleed 14 days after transplant 
and there was also no difference in the frequency or activation profile between cohorts. 
Taken together, the survival data and T cell response in vivo demonstrates that host 
Langerin+ DC are not required for the initiation of acute GVHD in this model. The 
depletion of host Langerin+ DC also had no effect on the severity of systemic GVHD 
that developed. This was not unexpected, as several reports published during the 
course of these experiments challenged the role of host haematopoietic APC in the 
development of acute GVHD125,129,310. In both MHC-matched, minor H mismatched 
models of CD8- and CD4- mediated acute GVHD, both donor haematopoietic and host 
non-haematopoietic APC were found to be sufficient to initiate GVHD. In this model, 
host LC and Langerin+ dDC in the skin are depleted. Many other host DC populations 
capable of priming alloresponses will remain in DT treated recipients. Thus, the lack of 
a systemic effect on the development of acute GVHD was not surprising. 
However, when the skin was assessed, the depletion of host Langerin+ DC did have a 
profound effect on the development of GVHD. Initial experiments depleting both host 
LC and Langerin+ dDC demonstrated a significant reduction in the accumulation of Mh 
T cells in the epidermis at day 7 and day 26 post transplant. The effect on CD4 T cells 
was not as pronounced, with a significant difference in the accumulation only observed 
in the epidermis by day 26. To delineate whether host LC or Langerin+ dDC were 
responsible for this reduction in the accumulation of T cells, two experimental 
approaches were developed. Taking advantage of the repopulation kinetics of 
Langerin+ dDC, which fully reconstitute its dermal niche 7 days after acute depletion, 
Langerin-DTR recipients were injected with DT 20 days before transplant to deplete 
host LC but not Langerin+ dDC. This proved remarkably effective. 20 days after a 
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single i.p. injection of 400 ng DT, LC remained depleted but host Langerin+ dDC has 
fully reconstituted the dermis, in line with previously published data. Adopting the same 
gating strategy used to analyse the skin when both host LC and Langerin+ dDC were 
depleted, a similar reduction in the accumulation of Mh T cells in both the epidermis 
and dermis was observed when only host LC but not Langerin+ dDC were depleted. 
To deplete host Langerin+ dDC but not LC, I developed a different approach. Using 
male BL/6 mice as recipients, I generated [Langerin-DTR → BL/6] chimeras where host 
Langerin+ dDC were susceptible to DT mediated depletion but not LC. I confirmed that 
host LC were not depleted 7 days after transplant. However, I was unable to directly 
confirm depletion of host Langerin+ dDC due to inflammation and cellular infiltrate 
rendering the detection of Langerin+ dDC found at relatively low frequencies technically 
difficult. Due to time constraints, I was unable to generate a cohort of [Langerin-DTR → 
BL/6] chimeras to specifically test the chimerism and depletion of Langerin+ dDC. 
However, in the previous chapter, I established that host Langerin+ dDC were 
radiosensitive and in MC were derived entirely from donor cells. Thus, host Langerin+ 
dDC will be depleted in this model. Interestingly, adopting the same gating strategy 
used to analyse the skin when both host LC and Langerin+ dDC were depleted, the 
reduction in the accumulation of Mh T cells in both the epidermis and dermis was 
abrogated when Langerin+ dDC but not LC were depleted.  
Taken together, these data demonstrates that host LC but not Langerin+ dDC are 
responsible for a reduction in the accumulation of Mh T cells in the skin. This reduction 
was also skin specific, as the depletion of either host LC or Langerin+ dDC had no 
effect on the accumulation of Mh and CD4 T cells in the liver, lung and LP+PP.  
To evaluate whether this reduction in Mh T cells in the skin correlated with a reduction 
in the development of cutaneous GVHD, histopathological sections of the skin, liver, 
lung and colon were taken from Langerin-DTR recipients 26 days after transplant when 
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host LC but not Langerin+ dDC were depleted and scored single blind for evidence of 
GVHD. Remarkably, the depletion of host LC resulted in a highly significant reduction 
in the severity of GVHD that developed. The depletion of host LC had no effect on the 
development of GVHD in the liver or colon. However, there was a reduction in the 
development of GVHD in the lung in the absence of host LC although the reduction 
was relatively minor.   
To investigate the mechanism underpinning the reduction in cutaneous GVHD in the 
absence of LC, the kinetics of Mh T cell infiltration was analysed. In the liver, lung and 
LP+PP, Mh T cells were detected in all three tissues 3 days after transplant and 
steadily increased in frequency. Interestingly, in the skin, a different pattern emerged, 
no Mh T cells were detected until day 6 after transplant and highlighted the site-specific 
differences of a T cell response targeting the same antigen between tissues. In 
addition, there was a significant difference in the accumulation of Mh T cells in the 
epidermis in absence of host LC at this early stage.  
Interestingly, the frequency of Mh T cells in the epidermis and magnitude of the 
difference in the absence of host LC increased from day 6 to day 26. However, by day 
26 the majority of host LC had been depleted, yet the response and magnitude of the 
difference was still maintained in situ. The presence of host LC during the initiation 
stage of acute GVHD appears to be sufficient to drive the response observed. It is also 
noteworthy that the repopulation kinetics of DC into the epidermis was influenced by 
the depletion of host Langerin+ DC. By day 26, there were significantly more MHCII+ 
CD11b+ in the skin of PBS controls than recipients treated with DT, despite the majority 
of cells in PBS controls being donor derived. However, this increase may be a result of 
the immunostimulatory cytokines and chemokines released due to the increased 
pathology associated with the presence of host LC, promoting the migration of 
inflammatory monocyte derived DC into the epidermis259.  
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5 Langerhans cells are required in situ for full effector 
function of donor CD8 T cells 
In the previous chapter, I established that the depletion of host LC, but not Langerin+ 
dDC, significantly reduced the severity of cutaneous GVHD in the skin in a model of 
acute GVHD. However, whether this reduction was the result of a difference in T cell 
priming or homing in the skin draining lymph node or an extrinsic signal mediated by 
host LC in situ remained to be determined.  
To investigate whether host LC influence the severity of cutaneous GVHD in situ, I 
initially developed a localised model of cutaneous GVHD where alloreactive donor T 
cells were injected directly into skin. This proved unsuccessful so two alternative 
experimental approaches were developed. One involved the secondary transfer of 
primed alloreactive Mh T cells into Langerin-DTR recipients, while the other focused on 
the localised depletion of host LC in situ. 
In the final part of my project, I flow sorted Mh T cells from the epidermis and skin 
draining lymph nodes of Langerin-DTR recipients 7 days after transplant and 
investigated the effect of host LC depletion on the transcriptional profile of Mh T cells. 
In addition, host LC were sorted from the epidermis of allogeneic (F→M) and 
syngeneic (F→F) recipients of BMT with Mh T cells. Mh T cells do not infiltrate the 
epidermis in syngeneic recipient. Thus, I was able to investigate the effects of 
infiltrating Mh T cells on the transcriptional profile of host LC. 
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5.1 A model of GVHD using antigen exposed MataHari T cells 
5.1.1 A dose of 0.1 x106 AEMTs is insufficient for Mh T cells to accumulate in the skin 
To establish whether host LC are required in situ to regulate cutaneous GVHD, I 
developed a new model of GVHD where antigen exposed MataHari T cells (AEMTs) 
taken from skin draining lymph nodes, along with BM and CD4 T cells from a female 
WT BL/6 donor, were injected i.v. into lethally irradiated male BL/6 recipients. The 
assumption in this experiment is that the majority of AEMTs, which had been exposed 
to antigen for 5 days in vivo in a lethally irradiated BL/6 male recipient, would be 
already primed against male antigen and ready to initiate GVHD. Therefore, any 
differences in the ability of these T cells to accumulate in the skin in the absence of 
host LC would provide strong evidence that LC are required in situ in the skin. 
Adapting the already established MataHari minor mismatch model of GVHD, an 
irradiated male BL/6 recipient was transplanted with 5 x106 BM and 2 x106 polyclonal 
CD4 T cells from a female BL/6 donor. However, the Mh T cell dose administered was 
increased from 1 x106 to 2 x106 cells (Figure 69, A). 5 days later, the male BL/6 
recipient was culled and skin draining lymph nodes harvested. This time point was 
chosen based on the kinetics data from the previous chapter where Mh T cells were 
found to accumulate in the skin from day 6 post transplant. The skin draining lymph 
node cell suspension was then passed through 0.5 g nylon wool to enrich lymphocytes. 
The majority of cells in the skin draining LN at this time point node were found to be 
donor Mh CD8 T cells (Figure 69, B). 0.1 x106 of these AEMTs were then transplanted 
into a lethally irradiated male Langerin-DTR mouse along with 5 x106 bone marrow and 
2 x106 CD4 T cells obtained from a female BL/6 donor (Figure 69C). AEMTs were 
tracked in vivo based on the expression of their expression of Vβ8.3, Thy1.1. 
7 day after transplant, the male Langerin-DTR recipient was culled. AEMTs were found 
to have accumulated and expanded in the spleen and skin draining lymph nodes 
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(Figure 70). The absolute number of AEMTs found in the spleen and skin draining 
lymph nodes was 128,064 and 56,532 respectively. AEMTs were also found to have 
infiltrated and accumulated in organs commonly affected by GVHD such as the liver, 
lung and LP+PP (Figure 70). However, in the skin no AEMTs were found to have 
accumulated in the epidermis by day 7 and few were found to have accumulated in the 
dermis compared to frequencies typically observed using 1 x106 naïve Mh T cells 
(Figure 71). 
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Figure 69: Initiating systemic GVHD using AEMTs. A. Male BL/6 mice were lethally irradiated with a 
split dose of 11 GY and reconstituted of 5 x106 BM and 2 x106 SC from a female BL/6 donor. 2-4 x106 
MataHari T cells were also transplanted to initiate systemic GVHD. On day 5 post transplant recipient male 
BL/6 mice were culled and the skin draining lymph nodes harvested. The skin draining lymph node cell 
suspension was then passed through 0.5 g nylon wool to enrich lymphocytes. B. Representative dot plots 
of a skin draining lymph node cell suspension that had been passed through nylon wool. The majority of 
cells in the lymph node at this time point were MataHari CD8 T cells. After an initial anti-apoptotic gate, 
MataHari CD8 T cells were identified based on their expression of Vβ8.3 and CD8. C Male Langerin-DTR 
were lethally irradiated with a split dose of 11 GY and reconstituted with a mixture of 5 x106 bone marrow 
and 2 x106 CD4 T cells obtained from a female BL/6 donor. 0.1-0.5 x106 AEMTs were also transplanted to 
initiate systemic GVHD.  
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Figure 70: A dose of 0.1 x106 AEMTs is sufficient for MataHari T cells to expand and accumulate in 
GVHD target organs. Dot plots of the spleen, skin draining lymph nodes, lung, LP+PP and liver from a 
male Langerin-DTR recipient 7 days after transplant with 0.1 x106 AEMTs. In the spleen and skin draining 
lymph nodes, after an initial anti-apoptotic gate followed by a lymphocyte gate, MataHari T cells were 
identified based on their expression of Vβ8.3, Thy1.1 and CD8. The lung, LP+PP and liver were 
additionally stained with PI and cells that were PI- were gated the same as the spleen and skin draining 
lymph nodes. AEMTs, which had previously been exposed to antigen in vivo for 5 days, were found to 
have successfully engrafted into the secondary recipient. 
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Figure 71: A dose of 0.1 x106 AEMTs was insufficient for AEMTs to accumulate in the skin. Dot plots 
of the epidermis and dermis from a male Langerin-DTR recipient 7 days after transplant with 0.1 x106 
AEMTs. After an initial anti-apoptotic gate followed by a lymphocyte gate, MataHari T cells were identified 
based on their expression of Vβ8.3, Thy1.1 and CD8. In contrast to the liver, lung and LP+PP, 
transplanting 0.1 x106 AEMTs was insufficient for MataHari T cells to accumulate in the skin. 
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5.1.2 Increasing the dose to 0.5 x106 AEMTs had no effect on the ability of Mh T cells 
to accumulate in the skin 
The experiment was repeated, increasing the dose of AEMTs to investigate whether 
the failure of Mh T cells to infiltrate the skin in the previous experiment was dose 
dependent. WT male BL/6 mice were irradiated with a split dose of 11 GY and 
transplanted with a mixture of 5 x106 bone marrow and 2 x106 CD4 T cells from female 
BL/6 donors along with 4 x 106 Vβ8.3+, Thy1.1+ Mh T cells. The number of MataHari T 
cells transplanted was increased from 2 x106 to 4 x106 to increase the number of 
AEMTs harvested (Figure 69A). 5 days after transplant, the skin draining lymph nodes 
were harvested and lymphocytes enriched as before. 
This time the dose of AEMTs transplanted was increased from 0.1 x106 to 0.5 x106 
(Figure 69B). 0.5 x106 AEMTs were injected into male Langerin-DTR recipients, along 
with bone marrow and CD4 T cells from female BL/6 donors as before. As a control, 
one male Langerin-DTR recipient received female BL/6 bone marrow only. To test the 
role of host Langerhans cells when Mh T cells have already been exposed and primed 
against male antigen, Langerin-DTR recipients were also treated with either 400 ng of 
DT (n=3) or PBS (n=3) i.p. 20 days before transplant. 
In the lung, LP+PP and liver, Mh T cells accumulated in all recipients that received 
AEMTs and the depletion of host LC had no effect on the accumulation of Mh T cells in 
these organs (Figure 72).  
In the skin, there was no evidence of Mh T cell accumulation in either the epidermis or 
dermis in the presence or absence of host LC (Figure 73). Increasing the dose to 0.5 
x106 cells had no effect on the accumulation of donor AEMTs in the skin at this time 
point. 
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Figure 72: The depletion of host Langerhans cells had no effect on the accumulation of AEMTs in 
the lung, LP+PP and liver. Summary data showing the accumulation of Vβ8.3+, Thy1.1+, CD8+ AEMTs as 
a percentage of the FSC-A, SSC-A lymphocyte gate in Langerin-DTR recipients transplanted 7 days 
previously (n=3, data representative of 1 experiment, the mean ±SD is indicated by the horizontal bars). 
There was no difference in the accumulation of AEMTs in the lung, LP+PP and liver in the presence or 
absences of host LC. 
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Figure 73: A dose of 0.5 x 106 AEMTs was insufficient for AEMTs to accumulate in the skin. 
Representative dot plots of the epidermis and dermis from a Langerin-DTR mouse transplanted with 0.5 
x106 AEMTs 7 days previously. After an initial anti-apoptotic gate followed by a lymphocyte gate, samples 
were examined for the expression of Vβ8.3 and Thy1.1. There was no evidence of AEMTs accumulating in 
either the epidermis or dermis in any of the samples tested (PBS/DT: n=3). 
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5.1.3 Reducing the time Mh T cells are exposed to antigen in vivo increases their 
ability to accumulate in the skin 
Increasing the dose of AEMTs transplanted from 0.1 x106 to 0.5 x106 had no effect on 
the accumulation of Mh T cells in the skin. To investigate whether the length of time 
donor Mh T cells were exposed to antigen in vivo affected their ability to accumulate in 
the skin, MataHari T cells exposed to antigen for 3, 4 and 5 days were mixed together 
at a 1:1:1 ratio and transplanted into male BL/6 recipients (Figure 74). The Mh T cells 
exposed to antigen for 3, 4 and 5 days could be tracked in vivo due to their differential 
expression of the congenic markers, CD45.1 and CD45.2 (Figure 75). 
0.75 x106 AEMTs from BL/6 recipients culled 3, 4 and 5 days after transplant, mixed at 
a 1:1:1 ratio were injected into male BL/6 recipients along with BM and CD4 T cells 
derived from a female BL/6 donor. To verify that infiltration into the skin was not dose 
dependant, another cohort of male BL/6 recipients were injected with 1 x106 Mh T cells 
exposed to antigen for 4 days, a similar number used in the naïve model. 
In the lung, LP+PP and liver, three distinct populations of MataHari T cells could be 
identified 7 days after transplant (Figure 76). In the cohort that received 1 x106 AEMTs, 
only one population of Mh T cells could be identified (Figure 76). AEMTs exposed to 
antigen for 4 days accumulated at higher frequencies than any other AEMTs in the 
lung, LP+PP and liver (Figure 78). 
Interestingly, in the skin a different pattern emerged. Only Mh T cells exposed to 
antigen for 3 and 4 days were identified in both the epidermis and dermis in all 
samples, accumulating in similar frequencies (Figure 77). AEMTs exposed to antigen 
for 5 days accumulated infrequently in the skin and were undetectable in a number of 
samples (Figure 78). In the cohort that received 1 x106 AEMTs, Mh T cells exposed to 
antigen for 4 days accumulated in the epidermis and dermis in all recipients (n=3, 
Figure 77). However, the average frequency at which the AEMTs accumulated in the 
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epidermis and dermis was much lower than the frequencies observed transplanting 1 
x106 naïve MataHari T cells.  
These data indicates that the length of time Mh T cells are exposed to antigen in vivo 
influences their ability to accumulate in the skin. Due to the development of a more 
robust model and issues yet to be resolved in this model, further work using AEMTs to 
initiate GVHD was discontinued. 
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Figure 74: Initiating systemic GVHD using a combination of AEMTs. A. Three cohorts of male BL/6 
mice were lethally irradiated with a split dose of 11 GY and reconstituted of 5 x106 BM and 2 x106 SC from 
a female BL/6 donor. 4 x106 MataHari T cells were also transplanted to initiate systemic GVHD. On days 3, 
4 and 5 post transplant recipient male BL/6 mice were culled and the skin draining lymph nodes harvested. 
The skin draining lymph node cell suspension was then passed through 0.5 g nylon wool to enrich 
lymphocytes. B. Male BL/6 mice were lethally irradiated with a split dose of 11 GY and reconstituted with a 
mixture of 5 x106 bone marrow and 2 x106 CD4 T cells obtained from a female BL/6 donor. To initiate 
GVHD, 0.75 x106 AEMTs from BL/6 recipients culled 3, 4 and 5 days post transplant mixed at a ratio of 
1:1:1 were also transplanted. This was possible as AEMTs from each time point could be separated based 
on their differential expression of the congenic markers CD45.1 and CD45.2. 
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Figure 75: AEMTs from BL/6 recipients culled 3, 4 and 5 days post transplant could be identified 
based on their expression of the congenic markers CD45.1 and CD45.2. Dot plots from skin draining 
lymph node cell suspensions from BL/6 mice 3, 4 and 5 days post transplant that had been passed 
through nylon wool. After an initial anti-apoptotic gate, MataHari CD8 T cells were identified based on their 
expression of Vβ8.3, Thy1.1, CD45.1 and CD45.2. MataHari T cells from BL/6 recipients culled 3, 4 and 5 
days post transplant based on their differential expression of the congenic markers CD45.1 and CD45.2. 
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Figure 76: MataHari T cells exposed to antigen for 4 days accumulate in higher frequencies in 
GVHD target organs than MataHari T cells exposed to antigen for 3 and 5 days. Representative dot 
plots from the lung, LP+PP and liver from male BL/6 recipients culled 7 days after transplant with AEMTs. 
After an initial anti-apoptotic gate followed by a lymphocyte gate, samples were examined for the 
expression of Vβ8.3, Thy1.1, CD8, CD45.1 and CD45.2. Top- In BL/6 recipients that received 0.75 x 106 
AEMTs, from BL/6 recipients culled 3, 4 and 5 days post transplant mixed at a 1:1:1 ratio, AEMTs exposed 
to antigen for 4 days accumulated in higher frequencies in the lung, LP+PP and liver than other AEMTs. 
Bottom- Another cohort of BL/6 recipients were transplanted with 1 x106 AEMTs exposed to antigen for 4 
days. AEMTs from this time point and dose accumulated in the lung, LP+PP and liver. 
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Figure 77: MataHari T cells exposed to antigen for 3 and 4 days accumulate in higher frequencies 
in the skin than MataHari T cells exposed to antigen for 5 days. Representative dot plots from the 
epidermis and dermis from male BL/6 recipients culled 7 days after transplant with AEMTs. After an initial 
anti-apoptotic gate followed by a lymphocyte gate, samples were examined for the expression of Vβ8.3, 
Thy1.1, CD45.1 and CD45.2. Top- In BL/6 recipients that received 0.75 x 106 AEMTs, from BL/6 recipients 
culled 3, 4 and 5 days post transplant mixed at a 1:1:1 ratio, AEMTs exposed to antigen for 3 and 4 days 
accumulated in higher frequencies in epidermis and dermis than AEMTs exposed to antigen for 5 days. 
Bottom- In BL/6 recipients transplanted with 1 x106 AEMTs exposed to antigen for 4 days, AEMTs 
accumulated in the both the epidermis and dermis. 
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Figure 78: In contrast to other GVHD target organs, MataHari T cells exposed to antigen for 3 days 
accumulate in high frequencies in the skin. Summary data showing the accumulation of Vβ8.3+ Thy1.1+ 
MataHari T cells exposed to antigen for 3, 4 and 5 days as a percentage of the total MataHari T cells gated 
in BL/6 recipients culled after 7 days (n=3, data representative of one experiment, horizontal lines 
represent the mean ±SD). A. In the liver, LP+PP and liver, when MataHari T cells exposed to antigen for 3, 
4 and 5 days were mixed together and transplanted into male BL/6 recipients, AEMTs exposed to antigen 
for 4 days accumulated at the highest frequencies. B. In the skin, AEMTs exposed to antigen for 3 and 4 
days accumulated in the skin at similar frequencies with AEMTs exposed to antigen for 5 days 
accumulating at much lower frequencies. 
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5.2 The localised depletion of Langerhans cells reduced cutaneous GVHD 
5.2.1.1 Injecting 50 ng i.d. is sufficient to locally deplete LC in Langerin-DTR mice 
Previous experiments to determine whether host LC in situ are required for cutaneous 
GVHD had focused on either changing the site of T cell injection (intravenous → skin) 
or phenotype of the donor alloreactive T cells (naïve → primed) themselves. Focusing 
on the skin itself, a new experimental approach was developed where DT was injected 
directly into the skin of Langerin-DTR mice to locally deplete LC in situ. 
To locally deplete LC, male Langerin-DTR mice were injected with 25 ng of DT in 20 µl 
i.d. into the dorsal and ventral side of the left ear (Figure 79, A). The right ear remained 
untreated and acted as an internal control. The mice were then allowed to recover for 9 
days before being transplanted with naive Mh T cells to initiate GVHD in accordance 
with the model developed in the previous chapter (Figure 79, B). This allowed 
Langerin+ dDC but not LC to recover in recipients before transplant275. 
The injection of 50 ng of DT was sufficient to locally deplete LC in Langerin-DTR mice. 
After an initial anti-apoptotic gate followed by a DC gate, host LC were characterised 
as being GFP+, MHCII+, CD45.2+, CD207+ and CD11b+ (Figure 80). Host LC were 
depleted in the left ears (treated) but not the right ears (untreated) of Langerin-DTR 
recipients that received DT 7 days after transplant (Figure 80). There were significantly 
more host LC in the right ears compared to the left ears of DT treated Langerin-DTR 
recipients (Figure 81). Localised LC depletion was also confirmed in epidermal sheets 
stained with MHCII, where LC were depleted in the left but not the right ear in mice that 
received DT 9 days earlier (Figure 79A). The i.d. injection of PBS in controls had no 
effect on the frequency of LC in the epidermis (Figure 80). However, there was a 
significant reduction in the frequency of host LC in the right ears of mice treated with 
DT versus PBS controls indicating some systemic depletion associated with DT (Figure 
81).  
 225 
 
Figure 79: Depleting Langerhans cells in situ in the MataHari minor H mismatch model of acute 
GVHD. A. Left- Male Langerin-DTR mice were injected i.d. with either 50 ng of DT or PBS in the left ear 9 
days before transplant. This was sufficient to locally deplete LC in that ear. Right- Fluorescent images of 
the epidermis taken from the left and right ear of a Langerin-DTR mouse treated i.d. with DT 9 days earlier. 
LC were visualised staining MHCII with Alexa Fluor 488. Images obtained at x20 magnification on a Zeiss 
Axio Scope A1 fluorescence microscope. In the left ear (DT treated), MHCII+ LC were depleted. However, 
in the right ear (untreated), a dense interlacing network of LC was observed. B. Male Langerin-DTR mice, 
which were treated with DT or PBS i.d., are irradiated with a split dose of 11 GY and transplanted with a 
mixture of 5 x106 BM and 2 x106 CD4 T cells from a female BL/6 donor and 1 x106 MataHari CD8 T cells. 
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Figure 80: The injection of DT but not PBS i.d. is sufficient to locally deplete Langerhans cells in 
Langerin-DTR mice. Representative dot plots of the epidermis from Langerin-DTR mice that received 50 
ng of DT or PBS i.d. 16 days previously. After an initial live gate followed by a DC gate, host LC were 
identified based on their expression of MHCII, CD45.2, CD207, CD11b and GFP. Top- The injection of 
PBS i.d. into the left ear of Langerin-DTR mice had no effect on LC. Bottom- The injection of 50 ng of DT 
i.d. into the left ear of Langerin-DTR mice was sufficient to locally deplete LC; LC remained in the 
untreated right ear. 
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Figure 81: 50 ng of DT injected i.d. is sufficient to locally deplete Langerhans cells in Langerin-DTR 
mice. Summary data showing the frequency of host LC in the epidermis as a percentage of the initial DC 
gate based on FSC-A, SSC-A 7 days after transplant (n=9-10, data pooled from 4 independent 
experiments, analysed using a Mann-Whitney test, the mean ±SD is indicated by the horizontal bars.). In 
Langerin-DTR recipients treated with DT i.d. in the left ear, host LC were significantly depleted in the left 
(treated) versus the right (untreated) ear. In Langerin-DTR recipients treated with PBS i.d. in the left ear, 
there was no difference in the frequency of host LC between the left (treated) and right (untreated) ears. 
However, there was a significant reduction in the frequency of host LC in the right ears (untreated) of 
recipients that received DT versus PBS controls. 
  
 228 
5.2.2 Localised depletion of LC had no effect on the systemic expansion of MataHari 
T cells 
The Langerin-DTR recipients were culled 7 days after transplant. In the spleen, after an 
initial anti-apoptotic gate followed by a lymphocyte gate, Mh CD8 T cells were again 
identified by their expression of the TCR Vβ8.3 and congenic marker Thy1.1 (Figure 
82, A). In addition, Mh T cells were also analysed for their expression of the T cell 
memory markers CD44 and CD62L (Figure 82, A).  
The localised depletion of host LC had no significant effect on either the expansion or 
activation profile of Mh T cells in the spleen. The absolute number and frequency of 
effector Mh T cells (CD44high CD62Llow) was similar in the presence or absence of host 
LC in the left ear (Figure 82, B). 
In the skin draining lymph nodes, a similar pattern was observed. Adopting a similar 
gating strategy used to analyse the spleen (Figure 83, A), the localised depletion of 
host LC had no effect on either the absolute number or frequency of effector Mh T cells 
(CD44high CD62Llow) in the skin draining lymph nodes (Figure 83, B). 
Taken together, these data shows that the localised depletion of host LC had no effect 
on the systemic expansion and activation of Mh T cells. This corresponds with the data 
from the systemic depletion of host LC in the previous chapter. 
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Figure 82: The localised depletion of host Langerhans cells had no effect on the expansion and 
activation of MataHari T cells in the spleen. A. Representative dot plots of splenocytes taken from 
Langerin-DTR recipients, treated with either DT or PBS i.d., 7 days after transplant. After an initial anti-
apoptotic gate followed by a lymphocyte gate, MataHari T cells were identified based on their expression 
of Vβ8.3, Thy1.1 and CD8. B. Left- Summary data showing the absolute number of donor Vβ8.3+ Thy1.1+ 
MataHari T cells in the spleen (n=9-10, data pooled from 4 independent experiments, analysed using a 
Mann-Whitney test, the mean ±SD is indicated by the horizontal bars.). There was no difference in the 
expansion of donor MataHari T cells when host LC were depleted in situ. Right- Summary data showing 
the percentage of donor Vβ8.3+ Thy1.1+ MataHari T cells that are CD44high CD62Llow (n=9-10, data pooled 
from 4 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is indicated by the 
horizontal bars.). There was no difference in the activation profile of donor MataHari T cells when host LC 
were depleted in situ. 
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Figure 83: The localised depletion of host Langerhans cells had no effect on the expansion and 
activation of MataHari T cells in the skin draining lymph nodes. A. Representative dot plots of skin 
draining LN samples taken from Langerin-DTR recipients, treated with either DT or PBS i.d., 7 days after 
transplant. After an initial anti-apoptotic gate followed by a lymphocyte gate, MataHari T cells were 
identified based on their expression of Vβ8.3, Thy1.1 and CD8. B. Left- Summary data showing the 
absolute number of donor Vβ8.3+ Thy1.1+ MataHari T cells in the skin draining LN (n=9-10, data pooled 
from 4 independent experiments, analysed using a Mann-Whitney test, the mean ±SD is indicated by the 
horizontal bars.). There was no difference in the expansion of donor MataHari T cells when host LC were 
depleted in situ. Right- Summary data showing the percentage of donor Vβ8.3+ Thy1.1+ MataHari T cells 
that are CD44high CD62Llow (n=9-10, data pooled from 4 independent experiments, analysed using a Mann-
Whitney test, the mean ±SD is indicated by the horizontal bars.). There was no difference in the activation 
profile of donor MataHari T cells when host LC were depleted in situ. 
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5.2.3 Host LC are required in situ for CD8-mediated GVHD 
In accordance with previous findings, Mh T cells were found to have accumulated in 
the skin 7 days after transplant. After an initial anti-apoptotic cell gate followed by a 
lymphocyte gate, Mh T cells were identified based on their expression of Vβ8.3, 
Thy1.1, and the congenic markers CD45.1 and CD45.2 (Figure 84). 
The localised depletion of host LC in the left ear had a significant effect on the ability of 
Mh T cells to accumulate in the skin (Figure 84). There was a significant reduction in 
the frequency of Mh T cells in the epidermis between the left (treated) and right 
(untreated) ears of DT treated Langerin-DTR recipients (Figure 85). In PBS treated 
controls, there was no difference in the accumulation of Mh T cells in the epidermis 
between the left and right ears of recipients (Figure 85). However, there was a 
significant reduction in the frequency of Mh T cells in the epidermis of the right ears of 
DT versus PBS mice (Figure 85). 
These data, in parallel with the data from the systemic depletion of host LC in the 
previous chapter, shows that host LC are in fact required in situ in the skin for 
cutaneous GVHD. 
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Figure 84: When Langerhans cells are depleted in situ, the accumulation of donor MataHari T cells 
is reduced. Representative dot plots of the epidermis from Langerin-DTR mice 7 days after transplant. 
After an initial anti-apoptotic gate followed by a lymphocyte gate, donor MataHari T cells were identified 
based on their expression of Vβ8.3, Thy1.1, CD45.1 and CD45.2. Top- There was no difference in the 
accumulation of donor MataHari T cells in the epidermis of Langerin-DTR recipients treated with PBS. 
Bottom- In the absence of host LC in the left ear, there was a reduction in the accumulation of donor 
MataHari T cells between the left and right ear of the same recipient. 
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Figure 85: Host Langerhans cells are required in situ for cutaneous GVHD. Summary data showing 
the accumulation of donor Vβ8.3+ Thy1.1+ MataHari T cells in the epidermis as a percentage of the initial 
lymphocyte gate based on FSC-A, SSC-A (n=9-10, data pooled from 4 independent experiments, 
analysed using a Mann-Whitney test, the mean ±SD is indicated by the horizontal bars.). In Langerin-DTR 
recipients treated with DT, there was a significant reduction in the accumulation of donor MataHari T cells 
in the left (treated) versus the right (untreated) ear. In PBS controls, there was no difference in the 
accumulation of donor MataHari T cells between the left (treated) and right (untreated) ears. However, 
there was a significant reduction in the accumulation of donor MataHari T cells in the right ears (untreated) 
of recipients that received DT versus PBS controls. 
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5.3 Gene expression analysis of MataHari T cells and Langerhans cells 
5.3.1 Host LC are required for full effector function and proliferation of MataHari T 
cells in the epidermis 
To investigate whether there was functional difference between Mh T cells in the skin 
of mice depleted of host Langerin+ DC versus controls, Vβ8.3+ Thy1.1+ Mh T cells were 
sorted by fluorescence-activated cell sorting (FACS) from the epidermis and dermis of 
Langerin-DTR recipients 7 days after transplant. 
This proved technically challenging with the number of Vβ8.3+ Thy1.1+ Mh T cells 
sorted from the epidermis (Mh+0: median 2.3 x103, range 0.4-5.7 x103; Mh+DT: 
median 0.9 x103, range 0.4-1.5 x106) and dermis (Mh+0: median 3 x103, range 1.5-3.8 
x103; Mh+DT: median 2 x103, range 1.4-3.1 x103) were very low and not appropriate to 
directly evaluate protein expression or direct CTL function in vitro. Instead, Mh T cells 
were sorted directly into RLT lysis buffer containing 1µM β-mercaptoethanol (to 
denature RNases) and the mRNA isolated for quantitative PCR of molecules 
associated with effector CTL function. A full list of the molecules analysed is outlined in 
the Materials and Methods. 
To deplete host Langerin+ DC (LC and Langerin+ dDC), Langerin-DTR recipients were 
treated with 400 ng of DT i.p. on day’s -1, 2, 4 and 7 post-transplant. In parallel, male 
Langerin-DTR were treated with a similar volume of PBS i.p. as a control. Before each 
sort, the depletion of host LC was verified by flow cytometry (Figure 86, A). Mh T cells 
were sorted using the following gating strategy. Firstly, after an anti-apoptotic gate, 
doublets were eliminated based on FSC-W and FSC-A. Then a very broad lymphocyte 
gate was taken and Mh cells sorted based on their expression of Vβ8.3 and Thy1.1 
(Figure 86, B). This resulted in sort purity ≥95%, when cells were sorted into FACS 
buffer instead of lysis buffer and checked via flow cytometry (Figure 86, B). 
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As shown in Figure 87, Mh T cells in the epidermis showed a significant reduction in 
the expression of mRNA transcripts for a number of key effector molecules including 
IFN-γ, TNF-α, Granzyme B, TRAIL and the pro-survival molecule Bcl-xL in the absence 
of host Langerin+ DC. Attempts to stain Mh T cells in the epidermis with antibodies for 
some of the molecules was not pursued as the number of events was very small. 
A similar pattern was not observed in the dermis. There was no significant difference in 
the expression of any mRNA transcript investigated by Mh T cells in the dermis in the 
absence of host Langerin+ DC (Figure 87). These data, along with the reduction in the 
accumulation of Mh T cells in by day 7, suggests that there is a significant reduction in 
the function of Mh T cells in the absence host Langerin+ DC. 
To further characterise the reduction in effector function of Mh T cells in the epidermis, 
a whole-transcriptome microarray analysis was carried out on Mh T cells when host 
LC, but not Langerin+ dDC, were depleted. To deplete host LC, male Langerin-DTR 
recipients were treated with 400 ng of DT i.p. 20 days before transplant as described in 
the previous chapter. In parallel, male Langerin-DTR were treated with PBS i.p. as a 
control.  
Vβ8.3+ Thy1.1+ Mh T cells were sorted by FACS directly into RLT lysis buffer 
containing 1µM β-mercaptoethanol from the epidermis and skin draining lymph nodes 
of Langerin-DTR recipients 7 days after transplant using the same gating strategy 
described before (Figure 86, B). For the epidermis, the samples from different 
recipients were pooled if necessary so that a minimum of 5 x103 Mh T cells was 
collected per biological replicate with sort purity ≥95%. For the skin draining lymph 
node, a minimum of 100 x103 Mh T cells was collected per biological replicate with sort 
purity ≥90%. The RNA was then purified and amplified for whole-transcriptome 
microarray analysis using the Affymetrix GeneChip Mouse Gene 2.0 ST Array. The 
microarray dataset was kindly analysed by Dr Pedro Sousa in our lab using the 
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Affymetrix Expression Console Software (v1.3.1.187), applying the RMA algorithm for 
probe-level normalisation and background correction.  
To initially explore any potential differences in the gene expression profile between Mh 
T cells in the skin draining lymph nodes and the epidermis, we used a PVCA. PVCA is 
a statistical technique that reduces the number of dimensions in a dataset in order to 
simplify the analysis. This is accomplished by performing covariance analysis between 
the factors which identifies directions (principal components) along which the variation 
in the dataset is maximal. This enables both a two- and three-dimensional scatter plot 
to be constructed that allows similarities or differences between datasets to be 
visualised, where each symbol represents the gene expression profile derived from T 
cells within a replicate. 
The PVCA on Mh T cells derived from the skin draining lymph nodes and epidermis of 
PBS and DT treated Langerin-DTR recipients demonstrated a striking divergence in the 
transcriptional profile of Mh T cells between the skin draining lymph nodes and 
epidermis (Figure 88, A). Interestingly, the principal components of effector Mh T cells 
derived from the epidermis when host LC were both present (PBS controls) and absent 
(DT treated) differed significantly from Mh T cells in the skin draining lymph node. In 
addition, there was a divergence in the transcriptional profile between effector Mh T 
cells in the epidermis when host LC were present or absent, although they did not form 
a cluster. However, the depletion of host LC had no effect on the transcriptional profile 
of Mh T cells in the skin draining lymph nodes, with both populations clustering 
together according to principal components 1 and 2. 
To investigate the change in the transcriptional profile between the skin draining lymph 
nodes and epidermis, a gene set enrichment analysis (GSEA) was performed between 
Mh T cells from the skin draining lymph nodes of control mice versus Mh T cells from 
the epidermis of control mice using the Molecular Signature Database Collection 2. 
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This was based on the assumption that by day 7 post-transplant, the majority of Mh T 
cells in the skin draining lymph nodes were primed. GSEA is an analytical technique 
that focuses on the change in gene expression at the level of gene sets between two 
biological states. These gene sets have been defined based on prior biological 
knowledge, obtained from studies published in the literature (e.g. co-expression of 
genes in certain disease states, the expression profile in an immune response to a 
particular pathogen). By detecting modest but coordinated changes in gene expression 
within a specified set of a related genes, variations in the activity of biologically 
significant pathways can be identified by GSEA that may otherwise be missed by 
focusing on a single gene that showed a 10-fold increase in expression. 
Comparing the transcription profile of effector Mh T cells from the epidermis where host 
LC were present versus Mh T cells from the skin draining lymph node, 63 biological 
pathways were active in effector Mh T cells in the epidermis. The majority of these 
pathways were involved in the cell cycle, metabolism, transcription and signal 
transduction, indicating that effector Mh T cells are undergoing a proliferative burst in 
the epidermis (Figure 89). Remarkably, when the transcription profile of effector Mh T 
cells from the epidermis when host LC were depleted was compared to Mh T cells from 
the skin draining lymph node, all of the active biological pathways identified when host 
LC were present were lost, with the exception of one that is involved in T cell apoptosis 
(Figure 89).    
Focusing on the skin, a heat map was generated from an unsupervised agglomerative 
clustering analysis of Mh T cells in the epidermis and revealed a noticeable difference 
in the expression of a number of genes in effector Mh T cells when host LC were 
depleted (Figure 88, B). A gene level differential expression analysis was then 
performed on Mh T cells in the epidermis in the presence versus the absence of host 
LC, using an absolute log fold change (LFC) ≥ ±2 and an ANOVA p-value ≤ 0.05 as the 
chosen cut off. Following this analysis, 94 genes were upregulated and 16 genes were 
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downregulated in effector Mh T cells in the epidermis in the presence versus the 
absence of host LC (Table 8 and Table 9). Interestingly, a number of key T cell effector 
molecules were upregulated in the presence of host LC, including Granzyme C, IFN-γ, 
TNF and TNFSF14 (LIGHT). This corresponds with earlier findings from initial qPCR 
experiments. Thus, in the absence of host LC, there is a significant reduction in the 
effector function of Mh T cells in the epidermis. 
In addition, the majority of genes that were upregulated in Mh T cells in the presence of 
host LC were indicative of pathway that favours proliferation (e.g. transcription, 
translation, cell cycle, signal transduction), with genes such as the transcription factor 
Myc and serine/threonine protein kinase Plk2 being significantly upregulated. 
The transcriptional profile of Mh T cells in the epidermis in the presence versus the 
absence of host LC was further scrutinised using a GSEA. 220 biological pathways 
were upregulated in Mh T cells in the presence of host LC. Interestingly, 14 out of the 
top 20 of these pathways, as determined by their FDR p-value, were involved the cell 
cycle (Table 10). Pathways related to the effector T cells response were also found to 
be upregulated in the presence of host LC. Taken together, the depletion of host LC 
has a significant effect on both the effector function and proliferation of effector Mh T 
cells in the epidermis. 
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Figure 86: Gating strategy used to sort LC and Mh T cells through flow cytometry. A. Representative 
dot plots of the epidermis from Langerin-DTR recipients 7 days after transplant. After an initial live cell gate 
followed by a FSC-W, FSC-A gate, to eliminate doublets, and a lymphocyte/DC gate, host LC cells were 
identified based on their expression of CD45.2, CD11b and GFP. LC were efficiently depleted in DT 
treated recipients 7 days after transplant. When sorts were performed using BL/6 recipients, CD24 was 
used instead of GFP. B. Representative dot plots of the epidermis from Langerin-DTR recipients 7 days 
after transplant. After an initial live cell gate doublets were eliminated based on a FSC-W, FSC-A gate. A 
broad lymphocyte gate was then gated and Mh T cells were sorted within this based on their expression of 
Vβ8.3 and Thy1.1. The purity of Mh T cells sorted remained >90%. 
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Figure 87: In the absence of host Langerin+ DC, MataHari T cells reduced their expression of a 
number of key effector molecules in the epidermis. Graphs represent the mean±SD mRNA 
quantification for each transcript relative to β2M from Vβ8.3+ Thy1.1+ Mh T cells flow sorted from the 
epidermis and dermis from Langerin-DTR recipients treated with either DT or PBS 7 days after transplant. 
Mh T cells from the spleen were from naïve MataHari mice and acted as a control (n=4-6, data pooled 
from 2 independent experiments, data analysed using a Mann-Whitney test). In the epidermis, Mh T cells 
significantly reduced their expression of IFN-γ, TNF-α, Granzyme B, TRAIL and the pro-survival molecule 
Bcl-xL in the absence of host Langerin+ DC. In the dermis, there was no difference in the expression of 
these transcripts by Mh T cells. 
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Figure 88: The depletion of host Langerhans cells significantly alters the transcriptional profile of 
MataHari T cells that infiltrate the epidermis. A. PVCA of microarray data plotting the transcriptional 
profile of Mh T cells derived from the epidermis and skin draining lymph nodes from host LC depleted (DT 
treated) recipients versus the control (PBS). The gene expression profile was determined using the 
Affymetrix GeneChip 2.0 Mouse Gene 2.0 ST Array. B. Heat map depicting the unsupervised 
agglomerative hierarchical clustering analysis of Mh T cells from the epidermis of host LC depleted (DT 
treated) and control (PBS) recipients (Each biological replicate represents pooled RNA, n=3-10 from 1-2 
independent experiments). 
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Figure 89: In the absence of host Langerhans cells the majority of biological pathways upregulated 
by effector MataHari T cells in the epidermis are lost. GSEA comparing Mh T cells from the skin 
draining lymph nodes to those derived from the epidermis in the presence or absence of host LC 
(Molecular Signatures Database Collection 2 – Canonical Pathways; FDR p-value ≤ 0.25). This led to the 
identification of 63 biological pathways that are active in Mh T cells in the presence of host LC. 
Remarkably, all but one of these biological pathways are lost in the absence of host LC. 
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Genes over-expressed in Mh T cells from the epidermis in PBS vs DT treated recipients 
Gene Description LFC 
Cytokine/Chemokine 
Gzmc 
Tnf 
Ifng 
Tnfsf14 
 
Transcription regulation 
Mir467f 
Mir1927 
Mir3096 
Znhit6 
Nolc1 
Taf1d 
Snhg3 
Zbtb41 
Polr1a 
Ttll4 
Nolc1 
Epas1 
Atf7 
Tnip2 
 
Translation regulation 
Snord16a 
Snora69 
Trit1 
Exosc2 
Mir343 
Myc 
Snord87 
Gnl2 
Utp20 
Parp8 
Dkc1 
Trmt5 
 
Regulation of cell cycle 
Plk2 
Cenpi 
Gnl3 
Nup43 
Usp33 
Hist3h2a 
Fancd2 
Mpg 
 
Signal transduction 
Gbp5 
Sdr39u1 
Slc15a3 
Serpine2 
Cish 
Gbp5 
Skap2 
Casd1 
Ric8b 
Atg7 
Tmem64 
Prkcd 
Nle1 
Stk3 
Frmd6 
 
Granzyme C 
Tumor necrosis factor 
Interferon gamma 
Tumor necrosis factor (ligand) superfamily, member 14 (Light) 
 
 
microRNA 467f 
microRNA 1927 
microRNA 3096 
Zinc finger, HIT type 6 
Zinc finger protein 119b 
TATA box binding protein (Tbp)-associated factor 
Small nucleolar RNA host gene 3 
Zinc finger and BTB domain containing 41 homolog 
Polymerase (RNA) I polypeptide A 
Tubulin tyrosine ligase-like family, member 4 
Nucleolar and coiled-body phosphoprotein 1 
Endothelial PAS domain protein 1 
Activating transcription factor 7 
TNFAIP3 interacting protein 2 
 
 
Small nucleolar RNA, C/D box 16A 
Small nucleolar RNA, H/ACA box 69 
tRNA isopentenyltransferase 1 
Exosome component 2 
microRNA 343 
Myelocytomatosis oncogene 
Small nucleolar RNA, C/D box 87 
Guanine nucleotide binding protein-like 2 (nucleolar) 
UTP20, small subunit (SSU) processome component 
Poly (ADP-ribose) polymerase family, member 8 
Dyskeratosis congenita 1, dyskerin 
TRM5 tRNA methyltransferase 5 
 
 
Polo-like kinase 2 
Centromere protein I 
Guanine nucleotide binding protein-like 3 (nucleolar) 
Nucleoporin 43 
Ubiquitin specific peptidase 33 
Histone cluster 3, H2a 
Fanconi anemia, complementation group D2 
N-methylpurine-DNA glycosylase 
 
 
Guanylate binding protein 5 
Short chain dehydrogenase/reductase family 39U 
Solute carrier family 15, member 3 
Serine (or cysteine) peptidase inhibitor, clade E, member 2 
Cytokine inducible SH2-containing protein 
Guanylate binding protein 5 
Src family associated phosphoprotein 2 
CAS1 domain containing 1 
Resistance to inhibitors of cholinesterase 8 homolog B 
Autophagy related 7 
Transmembrane protein 64 
Protein kinase C, delta 
Notchless homolog 1 (Drosophila) 
Serine/threonine kinase 3 
FERM domain containing 6 
 
3.00 
2.75 
2.38 
2.11 
 
 
13.47 
9.73 
5.17 
4.18 
3.35 
3.04 
2.93 
2.53 
2.51 
2.50 
2.32 
2.12 
2.07 
2.03 
 
 
5.52 
3.17 
2.85 
2.51 
2.71 
2.23 
2.13 
2.11 
2.10 
2.05 
2.03 
2.02 
 
 
3.01 
2.46 
2.39 
2.43 
2.32 
2.30 
2.05 
2.00 
 
 
5.11 
3.62 
3.56 
3.52 
3.02 
2.92 
2.87 
2.4 
2.28 
2.28 
2.26 
2.20 
2.18 
2.09 
2.02 
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Ctsc 
 
Proteasome 
Ublcp1 
Psmd3 
 
T cell receptor 
Traj53 
Trav6-6 
 
Nucleotide metabolism 
Uprt 
 
Membrane transport 
Pla2g15 
Chac2 
Slc7a6 
 
Metabolism 
Fasn 
Enoph1 
Tm9sf4 
Atad3a 
 
Protein transport 
Slc35e3 
Cpd 
 
DNA Repair 
Brca1 
Tonsl 
Xrcc2 
 
Peptidase inhibitor 
Serpina3f 
 
Apoptosis 
Smpd2 
 
Mitochondria biogenesis 
Pprc1 
Hemk1 
 
Glycoprotein synthesis 
St3gal2 
Chst14 
 
Lipid transport 
Stard7 
 
Nuclear Envelope 
Tmem43 
 
Uncharacterised 
1110038B12Rik 
Gm4129 
4930549G23Rik 
Ccdc90b 
n-R5s64 
Fundc2 
C230052I12Rik 
Gm15764 
1110008L16Rik 
LOC100505155 
D430020J02Rik 
Gm10688 
Gm11110 
Cathespin C 
 
 
Ubiquitin-like domain containing CTD phosphatase 1 
Proteasome 26S subunit 
 
 
T cell receptor alpha joining 53 
T cell receptor alpha variable 6-6 
 
 
Uracil phosphoribosyltransferase (FUR1) homolog 
 
 
Phospholipase A2, group XV 
ChaC, cation transport regulator 2 
Solute carrier family 7, member 6 
 
 
Fatty acid synthase 
Enolase-phosphatase 1 
Transmembrane 9 superfamily protein member 4 
ATPase family, AAA domain containing 3A 
 
 
Peroxisome proliferative activated receptor 1 
HemK methyltransferase family member 1 
 
 
Breast cancer 1 
Tonsoku-like, DNA repair protein 
X-ray repair complementing defective repair 2 
 
 
Serine (or cysteine) peptidase inhibitor, clade A, member 3F 
 
 
Sphingomyelin phosphodiesterase 2, neutral 
 
 
Peroxisome proliferative activated receptor 1 
HemK methyltransferase family member 1 
 
 
ST3 beta-galactoside alpha-2,3-sialyltransferase 2 
Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 14 
 
 
START domain containing 7 
 
 
Transmembrane protein 43 
 
 
RIKEN cDNA 1110038B12Rik gene 
Predicted gene 4129 
RIKEN cDNA 1110038B12Rik gene 
Coiled-coil domain containing 90B 
Nuclear encoded rRNA 5S 64 
FUN14 domain containing 2 
RIKEN cDNA C230052I12 gene 
Predicted gene 15764 
RIKEN cDNA 1110008L16 gene 
Uncharacterised LOC100505155 
RIKEN cDNA D430020J02 gene 
RIKEN cDNA A730077B16 gene 
Predicted gene 11110 
2.01 
 
 
6.81 
2.47 
 
 
3.40 
2.36 
 
 
3.16 
 
 
2.82 
2.23 
2.04 
 
 
2.40 
2.24 
2.13 
2.00 
 
 
2.39 
2.27 
 
 
2.30 
2.20 
2.19 
 
 
2.18 
 
 
2.50 
 
 
2.17 
2.00 
 
 
2.10 
2.07 
 
 
2.06 
 
 
2.12 
 
 
3.17 
3.12 
2.83 
2.72 
2.72 
2.69 
2.61 
2.60 
2.57 
2.52 
2.48 
2.34 
2.32 
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Gm2046 
Rasl11b 
Nudcd2 
Nnat 
Wdr53 
Gm17041 
Heatr3 
Cnih4 
Gm12316 
Gm13008 
Tmem8 
Ldlrad4 
Gm19412 
Fam212a 
Predicted gene 2046 
RAS-like, family 11, member B 
NudC domain containing 2 
Neuronatin 
WD repeat domain 53 
Predicted gene 17041 
HEAT repeat containing 3 
Cornichon homolog 4 (Drosophila) 
Predicted gene 12316 
Predicted gene 13008 
Transmembrane protein 8 (five membrane-spanning domains) 
Low density lipoprotein receptor class A domain containing 4 
Predicted gene 19412 
family with sequence similarity 212, member A 
2.21 
2.21 
2.19 
2.12 
2.11 
2.10 
2.10 
2.09 
2.07 
2.07 
2.05 
2.05 
2.04 
2.02 
Table 8: Genes upregulated in MataHari T cells derived from the epidermis in the presence versus 
the absence of host Langerhans cells. Mh T cells obtained from the epidermis of PBS and DT treated 
Langerin-DTR recipients 7 days after transplant. Dataset kindly analysed by Dr Pedro Sousa using 
Affymetrix transcriptome analysis console software. A linear fold change (LFC) ≥2 and ANOVA p-value 
≤0.05 was chosen as the cut off. 
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Genes under-expressed in Mh T cells from the epidermis in PBS versus DT treated recipients 
Gene Description LFC 
Signal transduction 
Dcaf12 
Serpinb1a 
CD7 
Klhl20 
 
Tumor suppressor 
Dear1 
Trp53cor1 
 
T cell receptor 
Traj29 
 
Metabolism 
Hba-a1 
 
Translation regulation 
Mir139 
 
Uncharacterised 
9430037G07Rik 
1700056E22Rik 
Klk1b5 
Gm10552 
Gm17106 
A130066N16Rik 
Tmem167b 
 
 
DDB1 and CUL4 associated factor 12 
Serine peptidase inhibitor, clade B, member 1a 
CD7 antigen 
Kelch-like 20 
 
 
Dual endothelin 1/angiotensin II receptor 1 
Tumor protein p53 pathway corepressor 1 
 
 
T cell receptor alpha joining 29 
 
 
Hemoglobin alpha, adult chain 1 
 
 
microRNA 139 
 
 
RIKEN cDNA 9430037G07 gene 
RIKEN cDNA 1700056E22 gene 
Kallikrein 1-related peptidase b5 
Predicted gene 10552 
Predicted gene 17106 
RIKEN cDNA A130066N16 gene 
Transmembrane protein 167B 
 
 
-4.67 
-2.40 
-2.40 
-2.03 
 
 
-2.51 
-2.17 
 
 
-2.44 
 
 
-2.27 
 
 
-2.09 
 
 
-3.23 
-2.72 
-2.40 
-2.34 
-2.28 
-2.18 
-2.02 
Table 9: Genes downregulated in MataHari T cells derived from the epidermis in the presence 
versus the absence of host Langerhans cells. Mh T cells obtained from the epidermis of PBS and DT 
treated Langerin-DTR recipients 7 days after transplant. Dataset kindly analysed by Dr Pedro Sousa using 
Affymetrix transcriptome analysis console software. A linear fold change (LFC) ≥2 and ANOVA p-value 
≤0.05 was chosen as the cut off. 
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Biological pathways upregulated in Mh T cells in PBS vs DT treated recipients FDR p-value 
Top 20 pathways as determined by FDR p-value 
Assembly of the pre-replicative complex 0.00001 
Cell cycle 0.00001 
Cell cycle checkpoints 0.00001 
Cell cycle mitotic 0.00001 
DNA replication 0.00001 
M G1 Transition 0.00001 
Mitotic M M G1 phases 0.00001 
Regulation of mRNA stability by proteins that bind AU rich elements 0.00001 
Synthesis of DNA 0.00001 
Transport of mature transcript to cytoplasm 0.00001 
Orc1 removal from chromatin 0.00002 
Processing of capped intron containing pre mRNA 0.00002 
CDT1 association with the CDC6 orc origin complex 0.00002 
S phase 0.00002 
Activation of ATR in response to replication stress 0.00002 
G1 S transition 0.00003 
mRNA processing 0.00003 
Cytosolic tRNA aminoacylation 0.00004 
CDH1 targeted proteins in late mitosis early G1 0.00005 
ER phagosome pathway 0.00005 
Pathways related to effector T cell function 
IL3, IL5 and GM CSF signalling 0.04708 
Cytokine signalling in the immune system 0.05983 
Immune system 0.09002 
Adaptive immune system 0.09885 
IL2 signalling 0.12634 
Interferon signalling 0.16782 
IL1 signalling 0.19632 
Table 10: GSEA comparing MataHari T cells derived from the epidermis in the presence versus the 
absence of host Langerhans cells. 220 biological pathways were active in Mh T cells in the presence 
versus the absence of host LC. The top 20 pathways were determined based on the FDR p-value. Dataset 
kindly analysed by Dr Pedro Sousa using the Molecular Signatures Database Collection 2 – Canonical 
Pathways. A FDR p-value ≤0.25 was chosen as the cut off. 
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5.3.2 Langerhans cells upregulate multiple genes and biological pathways in 
allogeneic versus syngeneic BMT with MataHari T cells 
To investigate the role of host LC in the development of acute GVHD, host LC were 
sorted by FACS directly into RLT lysis buffer containing 1µM β-mercaptoethanol from 
the epidermis of male Langerin-DTR (allogeneic) and female BL/6 (syngeneic) 
recipients 7 days after transplant with female BM, MataHari T cells and polyclonal CD4 
T cells. In addition, host LC were also collected from WT male BL/6 mice as a control 
for inflammation associated with the conditioning regime.  
The gating strategy used to sort these cells is described in Figure 86A. Samples from 
different recipients were pooled if necessary so that a minimum of 8 x103 LC were 
collected per biological replicate with sort purity ≥95%. The RNA was then purified and 
amplified for whole-transcriptome microarray analysis using the Affymetrix GeneChip 
Mouse Gene 2.0 ST Array. The microarray dataset was then analysed by Dr Pedro 
Sousa in our lab using the same software and statistical techniques described in the 
previous sections. 
In contrast to allogeneic (F→M) recipients, no Vβ8.3+ Thy1.1+ Mh T cells were detected 
in the epidermis of syngeneic (F→F) recipients 7 days after transplant. Female 
recipients lack the requisite HY antigen (UTY) Mh T cells are reactive to and are not 
exposed to antigen in syngeneic recipients (Figure 90). By directly comparing the gene 
expression of profile of host LC in the epidermis of allogeneic (F→M) recipients versus 
syngeneic (F→F) recipients of BMT at this timepoint, we were able to investigate the 
change in gene expression in host LC when alloreactive donor Mh T cells were either 
present or absent in the epidermis. 
Following an unsupervised agglomerative clustering analysis and PVCA of host LC in 
the epidermis, there was a noticeable divergence in the transcriptional profiles between 
all three sets of host LC (Figure 91). A gene level differential expression analysis of 
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host LC in the epidermis identified 57 genes that were upregulated and 24 genes that 
were downregulated in allogeneic versus syngeneic recipients of BMT (Table 11 and 
Table 12). Interestingly, the IFN-γ inducible chemokine CXCL9, which has been linked 
to the pathogenesis of GVHD, was significantly upregulated in host LC from allogeneic 
recipients. Comparing the transcriptional profiles of host LC from allogeneic versus 
syngeneic recipients of BMT through a GSEA, it was evident that host LC upregulate 
multiple biological pathways involved in chemoattraction, cell migration and co-
stimulation in response to signalling associated by type I and type II IFN (Table 13). 
Taken together, it appears that the presence of effector Mh T cells in the epidermis 
increases the immunostimulatory capacity of host LC. 
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Figure 90: In contrast to allogeneic (F→M) recipients of BMT, MataHari T cells do not infiltrate the 
epidermis in syngeneic (F→F) recipients of BMT 7 days after transplant. Representative dot plots of 
the epidermis from male Langerin-DTR and female C57BL/6 recipients of BMT 7 days after transplant. 
After an initial live cell gate doublets were eliminated based on a FSC-W, FSC-A gate. A broad lymphocyte 
gate was then gated and Mh T cells were identified within this based on their expression of Vβ8.3, Thy1.1 
and CD45.2. In male Langerin-DTR recipients of allogeneic (F→M) BMT, Mh T cells had infiltrated the 
epidermis by day 7 as previously described. In female C57BL/6 recipients of syngeneic (F→F) BMT, Mh T 
cells did not infiltrate the epidermis by day 7. 
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Figure 91: Heat map and principal variance component analysis of Langerhans cells from the 
epidermis. A. Heat map depicting the unsupervised agglomerative hierarchical clustering analysis of 
Langerhans cells from the epidermis of allogeneic and syngeneic recipients of BMT with Mh T cells and 
WT male Langerin-DTR mice according to the gene expression profile determined using the Affymetrix 
GeneChip 2.0 Mouse Gene 2.0 ST Array (Each biological replicate represents pooled RNA, n=3-9 from 1-
2 independent experiments). B. Principal variance component analysis of LC samples according to the 
gene expression profile determined using the Affymetrix GeneChip 2.0 Mouse Gene 2.0 ST Array. There is 
a divergence in the transcriptional profile of LC in all 3 groups. 
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Genes over-expressed in Langerhans cells in allogeneic versus syngeneic recipients 
Gene Description LFC 
Translation regulation 
Ddx3y 
Eif2s3y 
 
Cytokine/Chemokine 
Cxcl9 
 
Signal transduction 
Gbp2 
Cish 
Kmo 
CD209c 
Stat1 
Nlrc5 
CD33 
CD274 
Klrb1b 
Pram1 
Olfr99 
Gpr171 
Irf8 
II2rg 
Tbc1d8 
Gnb4 
Gbp7 
Zbp1 
Clec2d 
Ly6e 
Adcy6 
 
Cell adhesion 
Cd97 
Slamf7 
Vcl 
 
Epigenetic regulation 
Uty 
Kdm5d 
 
Inflammasome 
Gbp5 
 
Zinc metabolism 
Mt4 
 
Antigen presentation 
H2-Q10 
 
Apoptosis 
Dnase1l3 
Bcl2 
Bcl2l11 
Tmem173 
 
Transcription regulation 
Mir18 
Arid5b 
1810022K09Rik 
Apopbec3 
Mir186 
Ahcy 
 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 
Eukaryotic translation initiation factor 2, subunit 3, structural gene 
 
 
Chemokine (C-X-C motif) ligand 9 
 
 
Guanylate binding protein 2 
Cytokine inducible SH2-containing protein 
Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 
CD209c antigen 
Signal transducer and activator of transcription 1 
NLR family, CARD domain containing 5 
CD33 antigen 
CD274 antigen 
Killer cell lectin-like receptor subfamily B member 1b 
PML-RAR alpha-regulated adaptor molecule 1 
Olfactory receptor 99 
G protein-coupled receptor 171 
Interferon regulatory factor 8 
Interleukin 2 receptor, gamma chain 
TBC1 domain family, member 8 
Guanine nucleotide binding protein (G protein), beta 4 
Guanylate binding protein 7 
Z-DNA binding protein 1 
C-type lectin domain family 2, member d 
Lymphocyte antigen 6 complex, locus E 
Adenylate cyclase 6 
 
 
CD97 antigen 
SLAM family member 7 
Vinculin 
 
 
Ubiquitously transcribed tetratricopeptide repeat gene 
Lysine (K)-specific demethylase 5D 
 
 
Guanylate binding protein 5 
 
 
Metallothionein 4 
 
 
Histocompatibility 2, Q region locus 10 
 
 
Deoxyribonuclease 1-like 3 
B cell leukemia/lymphoma 2 
BCL2-like 11 (Apoptosis facilitator) 
Transmembrane protein 173 
 
 
MicroRNA 18 
AT rich interactive domain 5B (MRF1-like) 
RIKEN cDNA 1810022K09 gene 
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3 
MicroRNA 186 
S-adenosylhomocysteine hydrolase 
 
28.35 
17.64 
 
 
20.76 
 
 
9.89 
8.36 
6.85 
3.59 
3.46 
3.1 
2.82 
2.79 
2.72 
2.68 
2.65 
2.61 
2.56 
2.5 
2.46 
2.36 
2.28 
2.05 
2.04 
2.03 
2.02 
 
 
6.54 
2.97 
2.17 
 
 
6.02 
4.32 
 
 
5.11 
 
 
4.12 
 
 
4.11 
 
 
3.15 
3.05 
2.34 
2.2 
 
 
3.14 
2.42 
2.18 
2.17 
2.14 
2 
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Membrane Transport 
Mfsd2a 
Clcn7 
 
Cytoskeleton 
Coro2a 
 
Lipid metabolism 
Dgat2 
 
Protein transport 
Ehd1 
 
Regulation of cell cycle 
Suv39h1 
 
Flavin metabolism 
Rfk 
 
Uncharacterised 
Gm19951 
1600029D21Rik 
Gm19763 
AU020206 
Sectm1a 
2310030G06Rik 
A130040M12Rik 
Aim1 
 
 
Major facilitator superfamily domain containing 2A 
Chloride channel 7 
 
 
Coronin, actin binding protein 2A 
 
 
Diacylglycerol O-acyltransferase 2 
 
 
EH-domain containing 1 
 
 
Suppressor of variegation 3-9 homolog 1 
 
 
Riboflavin kinase 
 
 
Predicted gene, 19951 
RIKEN cDNA 1600029D21 gene 
Predicted gene, 19763 
Expressed sequence AU020206 
Secreted and transmembrane 1A 
RIKEN cDNA 2310030G06 gene 
RIKEN cDNA A130040M12 gene 
Absent in melanoma 1 
 
 
 
2.75 
2.63 
 
 
2.53 
 
 
2.4 
 
 
2.32 
 
 
2.06 
 
 
2.01 
 
 
17.32 
6 
3.26 
2.73 
2.68 
2.6 
2.25 
2.06 
Table 11: Genes upregulated in Langerhans cells from the epidermis of allogeneic versus 
syngeneic recipients of BMT. Dataset kindly analysed by Dr Pedro Sousa using Affymetrix transcriptome 
analysis console software. A linear fold change (LFC) ≥2 and ANOVA p-value ≤0.05 was chosen as the cut 
off. 
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Genes under-expressed in Langerhans cells in allogeneic versus syngeneic recipients 
Gene Description LFC 
Translation regulation 
Xist 
Mir146 
Trim27 
Kansl2 
Churc1 
 
Signal transduction 
Emr4 
Hax1 
Itga8 
 
Cell differentiation 
Pid1 
 
Oxidation/Reduction metabolism 
Higd1a 
Acot6 
 
Transmembrane transport 
Slc36a 
 
Regulation of cell cycle 
Ninl 
 
Cell adhesion 
St8sia4 
Itgame 
 
Cytoskeleton 
Cript 
 
Uncharacterised 
1600010M07Rik 
1110005A03Rik 
Zfp958 
Lrp2bp, Ankrd37 
4930447A16Rik 
4930522L14Rik 
1600002H07Rik 
 
Inactive X specific transcripts 
microRNA 146 
tripartite motif-containing 27 
KAT8 regulatory NSL complex subunit 2 
Churchill domain containing 1 
 
 
EGF-like module, hormone receptor-like sequence 4 
HCLS1 associated X-1 
Integrin alpha 8 
 
Phosphotyrosine interaction domain containing 1 
 
 
HIG1 domain family, member 1A 
Acyl-CoA thioesterase 6 
 
 
 
Solute carrier family 36, member 2 
 
 
Ninein-like 
 
 
ST8 alpha-N-acetyl-neuraminide alpha-2,8 
Integrin alpha M 
 
 
Cysteine-rich PDZ-binding protein 
 
 
Riken cDNA 1600010M07 gene 
Riken cDNA 1110005A03 gene 
Zinc finger protein 958 
Lrp2 binding protein, ankyrin repeat domain 
Riken cDNA 4930447A16 gene 
Riken cDNA 4930522L14 gene 
Riken cDNA 1600002H07 gene 
 
 
-72.91 
-3.52 
-3.05 
-2.80 
-2.07 
 
 
-3.04 
-2.19 
-2.18 
 
-2.63 
 
 
-2.44 
-2.39 
 
 
 
-2.40 
 
 
-2.35 
 
 
-2.15 
-2.09 
 
 
-2.13 
 
 
-3.02 
-2.59 
-2.28 
-2.16 
-2.09 
-2.09 
-2.05 
Table 12: Genes downregulated in Langerhans cells from the epidermis of allogeneic versus 
syngeneic recipients. Dataset kindly analysed by Dr Pedro Sousa using Affymetrix transcriptome 
analysis console software. A linear fold change (LFC) ≥-2 and ANOVA p-value ≤0.05 was chosen as the 
cut off. 
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Biological pathways upregulated in Langerhans cells in allogeneic versus 
syngeneic recipients 
FDR p-value 
Cytokine signalling in immune system 0.001 
Interferon gamma signalling 0.001 
Interferon signalling 0.001 
Growth hormone receptor signalling 0.002 
Interferon alpha beta signalling 0.008 
Regulation of IFNG signalling 0.030 
Interleukin 6 signalling 0.059 
Apoptotic cleavage of cell adhesion proteins 0.068 
Signalling by ILS 0.084 
NEF mediated downregulation of MHC Class I complex cell surface expression 0.158 
P2Y receptors 0.168 
Smooth muscle contraction 0.171 
Regulation of IFNA signalling 0.177 
P38MAPK events 0.182 
CTLA4 inhibitory signalling 0.182 
Immune system 0.185 
Extrinsic pathway for apoptosis 0.202 
Interleukin 7 signalling 0.224 
Antigen presentation: folding, assembly and peptide loading of MHC Class I 0.224 
Chemokine receptors bind chemokines 0.227 
Antiviral mechanism by IFN stimulated genes 0.227 
GPVI mediated activation cascade 0.227 
PI metabolism 0.230 
Nucleotide-like purinergic receptors 0.230 
Amine compound SLC transporters 0.230 
Double-strand break repair 0.244 
Table 13: GSEA comparing Langerhans cells from the epidermis of allogeneic (F→M) versus 
syngeneic (F→F) recipients of BMT. Dataset kindly analysed by Dr Pedro Sousa using the Molecular 
Signatures Database Collection 2 – Canonical Pathways. A FDR p-value ≤0.25 was chosen as the cut off. 
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5.4 Discussion 
5.4.1 LC are required in situ 
The majority of studies investigating the role of donor and host APC in the development 
of GVHD have focused on these cell populations in priming the T cell response. In the 
previous chapter, I established a role for host LC in the development of cutaneous 
GVHD. However, the severity of acute systemic GVHD that developed was unaffected. 
The activation and expansion profile of Mh T cells in the lymphoid tissue was also 
unaffected as well as the capacity of Mh T cells to infiltrate other peripheral tissues 
such as the liver, lung and gut. This indicated that the depletion of host LC had no 
effect on the initiation or priming of acute systemic GVHD in this model. However, 
mature host LC that migrate to the secondary lymphoid tissue may have an important 
‘cellular’ or ‘humoral’ interaction with T cells in the lymph node that effects their 
capacity to initiate cutaneous GVHD. To investigate whether host LC were required in 
situ to peripherally regulate alloreactive donor T cell responses, I developed three 
experimental approaches.  
I initially developed a model of cutaneous GVHD where alloreactive donor T cells were 
injected directly into the skin. This was based on a protocol adapted from a published 
study where OT-1 T cells directly injected into the dermis of K14-OVA mice, where 
keratinocytes express OVA in the epidermis, were sufficient to induce cutaneous 
GVHD311. Adapting this model, two MHC-mismatched strains, Langerin-DTR (H-2b) 
and DBA/2 (H-2d) mice, were mated to create the Langerin-DTR x DBA/2 (H-2db) 
strain. To generate alloreactive T cells for i.d. injection, Langerin-DTR x DBA/2 mice 
were lethally irradiated with a split dose of 11 GY and reconstituted with a mixture of 5 
x106 BM and 20 x106 SC from a WT BL/6 donor. This Primary→F1 MHC-mismatch was 
sufficient to induce severe systemic GVHD283. After 4 days, 0.5 x106 of these primed 
CD8+ T cells were then injected i.d. in 50 µl into the ears of Langerin-DTR x DBA/2 
mice, which had been treated with 4 mg of Imiquimod and either 400 ng of DT or PBS. 
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The ears were subsequently harvested 3 days later and examined for histopathological 
signs of GVHD.  
The assumption in this experiment was that if host LC were required in situ, then there 
would be a significant reduction in the severity of cutaneous GVHD that developed 
when host LC were depleted. However, controls treated with Imiquimod alone 
developed an observable pathology. The volume of liquid injected also added to 
background noise, with observable pathology developing in ears injected with 50 µl of 
PBS. Due to the high levels of background noise in control, it was difficult to discern 
any meaningful observations and further work using this approach was discontinued. 
Due to the technical issues associated with directly injecting cell into the ear, I 
developed a secondary transfer model of GVHD where Mh T cells exposed to antigen 
in vivo were infused back into lethally irradiated male BL/6 recipients. The assumption 
in this experiment is that the majority of AEMTs, which had been exposed to antigen for 
in vivo in another lethally irradiated BL/6 male recipient, would be already primed 
against male antigen and ready to initiate GVHD. Thus, any differences in the ability of 
these T cells to accumulate in the skin in the absence of host LC would provide strong 
evidence that LC are required in situ. Adapting the already established MataHari minor 
mismatch model of GVHD, an irradiated male BL/6 recipient was transplanted with Mh 
T cells. After 3, 4, or 5 days, the Mh T cells were harvested from the skin draining 
lymph nodes and enriched before secondary transfer into lethally irradiated male 
Langerin-DTR recipients treated with either 400 ng of PBS or DT. Initially, Mh T cells 
that were primed for 5 days were used due to kinetics data from the previous chapter 
where Mh T cells infiltrated the skin by day 6.  
Interestingly, the transfer of 0.1-0.5 x106 Mh T cells exposed to antigen for 5 days was 
sufficient for Mh T cells to infiltrate the liver, lungs and LP+PP but not the skin. To 
investigate whether the length of time donor Mh T cells were exposed to antigen in vivo 
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effected their ability to accumulate in the skin, Mh T cells exposed to antigen for 3, 4 
and 5 days were mixed together at a 1:1:1 ratio and transplanted into male BL/6 
recipients. In the lung, LP+PP and liver, three distinct populations of Mh T cells could 
be identified 7 days after transplant with Mh T cells exposed to antigen for 4 days 
accumulating at higher frequencies than any other AEMTs. Interestingly, in the skin a 
different pattern emerged. Only Mh T cells exposed to antigen for 3 and 4 days were 
identified in both the epidermis and dermis in all samples. However, the average 
frequency at which the AEMTs accumulated in the epidermis and dermis was much 
lower than the frequencies observed transplanting 1 x106 naïve Mh T cells even when 
1 x106 AEMTs primed for 4 days were transferred into secondary recipients. 
These data indicate that early effectors migrate more efficiently to peripheral tissues. 
Although the precise mechanism for this observation is unclear, a similar observation 
has also been made in lymphocytic choriomeningitis (LCMV) infection model in mice, 
where CD8 T cells isolated 7 days after LCMV infection lost their ability to migrate to 
the gut epithelium in contrast to early effectors transferred after 4.5 days312. Without 
further experimental evidence it is difficult to speculate what caused this phenomenon. 
The frequency of infiltrating cells is decreased even when 1 x106 AEMTs were 
transferred into secondary recipients. It could be that T cells primed for 5 days may be 
more sensitive to treatment ex vivo during harvesting, which effects their ability to 
initiate GVHD in vivo. Alternatively, primed T cells may require a secondary ‘licensing’ 
signal in a peripheral tissue in order to proliferate and survive, by the time the T cell 
infiltrates the skin it may be too late. Due to the time constraints on the project and the 
artificial nature of the experiment in the context of acute GVHD, further work on this 
model was discontinued. 
Previous experimental approaches to investigate a role for LC in situ had focused on 
the injection of antigen exposed donor T cells intravenously or directly into the skin. 
Focusing on the skin itself, a new experimental approach was developed where DT 
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was injected i.d. into the left ear of Langerin-DTR mice to locally deplete LC in situ. The 
premise is that host LC that remain in untreated skin are capable of migrating to skin 
draining lymph nodes and interacting with donor CD8 T cells upon activation. Thus, if 
there was no difference in the accumulation and function of donor CD8 T cells in the 
area of the skin where host LC had been locally depleted, this would provide strong 
evidence that host LC are required in situ to regulate the T cell response in the 
periphery. 
Taking into account data from the T cell injection model, the volume used was reduced 
from the 50 µl to 20 µl to reduce any potential inflammatory side effects. The injection 
of 25 ng into the dorsal and ventral side of the ear was sufficient to host LC in the 
treated left ear, but not the untreated right ear in the same mouse. There was a slight 
reduction in the frequency in the untreated ear of a mouse receiving DT versus the 
untreated ear of a mouse receiving PBS, indication some systemic effects of DT. 
However, there was a significant reduction in the frequency of LC between the left 
(treated) versus the right (untreated) ear in DT treated mice. This was also confirmed 
by immunofluorescence microscopy of epidermal sheets, where LC were absent in the 
left (treated) ear but present in the right (untreated) ear. The mice were then allowed to 
recover for 9 days to allow Langerin+ dDC to reconstitute before being transplanted 
with naïve Mh T cells using the model described in the previous chapter.  
Remarkably, the localised depletion of host LC in the left ear had a significant effect on 
the ability of Mh T cells to accumulate in the skin 7 days after transplant. This reduction 
was specific for host LC, as a similar volume of PBS injected into Langerin-DTR had no 
effect on either the frequency of host LC in situ or Mh T cells infiltrating into the 
epidermis after transplant. Interestingly, there was a significant difference in the 
accumulation of Mh T cells in the right (untreated) ear of DT treated recipients versus 
the right (untreated) ear of PBS treated recipients hinting that the relationship between 
host LC and the T cell response may initially be dependant on the number of LC. 
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However, when the corresponding frequencies of host LC and Mh T cells were directly 
compared from all experiments involving the MataHari minor H mismatch model a 
relationship was difficult to interpret.  
These data, in parallel with the data from the systemic depletion of host LC in the 
previous chapter, demonstrate a critical role for host LC in situ in peripheral regulation 
of CD8 T cell responses in the skin during acute GVHD. 
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5.4.2 Gene expression analysis of MataHari T cells and LC 
To investigate whether there was functional difference between Mh T cells in the skin 
of mice in the presence versus the absence of host LC, the transcriptional profile of Mh 
T cells derived from the epidermis, dermis and skin draining lymph nodes was 
examined. This proved technically challenging and required a high number of replicates 
to sort relatively low numbers of cells for the microarray study; 5 x103 epidermal Mh T 
cells, 100 x103 lymph node Mh T cells and 8 x103 host LC. However, using the NuGEN 
Ovation Pico WTA System V2, which can reliably amplify cDNA from as little as 500 pg 
of RNA, the study was feasible. 
Initially, the expression of effector molecules associated with CTL function was 
analysed in flow sorted Mh T cells derived from the epidermis and dermis by qPCR, 
which was kindly performed by Dr Terry Means at Massachusetts General Hospital. Mh 
T cells in the epidermis showed a significant reduction in the expression of mRNA 
transcripts for a number of key effector molecules including IFN-γ, TNF-α, Granzyme B, 
TRAIL and the pro-survival molecule Bcl-xL, demonstrating a significant reduction in 
effector function of Mh T cells in the absence of host LC. 
In the final part of my PhD, I analysed the transcriptional profile of Mh T cells from the 
epidermis and skin draining lymph nodes using a microarray. From the dataset, it was 
clear that the transcriptional profile of Mh T cells changes substantially after cells 
infiltrate the epidermis, with several pathways favouring proliferation and survival 
upregulated. Remarkably, when host LC were depleted all of these biological pathways 
were lost, with the exception of one that is involved in T cell apoptosis.  
This was also apparent when gene expression profile of Mh T cells in the epidermis in 
the presence versus the absence of host LC was analysed. Over 220 biological 
pathways were upregulated in the presence of host LC. The vast majority of these 
pathways favoured cell proliferation, exemplified by the observation that 14 out of the 
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top 20 of these pathways were involved the cell cycle. The expression of Myc was 
significantly upregulated in Mh T cells in the presence of host LC. Myc is a marker of 
cell activation and plays a key role in the metabolic switch that favours T cell growth. In 
addition, the expression of the T cell co-stimulatory molecule TNFS14 (LIGHT), which 
promotes T cell expansion in a T:T cell dependent manner, was significantly 
upregulated in the presence of host LC313.  A number of key T cell effector molecules 
were also upregulated in the presence of host LC, including Granzyme C, IFN-γ and 
TNF-α, thus, demonstrating a critical role for host LC in ‘licensing’ CD8 T cells to 
become fully competent effector cells in the skin, similar to our observations in the 
MHC-mismatched MC model. 
The transcriptional profile of host LC in the epidermis was then analysed to evaluate 
their role in the development of cutaneous GVHD. By directly comparing the gene 
expression profile of host LC in allogeneic (F→M) versus syngeneic (F→F) recipients 
of BMT, I was able to investigate the effect of infiltrating Mh T cells on the 
transcriptional profile of host LC, while controlling for the immunomodulatory effects of 
damage associated with the conditioning regime. However, it should be noted that the 
up- and downregulation of some genes in host LC in allogeneic (F→M) versus 
syngeneic (F→F) recipients is a result of the sex-mismatch between the recipients. For 
instance, the most highly downregulated gene in host LC in allogeneic versus 
syngeneic recipients is Xist, which is major effector of the X chromosome inactivation 
process in females. 
Through GSEA, it appears that type I- and type II IFN signalling is important to the 
activity of host LC in the epidermis. In the secondary lymphoid tissue, type-I interferons 
have been shown to augment CTL function, directly enhancing their expansion and 
differentiation, and indirectly by enhancing cross-presentation by APC and promoting 
DC maturation314–316. The role of type-II interferons in the development of acute GVHD 
remains controversial as it can have both immunosuppressive and pathogenic 
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effects316. However, in the presence of host LC, Mh T cell significantly upregulate their 
expression of IFN-γ and the most striking observation from the LC microarray data was 
the significant upregulation of the chemokine CXCL9, a chemokine induced by IFN-γ. 
CXCL9 is a potent chemokine involved in the migration of immune effector cells to sites 
of inflammation through its cognate receptor CXCR3. Several studies have already 
shown that CXCR3 is important in the pathogenesis of acute GVHD, with a recent 
study by Villarroel et al. demonstrating a critical role for CXCR3 in the skin-specific 
recruitment of effector CD8 T cells in a model cutaneous GVHD146,317,318. 
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6 Discussion 
The role of host haematopoietic APC in the development of acute GVHD remains 
controversial. In MHC-mismatched models of GVHD, host haematopoietic APC are 
important during the initiation phase of acute GVHD. A role for host DC in these models 
is not surprising, as a high frequency of donor T cell precursors will be alloreactive 
against host MHC, molecules that are ubiquitously expressed by DC. However, in 
MHC-matched, minor H mismatched models of acute GVHD, the role of host 
haematopoietic APC is less clear. Using Mh T cells to induce GVHD, Toubai et al. 
generated [BL/6 2M-/-→BL/6] chimeras where antigen presentation is restricted to host 
non-haematopoietic APC. GVHD was induced when [BL/6 β2M-/-→BL/6] chimeras were 
reirradiated and transplanted with female BL/6 β2M-/- BM and Mh T cells, indicating that 
antigen presentation by host non-haematopoietic APC alone was sufficient to initiate 
GVHD130. Similarly, in CD4-mediated models of acute GVHD using B6.H2-Ab1-/- mice, 
which are MHC Class II deficient, Koyama et al. demonstrated that antigen 
presentation by host non-haematopoietic was sufficient to induce severe and lethal 
GVHD when antigen presentation was restricted in both donor and host haematopoietic 
cells129. Thus, a wide array of cells are capable of stimulating naïve donor T cells and 
the likelihood that one particular subset of APC has a non-redundant role in the 
initiation of this response seems improbable. 
An area less well investigated is the role of tissue-resident APC populations in the 
regulation of alloreactive donor T cell responses in situ after T cell priming. It is 
becoming increasingly clear that APC, such as DC, are important at not only priming 
immune responses in secondary lymphoid tissues but also in modulating their 
responses in situ. A role for DC in the peripheral regulation of T cells in situ has been 
particularly well characterised in the lung, where direct DC:T cell interactions are 
required after priming for the clearance of influenza. The existence of such a secondary 
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‘licensing’ signal makes evolutionary sense, as dysregulated immune responses can 
mediate tissue injury that far exceeds that caused by the pathogen it was intended to 
clear.  
In this project, I demonstrate for the first time a critical role for host LC in situ in the 
peripheral regulation of donor CD8 T cells that infiltrate the skin during acute GVHD. 
The depletion of host LC, but not Langerin+ dDC was associated with a significant 
reduction in the accumulation and function of donor CD8 T cells in the epidermis, that 
resulted in a substantial decrease in the severity of pathology that developed in this 
skin. This phenotype also appears to be CD8 dependant. In a MHC-matched, minor H 
mismatch model of CD4-mediated GVHD using Tg Marilyn CD4 T cells, which bear a 
TCR specific for male H-Y antigen (derived from Dby gene)319, the depletion of host LC 
had no significant effect on the accumulation of Marilyn T cells in the epidermis 
although there was a trend towards a lower frequency in the absence of host LC (data 
not shown). 
Interestingly, two studies published during my project directly ruled out a role for LC in 
MHC-matched, minor H mismatch models of CD8-mediated GVHD. Using Langerin-
DTA mice, which specifically lack LC due to the expression of the diphtheria toxin A 
chain, Li et al. demonstrated that host LC were dispensable in a C3H.SW → BL/6 
model of acute GVHD126. In fact, the absence of host LC slightly exacerbated the 
severity of cutaneous GVHD in this model. Similarly, using CD11c-DTA mice, which 
constitutively lack CD11c+ cDC, LC and most plasmacytoid DC, Li et al. demonstrated 
that host cDC, LC and pDC were dispensable for the induction of acute GVHD in the 
C3H.SW → BL/6 model125. Considering these observations against the profound 
immunostimulatory role of LC in my model of GVHD, it is hard to ignore that 
Langerhans cells are constitutively depleted from the skin in both the Langerin-DTA 
and CD11c-DTA mouse model. This constitutive absence during development may 
have a significant effect on the immune microenvironment that develops within the 
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epidermis, which may account for the disparity between the two models. However, it 
would be interesting to see if a similar phenotype was observed if these recipients were 
transplanted Mh T cells. 
The key question that remains to be answered is why do host LC, which only persist for 
a short time after transplant, mediate such a potent immunostimulatory signal to CD8 T 
cells. Other APC subsets in the skin, such as Langerin+ dDC, are capable of presenting 
antigen while epithelial cells, such as keratinocytes, can express pro-inflammatory 
cytokines and chemokines in response to tissue damage associated with the 
conditioning regime. Keratinocytes are equipped with a variety of TLRs, NOD-like 
receptors (NLR) and RIG-I-like receptors (RLR) that makes them particularly adept at 
sensing and responding to a variety of PAMPs and DAMPs, producing cytokines and 
chemokines such as CXCL9, CXCL10, CXCL11, TNF, IL-1, IL-6 and IL-10320. LC on 
the other hand appear to favour the induction of tolerance, promoting the formation of 
Tregs, and are widely considered dispensable for the induction of CD8 T cell immunity 
in the skin263,321. Interestingly, the epidermis contains a large population of memory 
CD8+ T cells that persist for long periods of time and are largely sequestered from the 
wider circulation322. Commonly referred to as T resident memory (Trm) cells, they 
compete with epidermal γδ T cells for survival signals and can be rapidly reactivated in 
situ upon reinfection323. It may be that LC have a key role in the expansion and 
homeostasis of this population in situ and in the context of tissue damage associated 
with the conditioning regime promote the induction of a dysregulated response, which 
can persist long after host LC are depleted. Recent data in our lab has hinted at this 
possibility, with Mh T cells in the epidermis increasing their expression of CD103 and 
CD69, molecules associated with the formation of Trm cells324. 
However, the mechanism by which host LC mediate this potent immunostimulatory 
effect on alloreactive donor CD8 T cells remains elusive. It may involve a direct cis 
interaction between host LC and effector CD8 T cells in the epidermis or it could 
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involve a trans interaction via the secretion of a ‘humoral’ effector. In addition, host LC 
could indirectly stimulate donor T cells by interacting with other infiltrating immune 
effectors, such as NK cells or neutrophils, resident immune effectors (γδ T cells) or 
stromal cells (keratinocytes).  
From the microarray data, it appears that type I- and II-IFN signalling is important 
during the development of cutaneous GVHD in this model. One hypothesis we propose 
is that damage associated with the conditioning regime leads to the secretion of type I 
IFN by innate cells such as plasmacytoid DC or stromal cells such keratinocytes. In 
response to these activation signals LC stimulate infiltrating CD8 T cells to produce 
IFN-γ which in turn promotes the production of cytokines and chemokines such as 
CXCL9 by LC which further augments the infiltration and accumulation of immune 
effectors in the skin, thus, perpetuating cutaneous GVHD. 
In the lung, a direct MHC Class I mediated interaction between pulmonary DC and 
infiltrating CTL induces a proliferative burst in T cells upon entry that is necessary for 
the clearance of influenza. Similar to the lung, the most striking observation from the T 
cell array data was the significant increase in expression of genes and biological 
pathways associated with proliferation when Mh T cells transitioned from the skin 
draining lymph nodes to the epidermis, a transcriptional signature that was lost in the 
absence of host LC. Whether a similar MHC Class I mediated interaction between host 
LC and donor CD8 T cells in the epidermis is critical for the downstream effector 
function of T cells remains to be determined. Based on observations in the MC model, 
it is tempting to speculate that a direct MHC Class I mediated interaction between host 
LC and donor CD8 T cells is responsible for the phenotype observed, although I was 
unable to definitely show this. In the context of our MHC-mismatched MC model of 
localised cutaneous inflammation ([BL/6+BALB/c] → Langerin-DTR), the unexpected 
finding of donor LC derived from MHC-mismatched BALB/c donor BM is important to 
consider. In [BL/6+BALB/c] → Langerin-DTR MC, two populations of LC were present 
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in the epidermis, LC derived from the host (Langerin-DTR, H-2b) and LC derived from 
MHC-mismatched donor BM (BALB/c, H-2d). However, after topical application of the 
TLR 7-8 agonist Imiquimod and DLI using donor splenocytes derived from MHC-
mismatched BALB/s donors, the depletion of host LC (Langerin-DTR, H-2b) 
significantly reduced the effector function of alloreactive donor CD8 T cells in the 
epidermis despite the presence of donor LC (BALB/c, H-2d)229. This indicates that a 
direct interaction of host LC with alloreactive donor CD8 T cells or another 
immunomodulatory cell type that interacts donor CD8 T cells is important. Inflammation 
mediated by the TLR 7-8 agonist Imiquimod would have the same effect on donor and 
host derived LC in the epidermis. The cytokines and/or chemokines released by LC in 
response to Imiquimod could be compensated for by BALB/c derived LC when host LC 
have been depleted using DT. However, it is also important to consider that BALB/c 
derived LC in this model are derived from bone marrow progenitors in contrast to host 
LC which are derived from yolk sac derived precursors and fetal liver monocytes. This 
may affect their response upon stimulation although no differences between LC 
populations derived from long-term bone marrow progenitors, yolk sac derived 
precursors and fetal liver monocytes has been reported in the literature.  
To investigate whether host LC are required to directly interact with Mh T cells via MHC 
Class I, the ideal model would have LC deficient in MHC Class I when all other host 
haematopoietic and non-haematopoietic cells express MHC Class I. One way to 
achieve this is the use of Cre-lox mouse models. Kaplan et al. have created Langerin-
Cre mice where Cre recombinase inserted into a human Langerin gene is selectively 
expressed in LC325. FVB Db-LoxP transgenic mice have recently been created, inserting 
LoxP sites that flank the transmembrane exon of the Db class I gene (exon 5)326. 
Mating Langerin-Cre with FVB Db-LoxP mice, the expression of MHC Class I could be 
selectively depleted in host LC. Adopting this mouse to the MataHari minor H mismatch 
model, any deficiency in the accumulation and activation of Mh T cells in epidermis 
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would provide strong evidence supporting a direct cis interaction between host LC and 
donor CD8 T cells. 
Alternatively, the infiltration of Mh T cells into the skin could be visualised using 
intravital two-photon microscopy, a fluorescence imaging technique that permits live 
cell imaging up to 1 mm327. Mh T cells infiltrate the epidermis by day 6 post transplant 
and in the absence of host LC there is already a significant reduction in the 
accumulation of Mh T cells in the epidermis at this timepoint. Imaging the infiltration of 
Mh T cells into the epidermis in the presence or absence of host LC at this timepoint 
would give us a greater insight into the behaviour of these cells in vivo. 
The role of host LC may also be independent of an interaction with an immune effector 
cell. A recent study by Moussion and Girad has proposed an unexpected new function 
for DC in vivo. Using the CD11c-DTR model, they noted that the continued depletion of 
DC over a one-week period reduced both the size and cellularity of peripheral and 
mucosal lymph nodes328. In the absence of DC, high endothelial venules, which 
regulate the recruitment of lymphocytes, reverted from a mature phenotype to an 
immature neonatal phenotype preventing the entry of lymphocytes into the lymph node. 
In the skin, a role for LC in vasodilation has been described in response to the 
antidyslipidemic drug nicotinic acid329. Nicotinic acid induced the expression of 
prostanoid synthases in LC, which are required for the formation of vasodilators 
prostaglandin E2 and prostaglandin D2. Using the Langerin-DTR mouse model, the 
depletion of LC abrogated nicotinic acid induced skin flushing. In the context of 
cutaneous GVHD, vasodilators produced by LC may help increase the frequency of Mh 
T cells that infiltrate into the epidermis, which in turn promotes tissue damage and 
inflammation that further augments the severity of cutaneous GVHD. To test this 
hypothesis, Langerin-DTR recipients could be injected 3, 4 or 5 days post transplant 
before Mh T cells infiltrate the epidermis. The assumption in this experiment is that LC 
would mediate a vasodilatory effect before T cells infiltrate the skin. If there was no 
 270 
difference in the accumulation of Mh T cells in the epidermis when LC were depleted at 
any one of these timepoints then at the very least the requirement for a direct cell:cell 
contact between host LC and Mh T cells could be ruled out. 
Taking these data forward, the importance of host LC will need to be verified in a 
polyclonal T cell model of acute GVHD. Although LC had a role in the development of 
cutaneous GVHD in a model of localised cutaneous inflammation using polyclonal T 
cells, the majority of the work in my project has used monoclonal Mh CD8 T cells. This 
is not representative of GVHD in the clinic, where alloreactive donor polyclonal T cells 
respond to a multitude of different minor histocompatibility antigens, and will need to be 
addressed330. In addition, care needs to be taken when interpreting the results from a 
translational point of view, as substantial differences can exist between mice and 
humans. In the skin, epidermal γδ T cells are abundant in mice but absent in humans.  
To conclude, it is clear that host LC can mediate a potent immunostimulatory role in 
vivo. The precise role of LC remains enigmatic, but it appears they may have a 
‘sentinel’ like role in the epidermis. In the presence of the appropriate stimulus, in this 
study tissue damage associated with the conditioning regime, LC are capable of 
promoting potent immune responses. Similarly, they are equally capable of 
downregulating immune responses to promote tolerance. Dissecting the nature of 
these LC:T cell interaction in situ could lead to the identification of a novel mechanism 
to both control and promote CD8 T cell immune responses in the skin. In the context of 
GVHD, controlling the response locally at the site of inflammation is an attractive 
therapeutic strategy, as the beneficial anti-neoplastic effects of systemic GVL may be 
maintained. 
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